

FOR OFFICIAL USE ONLY

ACCESS DB #

172660

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Nyeemah Grazier Examiner #: 81002 Date: 11/28/05
Art Unit: 1626 Phone Number: 2-8782 Serial Number: 101509633
Location (Bldg/Room): B29 Rm (Mailbox #): 5C18 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: Chemical Compounds

Inventors (please provide full names): Jean-Claude Arnould

Earliest Priority Date: 9/29/04


Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search for compound

(claim 7)



X = O, S, SO, SO₂

P = 0-1

R₂ = H, alk

R₅ = H, alk, or $\text{-(CH}_2\text{)}_{0-1}\text{-C(=O)-}$ Y = NH or O

Z = NH, O, C(O)- or aband

R⁸ = H, alk, alkoxy, Aryl, Heterocycle (5-6 member) or 5-6 heteroaryl

STAFF USE ONLY

Searcher: _____

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: 12-9-05

Searcher Prep & Review Time: _____

Online Time: _____

Type of Search

____ NA Sequence (#)

____ AA Sequence (#)

____ Structure (#)

____ Bibliographic

____ Litigation

____ Fulltext

____ Other

Vendors and cost where applicable

____ STN _____ Dialog

____ Questel/Orbit _____ Lexis/Nexis

____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial _____ Oligomer _____ Score/Length

____ Interference _____ SPDI _____ Encode/Transl

____ Other (specify)

RECEIVED
NOV 29 2005
FISH/CHEM DIVISION
(STIC)

This Page Blank (uspto)



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 172660

TO: Nyeemah Grazier
Location: rem/5B29/5C18
Art Unit: 1626
December 8, 2005

Case Serial Number: 10/509633

From: P. Sheppard
Location: Remsen Building
Phone: (571) 272-2529

sheppard@uspto.gov

Search Notes

This Page Blank (uspto)

Grazier 10_509633- - History

=> d his ful

(FILE 'HOME' ENTERED AT 16:13:33 ON 09 DEC 2005)

FILE 'REGISTRY' ENTERED AT 16:13:41 ON 09 DEC 2005

L3 STR
L5 STR
L7 STR
L9 STR
L11 49 SEA SSS SAM L3 OR L5 OR L7 OR L9
L12 11678 SEA SSS FUL L3 OR L5 OR L7 OR L9
L13 STR
L14 7996 SEA SUB=L12 SSS FUL L13

FILE 'HCAPLUS' ENTERED AT 16:19:52 ON 09 DEC 2005

L15 1916 SEA ABB=ON PLU=ON L14
L16 30199 SEA ABB=ON PLU=ON ANGIOGENESIS/CV OR ?ANGIOGENE?
L17 44 SEA ABB=ON PLU=ON L15 AND L16
L18 37 SEA ABB=ON PLU=ON L17 AND PD=<SEPTEMBER 29, 2004
D STAT QUE
D IBIB ABS HITSTR L18 1-37
L19 41 SEA ABB=ON PLU=ON ("ARNOULD J"/AU OR "ARNOULD J C"/AU) OR
("ARNOULD JEAN"/AU OR "ARNOULD JEAN C"/AU OR "ARNOULD JEAN
CLAUDE"/AU)
L20 3 SEA ABB=ON PLU=ON L19 AND L15
L21 0 SEA ABB=ON PLU=ON L20 NOT L18
L22 38 SEA ABB=ON PLU=ON L19 NOT L18
L23 38 SEA ABB=ON PLU=ON L21 OR L22
D STAT QUE L23
D IBIB ABS HITSTR L23 1-38

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 8 DEC 2005 HIGHEST RN 869627-02-1

DICTIONARY FILE UPDATES: 8 DEC 2005 HIGHEST RN 869627-02-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

This Page Blank (uspto)

Grazier 10_509633- - History

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Dec 2005 VOL 143 ISS 25
FILE LAST UPDATED: 8 Dec 2005 (20051208/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>

This Page Blank (uspto)

=> fil hcaplus
 FILE 'HCAPLUS' ENTERED AT 16:19:52 ON 09 DEC 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 9 Dec 2005 VOL 143 ISS 25
 FILE LAST UPDATED: 8 Dec 2005 (20051208/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=>
 =>

=> d stat que
 L3 STR




REP G1=(0-1) CH2
 VAR G2=O/S
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE


L5 STR



REP G1=(0-1) CH2
 VAR G2=O/S
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17


STEREO ATTRIBUTES: NONE
 L7 STR



REP G1=(0-1) CH2
 VAR G2=O/S
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
 L9 STR



REP G1=(0-1) CH2

VAR G2=O/S

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

L12 11678 SEA FILE=REGISTRY SSS FUL L3 OR L5 OR L7 OR L9

L13 STR



REP G1=(0-1) CH2

VAR G2=O/S

VAR G3=10/11/14/15

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L14 7996 SEA FILE=REGISTRY SUB=L12 SSS FUL L13

L15 1916 SEA FILE=HCAPLUS ABB=ON PLU=ON L14

L16 30199 SEA FILE=HCAPLUS ABB=ON PLU=ON ANGIOGENESIS/CV OR ?ANGIOGENE?

L17 44 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND L16

L18 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND PD=<SEPTEMBER 29,
2004

=>

=>

=> d ibib abs hitstr 118 1-37

L18 ANSWER 1 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:569863 HCAPLUS

DOCUMENT NUMBER: 141:123559

TITLE: A preparation of indole derivatives, useful as integrin inhibitors

INVENTOR(S): Wiesner, Matthias; Goodman, Simon; Gottschlich, Rudolf

PATENT ASSIGNEE(S): Germany

SOURCE: U.S. Pat. Appl. Publ., 33 pp., Cont.-in-part of U.S. Ser. No. 203,406.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004138284	A1	20040715	US 2004-750879	20040105 <--
DE 10006139	A1	20010816	DE 2000-10006139	20000211 <--
WO 2001058893	A2	20010816	WO 2001-EP84	20010105 <--
WO 2001058893	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2003045728	A1	20030306	US 2002-203406	20020809 <--
US 6743810	B2	20040601		
PRIORITY APPLN. INFO.:			DE 2000-10006139	A 20000211
			WO 2001-EP84	W 20010105
			US 2002-203406	A2 20020809

OTHER SOURCE(S): MARPAT 141:123559

GI



AB The invention relates to a preparation of indole derivs. of formula I [wherein: A and B are independently selected from O, S, NH, NH, C(O), or C(O)NH, etc.; X is (un)substituted alkylene; R1 is H, C1-6alkyl, or (CH2)0-2-aryl; R2 is H, (cyclo)alkyl, or -C(O)-alkyl; R3 is NH2, -NHC(O)-alkyl,


-NH(CO)-aryl, etc.; R4 and R5 are independently selected from H, oxo, (cyclo)alkyl, C(O)NH2, or NH-heterocycle, etc.], useful as integrin inhibitors (no biol. data). Compds. of formula I can be employed for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammations, tumors, osteoporosis, rheumatic arthritis, macular degenerative disease, and diabetic retinopathy, etc. The invention compds. act as integrin inhibitors, inhibiting, in particular, the interaction of the αv -, $\beta 3$ - and $\beta 5$ -integrin receptors with ligands (no biol. data).

IT 15903-94-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indole derivs., useful as integrin inhibitors)

RN 15903-94-3 HCAPLUS

CN 1H-Indole, 6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




IT 354822-51-8P 354822-52-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indole derivs., useful as integrin inhibitors)


RN 354822-51-8 HCAPLUS

CN 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-[phenyl[6-(phenylmethoxy)-1H-indol-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 354822-52-9 HCAPLUS

CN 1H-Indole-3-propanoic acid, β -phenyl-6-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 2 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN



ACCESSION NUMBER: 2004:546484 HCAPLUS

DOCUMENT NUMBER: 141:106462

TITLE: Preparation of pyrazoles as inhibitors of HSP90

INVENTOR(S): Beswick, Mandy Christine; Drysdale, Martin James;
 Dymock, Brian William; McDonald, Edward
 PATENT ASSIGNEE(S): Vernalis Cambridge Limited, UK; Cancer Research
 Technology Ltd.; The Institute of Cancer Research
 SOURCE: PCT Int. Appl., 98 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056782	A1	20040708	WO 2003-GB5501	20031218 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509403	AA	20040708	CA 2003-2509403	20031218 <--
EP 1572664	A1	20050914	EP 2003-768007	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			GB 2002-29618	A 20021219
			WO 2003-GB5501	W 20031218
OTHER SOURCE(S):			MARPAT 141:106462	
GI				



AB The title compds. [I or II; Ar = (un)substituted aryl, arylalkyl, heteroaryl, heteroarylalkyl; R1 = H, alkyl; R2 = H, (un)substituted cycloalkyl, cycloalkenyl, alkyl, alkenyl, alkynyl, carboxyl, carboxamide or carboxyl ester group; A = non-aromatic carbocyclic or heterocyclic ring wherein (i) a ring carbon is optionally substituted, and/or (ii) a ring nitrogen is optionally substituted by a group of formula - (Alk1)p(Cyc)n(Alk3)m(Z)r(Alk2)sQ where Alk1, Alk2 and Alk3 = alkyl; Cyc = carbocyclic or heterocyclic radical; m, n, p, r and s = 0-1; Z = O, S, CO, SO2, etc.; Q = H, (un)substituted carbocyclic or heterocyclic radical] which are inhibitors of HSP90, and are of value in the treatment of diseases responsive to HSP90 inhibition such as cancer, were prepared E.g., a multi-step synthesis of 4-chloro-6-(4-piperazin-1-yl-1H-pyrazol-3-yl)benzene-1,3-diol which showed IC50 of <50 µM in the malachite green ATPase assay, was given.


IT 719288-34-3P 719288-35-4P 719288-36-5P
 719288-37-6P 719288-38-7P 719288-39-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of pyrazoles as inhibitors of HSP90)


RN 719288-34-3 HCAPLUS

CN 1H-Indole, 1,5-diacetyl-2-methyl-6-(phenylmethoxy) - (9CI) (CA INDEX NAME)




RN 719288-35-4 HCAPLUS

CN 1H-Indole, 1-acetyl-5-(dibromoacetyl)-2-methyl-6-(phenylmethoxy) - (9CI)
(CA INDEX NAME)




RN 719288-36-5 HCAPLUS

CN 1H-Indole, 1-acetyl-5-(bromoacetyl)-2-methyl-6-(phenylmethoxy) - (9CI) (CA
INDEX NAME)



RN 719288-37-6 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[1-acetyl-2-methyl-6-(phenylmethoxy)-1H-
indol-5-yl]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 719288-38-7 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[1-[[1-acetyl-2-methyl-6-(phenylmethoxy)-1H-
indol-5-yl]carbonyl]-2-(dimethylamino)ethenyl]-, phenylmethyl ester (9CI)

(CA INDEX NAME)



RN 719288-39-8 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[3-[2-methyl-6-(phenylmethoxy)-1H-indol-5-yl]-1H-pyrazol-4-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:493561 HCAPLUS

DOCUMENT NUMBER: 141:54365

TITLE: Preparation of 1,3,5-triazines as kinase inhibitors for treatment of **angiogenesis** or vasculogenesis

INVENTOR(S): Armistead, David M.; Bemis, Jean E.; Buchanan, John L.; Dipietro, Lucian V.; Elbaum, Daniel; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Kim, Joseph L.; Marshall, Teresa L.; Novak, Perry M.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.; Zhu, Xiaotian

PATENT ASSIGNEE(S): Amgen Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 300 pp., Cont. of U.S. Ser. No. 85,053, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 US 2004116388 A1 20040617 US 2003-699518 20031031 <--
 PRIORITY APPLN. INFO.: US 2000-685053 B1 20001006
 OTHER SOURCE(S): MARPAT 141:54365
 GI



AB Title compds. I [wherein R1 and R2 = independently R3, R8, NHR3, NHR5, NHR6, NR5R5, NR5R6, SR5, SR6, SR3, OR5, OR6, OR3, COR3, (un)substituted heterocyclyl, alkyl; R3 = independently aryl, (un)substituted Ph, heteroaryl; R5 = independently H, alkynyl, cycloalkenyl, aryl, R9, (un)substituted (cyclo)alkyl, alkenyl; R6 = independently COR5, CO2R5, CONR5R5, C(=NR5)NR5R5, SO1-2R5; R8 = independently (un)substituted (hetero)monocyclyl, (hetero)bicyclyl, (hetero)tricyclyl] were prepared as inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer. Examples include a number of general synthetic methods, specific exptl. details for the preparation of selected invention compds., and phys. and bioassay data. For instance, 2,4-dichloro-1,3,5-triazine was coupled with 3,4,5-trimethoxyaniline in the presence of diisopropylethylamine in DMF to give the triazinamine (37%). Subsequent reaction with 4-aminoveratrole using diisopropylethylamine in EtOH provided II (66%). The latter was one of over 950 invention compds. tested for activity against the EGFR-1, IGFR-1, Akt3-1, Met-1, KDR-1, Zap-1, Lck-1, Itk-1, PDGFRB-1, Tek-1, ErbB2-2, EPHB4-1, ErbB4-1, FGFR1-1, Flt-1, Fyn-1, Hck-1, Lyn-1, Ret-1, and/or Src-1 receptors with IC50 values in ranges from <0.4 µg/mL to >4.5 µg/mL. Thus, I and their compns. are useful for the treatment of diseases or conditions involving **angiogenesis** or **vasculogenesis** (no data).


IT 333727-64-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(kinase inhibitor; preparation of triazines as kinase inhibitors for treatment of **angiogenesis** or **vasculogenesis**)

RN 333727-64-3 HCAPLUS



CN 1,3,5-Triazin-2-amine, 4-[5-(phenylmethoxy)-1H-indol-1-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



DOCUMENT NUMBER: 141:7139
 TITLE: Preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with **angiogenesis**
 INVENTOR(S): Ladouceur, Gaetan H.; Bear, Brian; Bi, Cheng; Brittelli, David R.; Burke, Michael J.; Chen, Gang; Cook, James; Dumas, Jacques; Sibley, Robert; Turner, Michael R.
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 217 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043950	A1	20040527	WO 2003-US36003	20031110 <--
W:				AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW:				BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2505819	AA	20040527	CA 2003-2505819	20031110 <--
EP 1565455	A1	20050824	EP 2003-783328	20031110
R:				AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
BR 2003016169	A	20050927	BR 2003-16169	20031110
NO 2005002796	A	20050609	NO 2005-2796	20050609
PRIORITY APPLN. INFO.:			US 2002-425490P	P 20021112
			US 2003-460915P	P 20030407
			US 2003-484202P	P 20030630
			WO 2003-US36003	W 20031110

OTHER SOURCE(S): MARPAT 141:7139
 GI



AB The invention relates to title compds. I [wherein Ar = 6-membered aromatic

ring containing 0-2 N atoms; R1 and R2 = independently H, halo, CF₃, acyl, piperidinyl, piperazinyl, morpholinyl, or (un)substituted alkyl, alkoxy, amino, pyrrolidinyl, Ph, etc.; R3 = H, alkyl, OH, NO₂, NH₂, alkylamino, alkoxyamino, or (un)substituted benzoylamino; R4 = H, OH, halo, CN, acyl, sulfamoyl, trialkylsiloxy, tetrazolyl, thienyl, pyrrolyl, pyrimidinyl, oxazolyl, furanyl, or (un)substituted alkyl, alkenyl, alkynyl, alkoxy, amino, oxadiazolyl, Ph, pyridyl(oxy), carbamoyl; R11 and R12 = independently H, F, or Cl with the proviso that when one of R11 and R12 = F or Cl, the other must be H; and pharmaceutically acceptable salts and esters thereof]. The invention also relates to the use of I and their pharmaceutical compns. for treating hyperproliferative disorders and diseases associated with **angiogenesis** (no data). Examples include representative syntheses for compds. of the invention, pharmaceutical compns. comprising them, and tumor model assays (no specific data given). For instance, N-Boc-indole was coupled with di-Me oxalate using t-BuLi to give tert-Bu 2-[methoxy(oxo)acetyl]-1H-indole-1-carboxylate (72%). Cyclization of the dione with 1,2-phenylenediamine in AcOH afforded the quinoxalinone II (77%).


IT 170147-29-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of indolylquinoxalinones for treating hyperproliferative disorders and diseases associated with **angiogenesis**)

RN 170147-29-2 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 5 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:203828 HCAPLUS

DOCUMENT NUMBER: 140:253450

TITLE: Preparation of azaarene derivatives as neovascularization inhibitors

INVENTOR(S): Tsuruoka, Akihiko; Matsushima, Tomohiro; Matsukura, Masayuki; Miyazaki, Kazuki; Takahashi, Keiko; Kamata, Junichi; Fukuda, Yoshio

PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan

SOURCE: PCT Int. Appl., 347 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004020434	A1	20040311	WO 2003-JP10964	20030828 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2488739 AA 20040311 CA 2003-2488739 20030828 <--
 EP 1522540 A1 20050413 EP 2003-791389 20030828
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 BR 2003013871 A 20050719 BR 2003-13871 20030828
 US 2005187236 A1 20050825 US 2003-651496 20030829
 NO 2005001577 A 20050527 NO 2005-1577 20050329
 PRIORITY APPLN. INFO.: JP 2002-253123 A 20020830
 US 2003-464690P P 20030422
 WO 2003-JP10964 W 20030828
 OTHER SOURCE(S): MARPAT 140:253450
 GI



AB The title compds. I [X1 is nitrogen or a group represented by the general formula CR10 ; X2 is nitrogen or a group represented by the general formula CR11 ; Y is oxygen or the like; R1 is C1-6 alkoxy, optionally substituted C6-10 aryloxy, a group represented by the general formula NR12aR12b, or the like; R2 is hydrogen, optionally substituted C1-6 alkyl, or the like; R3 - R8, R10, and R11 are each independently hydrogen, halogeno, optionally substituted C1-6 alkyl, or the like; R9 is a group represented by the general formula NR16aR16b, or the like; and R12a, R12b, R16a, and R16b are each independently hydrogen, optionally substituted C1-6 alkyl, or the like] are prepared Compds. of this invention showed IC50 values of 3 nM to 40 nM against VEGFR2 kinase.


IT 1215-59-4, 5-Benzyloxyindole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of azaarene derivs. as neovascularization inhibitors)

RN 1215-59-4 HCAPLUS

CN 1H-Indole, 5-(phenylmethoxy) - (9CI) (CA INDEX NAME)




IT 670252-55-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of azaarene derivs. as neovascularization inhibitors)

RN 670252-55-8 HCAPLUS

CN 1H-Indole-1-carboxamide, N-methyl-5-(phenylmethoxy)- (9CI) (CA INDEX
NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 6 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:80847 HCAPLUS

DOCUMENT NUMBER: 140:124558

TITLE: Pyrrolotriazine inhibitors of kinases for use in
treatment of diseases associated with growth factor
receptor signal transduction

INVENTOR(S): Bhide, Rajeev; Cai, Zhen-wei; Qian, Ligang; Barbosa,
Stephanie

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009784	A2	20040129	WO 2003-US22826	20030718 <--
WO 2004009784	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2492804	AA	20040129	CA 2003-2492804	20030718 <--

US 2004063707	A1	20040401	US 2003-622593	20030718 <--
US 6969717	B2	20051129		
US 2004072832	A1	20040415	US 2003-623171	20030718 <--
US 6869952	B2	20050322		
EP 1534290	A2	20050601	EP 2003-765881	20030718
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012940	A	20050621	BR 2003-12940	20030718
NO 2005000072	A	20050203	NO 2005-72	20050106
US 2005124621	A1	20050609	US 2005-35248	20050113
PRIORITY APPLN. INFO.:			US 2002-397256P	P 20020719
			US 2003-447213P	P 20030213
			US 2003-623171	A1 20030718
			WO 2003-US22826	W 20030718

OTHER SOURCE(S): MARPAT 140:124558
GI



AB The present invention provides pyrrolo[2,1-f][1,2,4]triazine compds. I (Z = O, S, N, OH, Cl; when Z = O or S, R4 is absent; when Z = OH or Cl, both R4 and R5 are absent; when Z = N, R4 = H; X, Y = O, OCO, S, SO, SO2, CO, CO2, halo, NO2, CN, etc., or X and Y are absent; R1 = H, Me, OH, OMe, SH, SMe, halo, NO2, CN, etc.; R2, R3 = H, (substituted)alkyl, (substituted)alkenyl, (substituted)alkynyl, (substituted)aryl, (substituted)heterocyclo, etc.; when X = halo, NO2, or CN, R2 is absent; when Y = halo, NO2, or CN, R3 is absent; R5 = (unsubstituted)indole; R6 = H, (substituted)alkyl, (substituted)aryl, (substituted)heterocyclo, halo, etc.), and pharmaceutically acceptable salts thereof. I compds. inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1 (no data), thereby making them useful as anti-cancer agents. I compds. are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. Thus, many I (R1, R4, R6 absent; R3Y = Me; Z = O; R5 = 2-methyl-4-fluoro-1H-indol-5-yl; X = O; R2 = (substituted)alkyl, arylalkyl, etc.) were synthesized.


IT **649736-47-0**

RL: RCT (Reactant); RACT (Reactant or reagent)

(pyrrolotriazine inhibitors of kinases for use in treatment of diseases associated with growth factor receptor signal transduction)

RN 649736-47-0 HCAPLUS

CN 1H-Indole, 4-fluoro-2-methyl-5-(phenylmethoxy) - (9CI) (CA INDEX NAME)



L18 ANSWER 7 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:80644 HCAPLUS

DOCUMENT NUMBER: 140:146018

TITLE: Process for preparation of indolyloxypyrrolotriazines and their use as drugs.

INVENTOR(S): Bhide, Rajeev; Fan, Junying; Parlanti, Luca; Barbosa, Stephanie; Qian, Ligang; Cai, Zhen-wei; Gibson, Francis S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009542	A2	20040129	WO 2003-US22755	20030721 <--
WO 2004009542	A3	20040513		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004077858	A1	20040422	US 2003-622280	20030718 <--
US 6933386	B2	20050823		
CA 2492861	AA	20040129	CA 2003-2492861	20030721 <--
EP 1554281	A2	20050720	EP 2003-765846	20030721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012648	A	20050802	BR 2003-12648	20030721
US 2005124621	A1	20050609	US 2005-35248	20050113
PRIORITY APPLN. INFO.:				
			US 2002-397256P	P 20020719
			US 2003-447213P	P 20030213
			US 2003-622280	A 20030718
			US 2003-623171	A1 20030718
			WO 2003-US22755	W 20030721
OTHER SOURCE(S): MARPAT 140:146018				
GI				



I



II

AB Title compds. [I; X, Y = O, O₂C, S, SO, SO₂, CO, CO₂, NR₁₀, NR₁₁CO, NR₁₂CONR₁₃, NR₁₄CO₂, NR₁₅SO₂, NR₁₆SO₂NR₁₇, SO₂NR₁₈, CONR₁₉, halo, NO₂, cyano, null; R₁, R₆ = H; R₂, R₃ = H, (substituted) alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl, heteroaryl, heterocycloalkyl; R₇-R₁₉ = H, (substituted) alkyl, aryl, heteroaryl, heterocyclyl; R₄₃ = H, F, Cl, Me; n = 0-2; R₄₄ = H, Me; with provisos], were prepared in a 6-step procedure starting from pyrrolotriazinecarboxylates (II; R₅₀ = alkyl, aryl; X₁ = halo). Thus, Et 4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate (preparation given) was stirred with NaOEt in EtOH at 0° for 1 h to give 98% Et 4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylate. The latter was stirred with MeMgBr in THF/Et₂O at 0° for 4 h to give 100% 2-(4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)propan-2-ol. This was stirred with H₂O₂/BF₃·Et₂O in CH₂Cl₂ at -3° to -40° to give 76% 4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol. Benzylation of the latter with PhCH₂Br/K₂CO₃ in DMF gave 6-benzyloxy-4-ethoxy-5-methylpyrrolo[2,1-f][1,2,4]triazine. Reflux of this with 1N HCl in EtOH gave 6-benzyloxy-4-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazine. This was added to a mixture prepared from 4-fluoro-2-methyl-1H-indol-5-ol and NaH in DMF at -20° followed by warming to room temperature to give 95% 6-benzyloxy-4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazine. Stirring of the latter with ammonium formate and Pd/C in DMF at room temperature for 2 h gave 64% 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-ol.


IT 649736-47-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(process for preparation of indolyloxypyrrolotriazines and their use as drugs)

RN 649736-47-0 HCAPLUS

CN 1H-Indole, 4-fluoro-2-methyl-5-(phenylmethoxy) - (9CI) (CA INDEX NAME)



L18 ANSWER 8 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2003:818147 HCAPLUS

DOCUMENT NUMBER: 139:323432

TITLE: Preparation of indole compounds for treating an

angiogenesis-related disorders
 INVENTOR(S): Hsieh, Hsing-pang; Liou, Jing-ping; Chang, Jang-yang;
 Chang, Chun-wei
 PATENT ASSIGNEE(S): National Health Research Institutes, Taiwan
 SOURCE: U.S. Pat. Appl. Publ., 31 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003195244	A1	20031016	US 2002-318337	20021212 <--
US 6933316	B2	20050823		
EP 1506960	A1	20050216	EP 2003-254909	20030807
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CA 2437104	AA	20050213	CA 2003-2437104	20030813
US 2005267194	A1	20051201	US 2005-195524	20050801
US 2005267108	A1	20051201	US 2005-195531	20050801
PRIORITY APPLN. INFO.:			US 2001-340317P	P 20011213
			US 2002-318337	A2 20021212
OTHER SOURCE(S):	MARPAT 139:323432			
GI				



AB The title compds. [I; L1 = CO; L2 = a bond; R1 = (hetero)aryl; R2 = H, aryl, heteroaryl, halo, etc.; R3-R6 = halo, nitro, nitroso, CN, etc.; or R4 and R5, R3 and R4, or R5 and R6 taken together are O(CH₂)_nO; R5 = H, alkyl, alkenyl, alkynyl, etc.; n = 1-5], were prepared Thus, treating 6-methoxyindole with ZnCl₂ and EtMgBr in CH₂Cl₂ in CH₂Cl₂ followed by addition of solution of 3,4,5-trimethoxybenzoyl chloride in CH₂Cl₂ and after 1

h
 AlCl₃ afforded 72% II. When tested in cell growth inhibition assay, at least 28 compds. I had IC₅₀ values of at least 5 μM and, unexpectedly, some of the test compds. had IC₅₀ values as low as <10 nM. The compds. I were tested in tubulin polymerization assay and results showed that a test indole


compound of 2 μM inhibited tubulin polymerization

IT **613679-40-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of indole compds. for treating an **angiogenesis** -related disorders)

RN 613679-40-6 HCAPLUS
 CN 1H-Indole, 5,6-bis(phenylmethoxy)-1-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



L18 ANSWER 9 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2003:796476 HCAPLUS
 DOCUMENT NUMBER: 139:307677
 TITLE: Preparation of indole derivatives for use as **angiogenesis** inhibitors
 INVENTOR(S): Arnould, Jean Claude
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 77 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082271	A2	20031009	WO 2003-GB1405	20030331 <--
WO 2003082271	A3	20040325		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1515716	A2	20050323	EP 2003-710036	20030331
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2005159474	A1	20050721	US 2003-509633	20030331
JP 2005532280	T2	20051027	JP 2003-579809	20030331
PRIORITY APPLN. INFO.:			EP 2002-290822	A 20020403
			WO 2003-GB1405	W 20030331
OTHER SOURCE(S):	MARPAT 139:307677			
GI				



AB The invention relates to the use of a compound of formula (I) [R1 = independently halo, HO or its ester, (un)substituted NH₂, alkanoylamino, OPO₃H₂, C1-4 alkoxy; X = O, S, SO, SO₂; R2 = H, C1-4 alkyl, C1-4 alkoxy; R3, R4 = H, C1-4 alkyl, C1-4 alkanoyl, C1-4 alkoxycarbonyl, C1-4 alkoxycarbonyl-C1-4 alkyl, C1-4 alkoxycarbonylamino, optionally alkylated amino, amino-C1-4 alkyl, CONH₂, carbamoyl-C1-4 alkyl, cyano, cyano-C1-4 alkyl, HO, hydroxy-C1-4 alkyl; R5 = H, C1-4 alkyl, a group of formula (CH₂)_tCO-Y-(CH₂)_r-Z-R8 (wherein Y = NH, O or a bond; Z = NH, O, CO, a bond; r = an integer from 0 to 4; t = 0, 1; R8 = H, C1-4 alkyl, C1-4 alkoxy, each (un)substituted aryl, 5 or 6 membered heterocyclyl, 5- or 6-membered heteroaryl); p = 0, 1; q = an integer from 0 to 3; with the proviso that: (i) when R3 is cyano then R4 cannot be an (un)substituted amino, and (ii) when q is 0, R3 is cyano and X is S then R4 is other than amino] or a salt, prodrug or solvate thereof, for the manufacture of a medicament to inhibit and/or reverse and/or alleviate symptoms of **angiogenesis** and/or any disease state associated with **angiogenesis**. The invention also relates to use of compds. I as medicaments and also to novel compds. I. The invention further provides pharmaceutical compns. of compds. I and processes for the synthesis of compds. I. A subset of the compds. I, e.g. 3-cyano-5-phenylsulfanyl-1H-indole, 3-cyano-5-phenoxy-1H-indole, 3-cyano-5-(4-hydroxyphenoxy)-1H-indole, 2-cyano-5-benzyloxy-1H-indole, 1-methyl-3-cyano-5-(4-hydroxy-3,5-dimethoxyphenoxy)-1H-indole, and 1-methyl-3-cyano-5-(4-phosphonoxy-3,5-dimethoxyphenoxy)-1H-indole, are also claimed.


IT 611228-61-6P 611228-64-9P 611228-65-0P
 611228-66-1P 611228-67-2P 611228-68-3P
 611228-70-7P 611228-71-8P 611228-72-9P
 611228-73-0P 611228-74-1P 611228-75-2P
 611228-76-3P 611228-77-4P 611228-79-6P
 611228-80-9P 611228-83-2P 611228-87-6P
 611228-88-7P 611228-91-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; preparation of indole derivs. for medicament to inhibit and/or reverse and/or alleviate symptoms of **angiogenesis** and/or any disease state associated with **angiogenesis**)

RN 611228-61-6 HCAPLUS

CN 1H-Indole-2-carboxamide, 1-methyl-5-[(3-nitrophenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 611228-64-9 HCAPLUS
 CN 1H-Indole-2-carboxamide, 5-[(3-nitrophenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 611228-65-0 HCAPLUS
 CN Pentanoic acid, 4-amino-5-[[3-[[[2-(aminocarbonyl)-1H-indol-5-yl]oxy]methyl]phenyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 611228-66-1 HCAPLUS
 CN Pentanoic acid, 5-[[3-[[[2-(aminocarbonyl)-1H-indol-5-yl]oxy]methyl]phenyl]amino]-4-[[[9H-fluoren-9-ylmethoxy]carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 611228-67-2 HCAPLUS
 CN Pentanoic acid, 4-amino-5-[[3-[[[2-(aminocarbonyl)-1-methyl-1H-indol-5-yl]oxy]methyl]phenyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 611228-68-3 HCAPLUS
CN 1H-Indole-3-acetamide, 5-[(3-nitrophenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 611228-70-7 HCAPLUS
CN 1H-Indole, 5-[4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 611228-71-8 HCAPLUS
CN 1H-Indole-1-carboxylic acid, 3-(aminocarbonyl)-5-[4-(phosphonooxy)phenoxy]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 611228-72-9 HCAPLUS
CN 1H-Indole-1-carboxylic acid, 3-(aminocarbonyl)-5-[4-(phenylmethoxy)phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 611228-73-0 HCAPLUS
 CN 1H-Indole-1-carboxylic acid, 3-(aminocarbonyl)-5-(4-hydroxyphenoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 611228-74-1 HCAPLUS
 CN 1H-Indole-1-carboxylic acid, 3-(aminocarbonyl)-5-[4-[[bis(phenylmethoxy)phosphinyl]oxy]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 611228-75-2 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 611228-76-3 HCAPLUS
 CN 1H-Indole-3-carboxamide, 1-methyl-5-[4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 611228-77-4 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 1-methyl-5-(3,4,5-trimethoxyphenoxy)- (9CI) (CA INDEX NAME)




RN 611228-79-6 HCAPLUS
 CN 1H-Indole, 5-(3,4,5-trimethoxyphenoxy)- (9CI) (CA INDEX NAME)




RN 611228-80-9 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-(3,4,5-trimethoxyphenoxy)- (9CI) (CA INDEX NAME)




RN 611228-83-2 HCAPLUS
CN 1H-Indole, 5-[(3,4-dimethoxyphenyl)thio]- (9CI) (CA INDEX NAME)



RN 611228-87-6 HCAPLUS
CN 1H-Indole-3-carboxamide, 5-[4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 611228-88-7 HCAPLUS
CN 1H-Indole-2-carboxamide, 5-[4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 611228-91-2 HCAPLUS
CN Pentanoic acid, 5-[[[3-[[[2-(aminocarbonyl)-1-methyl-1H-indol-5-yl]oxy]methyl]phenyl]amino]-4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester], (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 611228-36-5P 611228-37-6P 611228-46-7P
611228-57-0P 611228-58-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indole derivs. for medicament to inhibit and/or reverse and/or alleviate symptoms of **angiogenesis** and/or any disease state associated with **angiogenesis**)


RN 611228-36-5 HCAPLUS

CN 1H-Indole-2-carboxamide, 5-[(3-aminophenyl)methoxy]-1-methyl- (9CI) (CA INDEX NAME)




RN 611228-37-6 HCAPLUS

CN 1H-Indole-2-carboxamide, 5-[(3-aminophenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 611228-46-7 HCAPLUS


CN 1H-Indole-3-carbonitrile, 5-phenoxy- (9CI) (CA INDEX NAME)



RN 611228-57-0 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[(3,4-dimethoxyphenyl)thio]- (9CI) (CA INDEX NAME)



RN 611228-58-1 HCAPLUS
CN 1H-Indole-3-carbonitrile, 5-[(3,4-dimethoxyphenyl)thio]-1-methyl- (9CI) (CA INDEX NAME)




IT 611228-38-7P 611228-39-8P 611228-40-1P
611228-41-2P 611228-42-3P 611228-43-4P
611228-44-5P 611228-45-6P 611228-47-8P
611228-48-9P 611228-49-0P 611228-50-3P
611228-51-4P 611228-52-5P 611228-53-6P
611228-54-7P 611228-56-9P 611228-59-2P
611228-60-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indole derivs. for medicament to inhibit and/or reverse and/or alleviate symptoms of **angiogenesis** and/or any disease state associated with **angiogenesis**)

RN 611228-38-7 HCAPLUS
CN Pentanoic acid, 4-amino-5-[[3-[[[2-(aminocarbonyl)-1H-indol-5-yl]oxy]methyl]phenyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 611228-39-8 HCAPLUS


CN Pentanoic acid, 4-amino-5-[[3-[[[2-(aminocarbonyl)-1-methyl-1H-indol-5-yl]oxy]methyl]phenyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 611228-40-1 HCAPLUS


CN 1H-Indole-3-acetamide, 5-[(3-aminophenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 611228-41-2 HCAPLUS


CN Pentanoic acid, 4-amino-5-[[3-[[[3-(2-amino-2-oxoethyl)-1H-indol-5-yl]oxy]methyl]phenyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 611228-42-3 HCAPLUS


CN 1H-Indole-2-carboxamide, 6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 611228-43-4 HCAPLUS
 CN Ethanone, 1-(5-phenoxy-1H-indol-3-yl)- (9CI) (CA INDEX NAME)




RN 611228-44-5 HCAPLUS
 CN 1H-Indole-3-carboxylic acid, 5-(phenylthio)-, methyl ester (9CI) (CA INDEX NAME)



RN 611228-45-6 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-(phenylthio)- (9CI) (CA INDEX NAME)




RN 611228-47-8 HCAPLUS
 CN 1H-Indole-3-carboxamide, 5-phenoxy- (9CI) (CA INDEX NAME)




RN 611228-48-9 HCAPLUS

CN 1H-Indole-3-carboxamide, 5-(4-hydroxyphenoxy) - (9CI) (CA INDEX NAME)




RN 611228-49-0 HCAPLUS

CN 1H-Indole-3-carboxamide, 5-[4-(phosphonooxy)phenoxy] - (9CI) (CA INDEX NAME)




RN 611228-50-3 HCAPLUS

CN 1H-Indole-3-carbonitrile, 5-(4-hydroxyphenoxy) - (9CI) (CA INDEX NAME)




RN 611228-51-4 HCAPLUS

CN 1H-Indole-3-carboxamide, 5-(4-hydroxyphenoxy)-1-methyl- (9CI) (CA INDEX NAME)




RN 611228-52-5 HCAPLUS

CN 1H-Indole-2-carbonitrile, 5-(phenylmethoxy) - (9CI) (CA INDEX NAME)




RN 611228-53-6 HCAPLUS

CN 1H-Indole-3-carbonitrile, 5-(4-hydroxy-3,5-dimethoxyphenoxy)-1-methyl- (9CI) (CA INDEX NAME)




RN 611228-54-7 HCAPLUS

CN 1H-Indole-3-carbonitrile, 5-[3,5-dimethoxy-4-(phosphonooxy)phenoxy]-1-methyl- (9CI) (CA INDEX NAME)




RN 611228-56-9 HCAPLUS

CN 1H-Indole-2-carboxamide, 5-[(2,5-dimethoxyphenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 611228-59-2 HCAPLUS


CN 1H-Indole-3-carbonitrile, 5-[(3,4-dimethoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 611228-60-5 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 5-[(3,4-dimethoxyphenyl)sulfonyl]-1-methyl-
 (9CI) (CA INDEX NAME)




IT 78304-53-7, 5-Phenoxyindole 163258-14-8
 611228-90-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of indole derivs. for medicament to inhibit and/or reverse
 and/or alleviate symptoms of **angiogenesis** and/or any disease
 state associated with **angiogenesis**)
 RN 78304-53-7 HCAPLUS
 CN 1H-Indole, 5-phenoxy- (9CI) (CA INDEX NAME)



RN 163258-14-8 HCAPLUS
 CN 1H-Indole, 5-(phenylthio)- (9CI) (CA INDEX NAME)



RN 611228-90-1 HCAPLUS
 CN 1H-Indole-2-carboxamide, 5-phenoxy- (9CI) (CA INDEX NAME)




IT 611228-55-8P 611228-84-3P 611228-85-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indole derivs. for medicament to inhibit and/or reverse and/or alleviate symptoms of **angiogenesis** and/or any disease state associated with **angiogenesis**)

RN 611228-55-8 HCAPLUS


CN Phosphoric acid, 4-[[3-cyano-1-methyl-1H-indol-5-yl]oxy]-2,6-dimethoxyphenyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 611228-84-3 HCAPLUS

CN Pentanoic acid, 5-[[[3-[[[3-(2-amino-2-oxoethyl)-1H-indol-5-yl]oxy]methyl]phenyl]amino]-4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 611228-85-4 HCAPLUS

CN 4-Imidazolidinepropanoic acid, 1-[3-[[[3-(2-amino-2-oxoethyl)-1H-indol-5-yl]oxy]methyl]phenyl]-2,2-dimethyl-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 40047-22-1 133845-43-9 133845-45-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of indole derivs. for medicament to inhibit and/or reverse and/or alleviate symptoms of **angiogenesis** and/or any disease state associated with **angiogenesis**)


RN 40047-22-1 HCAPLUS

CN 1H-Indole-2-carboxylic acid, 6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 133845-43-9 HCAPLUS

CN 1H-Indole-2-carboxamide, 5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 133845-45-1 HCAPLUS

CN 1H-Indole-2-carboxamide, 1-methyl-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L18 ANSWER 10 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:356415 HCAPLUS

DOCUMENT NUMBER: 138:368759

TITLE: Preparation of 2-acylindoles as tubulin polymerization inhibitors for the treatment of metastatic tumors

INVENTOR(S): Beckers, Thomas; Mahboobi, Siavosh; Pongratz, Herwig; Frieser, Markus; Hufsky, Harald; Hockemeyer, Joerg; Vanhoefer, Udo

PATENT ASSIGNEE(S): Baxter Healthcare SA, Switz.

SOURCE: PCT Int. Appl., 110 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003037861	A1	20030508	WO 2002-EP11883	20021024 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10152306	A1	20030724	DE 2001-10152306	20011026 <--
EP 1442015	A1	20040804	EP 2002-802302	20021024 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516895	T2	20050609	JP 2003-540143	20021024
PRIORITY APPLN. INFO.:			DE 2001-10152306	A 20011026
			WO 2002-EP11883	W 20021024
OTHER SOURCE(S):			MARPAT 138:368759	
GI				



I



II



III

AB Title compds. I [R1 = H, alkylcarbonyl, e.g., acetyl, alkyl etc.; R2 = H, halo, CN, etc.; A = B, C, D = independently for a N or C with provisos; Y = electron pair, H, halo with provisos; X = O, S, NH, etc.] and their pharmaceutically acceptable salts were prepared For example, sodium hydroxide mediated deprotection of N-sulfone II, e.g., prepared from benzoyl chloride and 5-methoxy-1-(phenylsulfonyl)-1H-indole, afforded acylindole III. In tubulin polymerization inhibition studies, 8-examples of I exhibited IC50 values ranging from 0.53->10 µM, e.g., the IC50 value of acylindole III was 0.53 µM. Compds. I are claimed useful for the treatment of therapy-resistant and metastatic tumors.

IT 370580-71-5P 370580-74-8P 370580-77-1P
370580-78-2P 370580-81-7P 370580-83-9P
521309-87-5P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of acylindoles as tubulin polymerization inhibitors

for the treatment of metastatic tumors)


RN 370580-71-5 HCAPLUS

CN 1H-Indole, 2-(3-chlorobenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI)
(CA INDEX NAME)




RN 370580-74-8 HCAPLUS

CN 1H-Indole, 2-(4-chlorobenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI)
(CA INDEX NAME)




RN 370580-77-1 HCAPLUS

CN 1H-Indole, 2-(4-methoxybenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 370580-78-2 HCAPLUS

CN 1H-Indole, 5-(phenylmethoxy)-1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)




RN 370580-81-7 HCAPLUS

CN 1H-Indole, 2-(2-methoxybenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 370580-83-9 HCAPLUS

CN 1H-Indole, 2-(3-methoxybenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 521309-87-5 HCAPLUS
 CN 1H-Indole, 2-(3-amino-2-methylbenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




IT 370581-40-1P 370581-41-2P 370581-42-3P
 370581-43-4P 370581-44-5P 370581-45-6P
 521309-93-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of acylindoles as tubulin polymerization inhibitors

for the treatment of metastatic tumors)


RN 370581-40-1 HCAPLUS
 CN Methanone, (3-chlorophenyl) [5-(phenylmethoxy)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 370581-41-2 HCAPLUS
 CN Methanone, (4-chlorophenyl) [5-(phenylmethoxy)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 370581-42-3 HCAPLUS
 CN Methanone, (4-methoxyphenyl) [5-(phenylmethoxy)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 370581-43-4 HCAPLUS
 CN Methanone, [5-(phenylmethoxy)-1H-indol-2-yl] (3,4,5-trimethoxyphenyl) - (9CI) (CA INDEX NAME)




RN 370581-44-5 HCAPLUS
 CN Methanone, (2-methoxyphenyl) [5-(phenylmethoxy)-1H-indol-2-yl] - (9CI) (CA INDEX NAME)



RN 370581-45-6 HCAPLUS
 CN Methanone, (3-methoxyphenyl) [5-(phenylmethoxy)-1H-indol-2-yl] - (9CI) (CA INDEX NAME)



RN 521309-93-3 HCAPLUS
 CN Methanone, (3-amino-2-methylphenyl) [5-(phenylmethoxy)-1H-indol-2-yl] - (9CI) (CA INDEX NAME)



IT 170147-24-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of acylindoles as tubulin polymerization inhibitors for the treatment

of metastatic tumors)

RN 170147-24-7 HCAPLUS

CN 1H-Indole, 5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:5957 HCAPLUS

DOCUMENT NUMBER: 138:55984

TITLE: Preparation of azaindoles as protein kinase inhibitors

INVENTOR(S): Cox, Paul Joseph; Majid, Tahir Nadeem; Lai, Justine
Yeun Quai; Morley, Andrew; Amendola, Shelley; Deprets,
Stephanie Daniele; Edlin, Chris; Gardner, Charles J.;
Kominos, Dorothea; Pedgrift, Brian Leslie; Halley,
Frank; Gillespy, Timothy Alan; Edwards, Michael;
Clerc, Francois Frederic; Nemecek, Conception;
Houille, Olivier; Damour, Dominique; Bouchard, Herve;
Bezard, Daniel; Carrez, Chantal

PATENT ASSIGNEE(S): Aventis Pharma Limited, UK

SOURCE: PCT Int. Appl., 373 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000688	A1	20030103	WO 2002-GB2799	20020620 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2451678	AA	20030103	CA 2002-2451678	20020620 <--
EP 1397360	A1	20040317	EP 2002-730531	20020620 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EE 200400015	A	20040415	EE 2004-15	20020620 <--
BR 2002010507	A	20040615	BR 2002-10507	20020620 <--
SI 21462	C	20041031	SI 2002-20015	20020620
JP 2004534826	T2	20041118	JP 2003-507091	20020620
US 2004053931	A1	20040318	US 2002-177804	20020621 <--
US 6897207	B2	20050524		
ZA 2003009648	A	20050311	ZA 2003-9648	20031211
BG 108481	A	20050531	BG 2003-108481	20031219
US 2005267304	A1	20051201	US 2004-995103	20041123
PRIORITY APPLN. INFO.:			GB 2001-15109	A 20010621
			US 2001-300257P	P 20010622
			WO 2002-GB2799	W 20020620
			US 2002-177804	A1 20020621

OTHER SOURCE(S): MARPAT 138:55984
 GI



AB The invention is directed to physiologically active azaindoles (shown as I; variables defined below; e.g. 6-(5-methoxy-1-methyl-1H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine) and compounds containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs. Such compounds and compounds have valuable pharmaceutical properties, in particular the ability to inhibit kinases, especially Syk, FAK, KDR, Aurora2 and IGF1R (data given in general rather than for specific I). Although the methods of preparation are not claimed, >100 example preparations of intermediates and I are included. For I: R1 = aryl or heteroaryl each optionally substituted by ≥1 groups = alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, R4, -C(O)R, -C(O)OR5, -C(O)NY1Y2, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)C(O)OR7, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -SO2NY1Y2 and -Z2R. R2 = H, acyl, cyano, halo, lower alkenyl, -Z2R4, -SO2NY3Y4, -NY1Y2 or lower alkyl optionally substituted by aryl, cyano, heteroaryl, heterocycloalkyl, hydroxy, -Z2R4, -C(O)NY1Y2, -C(O)R, -CO2R8, -NY3Y4, -N(R6)C(O)R, -N(R6)C(O)NY1Y2, -N(R6)C(O)OR7, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -SO2NY1Y2 and ≥1 halogen atoms. R3 = H, aryl, cyano, halo, heteroaryl, lower alkyl, -Z2R4, -C(O)OR5 or -C(O)NY3Y4. R4 = alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO (or a 5- 6- or 7-membered cyclic acetal derivative thereof), -C(O)NY1Y2, -C(O)OR5, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -Z3R7 and ≥1 hydroxy, alkoxy and carboxy. R5 = H, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl. R6 = H or lower alkyl; R7 = alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8 = H or lower alkyl. R = aryl or heteroaryl;

alkenyl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO (or a 5- 6- or 7-membered cyclic acetal derivative thereof), -C(O)NY₁Y₂, -C(O)OR₅, -NY₁Y₂, -N(R₆)C(O)R₇, -N(R₆)C(O)NY₃Y₄, -N(R₆)SO₂R₇, -N(R₆)SO₂NY₃Y₄, -Z₃R₇ and ≥1 hydroxy, alkoxy and carboxy. X₁ = N, CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-halo, C-CN, C-R₄, CNY₁Y₂, COH, CZ₂R, CC(O)R, CC(O)OR₅, CC(O)NY₁Y₂, CN(R₈)C(O)R, CN(R₆)C(O)OR₇, CN(R₆)C(O)NY₃Y₄, CN(R₆)SO₂NY₃Y₄, CN(R₆)SO₂R, CSO₂NY₃Y₄, C-NO₂, or C-alkenyl or C-alkynyl optionally substituted by ≥1 aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, -C(O)NY₁Y₂, -C(O)OR₅, -NNY₁Y₂, -N(R₆)C(O)R₇, -N(R₆)C(O)NY₃Y₄, -N(R₆)C(O)OR₇, -N(R₆)SO₂R₇, -N(R₆)SO₂NY₃Y₄, -SO₂NY₁Y₂ and -Z₂R₄. Y₁ and Y₂ = H, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by ≥1 aryl, halo, heteroaryl, heterocycloalkyl, hydroxy, -C(O)NY₃Y₄, -C(O)OR₅, NY₃Y₄, -N(R₆)C(O)R₇, -N(R₆)C(O)NY₃Y₄, -N(R₆)SO₂R₇, -N(R₆)SO₂NY₃Y₄ and -OR₇, or the group -NY₁Y₂ may form a cyclic amine. Y₃ and Y₄ = H, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY₃Y₄ may form a cyclic amine; Z₁ = O or S; Z₂ = O or S(O)_n; Z₃ = O, S(O)_n, NR₆; n = 0-2.


IT 2426-59-7, 6-Benzyloxy-5-methoxyindole 4790-04-9,
5-Benzyloxy-6-methoxyindole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of azaindoles as protein kinase inhibitors with therapeutic uses)


RN 2426-59-7 HCAPLUS

CN 1H-Indole, 5-methoxy-6-(phenylmethoxy) - (9CI) (CA INDEX NAME)



RN 4790-04-9 HCAPLUS


CN 1H-Indole, 6-methoxy-5-(phenylmethoxy) - (9CI) (CA INDEX NAME)



IT 348640-14-2P, 5-Benzyloxy-3-bromo-6-methoxyindole-1-carboxylic acid tert-butyl ester 348640-22-2P, 2-(5-Benzyloxy-6-methoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 348640-33-5P, 2-(5-Benzyloxy-6-methoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 479552-89-1P, 6-Benzyloxy-3-iodo-5-methoxyindole-1-carboxylic acid tert-butyl ester 479552-90-4P, 2-(6-Benzyloxy-5-methoxy-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine 479552-91-5P, 2-(6-Benzyloxy-5-methoxy-1-methyl-1H-indol-3-yl)-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azaindoles as protein kinase inhibitors with therapeutic uses)


RN 348640-14-2 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 3-bromo-6-methoxy-5-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 348640-22-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-[6-methoxy-5-(phenylmethoxy)-1H-indol-3-yl]-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 348640-33-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-[6-methoxy-1-methyl-5-(phenylmethoxy)-1H-indol-3-yl]-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 479552-89-1 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 3-iodo-5-methoxy-6-(phenylmethoxy)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 479552-90-4 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-[5-methoxy-6-(phenylmethoxy)-1H-indol-3-yl]-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 479552-91-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2-[5-methoxy-1-methyl-6-(phenylmethoxy)-1H-indol-3-yl]-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 12 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:927188 HCAPLUS

DOCUMENT NUMBER: 138:14005

TITLE: Preparation of 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors

INVENTOR(S): Cui, Jingrong; Ramphal, Yudhi; Liang, Congxin; Sun, Li; Wei, Chung Chen; Tang, Peng Cho

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 479 pp.
CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096361	A2	20021205	WO 2002-US16841	20020530 <--
WO 2002096361	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003125370	A1	20030703	US 2002-157007	20020530 <--
US 6599902	B2	20030729		
PRIORITY APPLN. INFO.:			US 2001-294544P	P 20010530
			US 2001-328408P	P 20011010
OTHER SOURCE(S):			MARPAT 138:14005	
GI				



AB The present invention relates to certain 5-aralkylsulfonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivs. (shown as I; see below for variable definitions; e.g. 2,4-dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-(3Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide) that inhibit kinases (no data), in particular met kinase. Pharmaceutical compns. comprising these compds., methods of treating diseases mediated by kinases using pharmaceutical compns. comprising these compds., and methods of preparing them are also disclosed.

In I: n = 0-2; m = 1-3; R1 and R2 = H or alkyl; R3, R4, and R5 = H, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, alkoxycarbonyl, haloalkoxy, cyano, carboxy, carboxyalkyl, nitro, aryl, aryloxy, heteroaryl, heteroaryloxy, -(alkylene)-CONR10R11, -CONR10R11, or -NR10R11 (R10 is H or alkyl, and R11 is aryl, heteroaryl, heterocycle, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, aralkyl, or heterocyclalkyl wherein the alkyl chain in aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, aralkyl, heteroaralkyl, or heterocyclalkyl is optionally substituted with one or two hydroxy, or R10 and R11 together with the N atom to which they are attached combine to form saturated or unsatd. heterocycloamino). R6 is H, alkyl, cycloalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, heterocyclalkyl, aryl, heteroaryl, carboxy, alkoxycarbonyl, heterocyclcarbonyl, aminoalkylcarbonyl, alkylaminoalkylcarbonyl, dialkylaminoalkylcarbonyl, -CONR10R11 or -(alkylene)-CONR10R11. R7 and R8 = H, alkyl, cycloalkyl, heterocyclalkyl, -COR12, -(alkylene)-COR12 (R12 = alkoxy, hydroxy, or heterocycle, alkylamino, dialkylamino), -SO2R14, -CONR13R14, or -(alkylene)-CONR13R14 (R13 is H or alkyl, and R14 is aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, hydroxyalkyl, acetylalkyl, cyanoalkyl, carboxyalkyl, alkoxycarbonylalkyl, heteroaralkyl, or heterocyclalkyl wherein the alkyl chain in aminoalkyl, heteroaralkyl, heterocyclalkyl, or heterocyclalkyl is optionally substituted with one or two hydroxy group(s), or when R13 and R14 are attached to a N atom R13 and R14 together with the N atom to which they are attached form saturated or unsatd. heterocycloamino). R6 and R7 or R7 and R8 can combine to form a saturated or unsatd. 5 to 8 membered ring; and R9 is: H or alkyl; -PO(OR15)2 where each R15 = H or alkyl; -COR16 where R16 is H or alkyl; or -CHR17NR18R19 where R17 is H or alkyl, and R18 and R19 = H or alkyl or R18 and R19 together with the N atom to which they are attached form heterocycloamino. Although the methods of preparation are not claimed, 375 example preps. of I plus addnl. preps. of intermediates are included.


IT **477574-57-5P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid
477574-82-6P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
477574-92-8P, 2-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid
477574-93-9P, [5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetic acid
477575-20-5P, 5-[5-(2,6-Dimethylphenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
477575-21-6P, 5-[5-(2,3-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
477575-28-3P, [2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrol-3-yl]acetic acid
477575-66-9P, 3-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]propionic acid
477575-81-8P, 5-[5-(3,5-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
477575-83-0P, 5-[5-(2,5-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
477576-36-6P, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-piperazin-1-yl)ethyl)acetamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate; preparation of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and other disorders)

RN 477574-57-5 HCAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 477574-82-6 HCAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-[[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-92-8 HCAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2-[(Z)-[5-[[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-93-9 HCAPLUS

CN 1H-Pyrrole-3-acetic acid, 5-[(Z)-[5-[[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

INDEX NAME)


Double bond geometry as shown.



RN 477575-20-5 HCAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-[[[(2,6-dimethylphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-21-6 HCAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-[[[(2,3-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-28-3 HCAPLUS

CN 1H-Pyrrole-3-acetic acid, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-66-9 HCAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-81-8 HCAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-[(3,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-83-0 HCAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-[(2,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-36-6 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 477573-60-7P, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide 477573-61-8P, 5-[5-(2-Cyanophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide 477573-62-9P, 2,4-Dimethyl-5-[2-oxo-5-(3-trifluoromethylphenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide 477573-63-0P, 5-[5-(3-Methoxyphenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide 477573-64-1P, 2-[[[3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl) carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]benzonitrile 477573-65-2P, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl) carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(3-methoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one 477573-66-3P, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl) carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one 477573-67-4P, 2,4-Dimethyl-5-[5-(2-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl) amide 477573-68-5P, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-[1,2,3]triazol-1-ylethyl) amide 477573-69-6P, 2,4-Dimethyl-5-[5-(2-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-

(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-[1,2,3]triazol-1-ylethyl)amide **477573-70-9P**, 3-[1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477573-71-0P**, 4-[[[3-[1-(3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]benzoic acid **477573-72-1P**, [4-[[[3-[1-(3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]phenyl]acetic acid **477573-73-2P**, 4-[[[3-[1-(3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]-3-nitrobenzoic acid **477573-74-3P**, 4-[[[3-[1-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]benzoic acid **477573-75-4P**, [4-[[[3-[1-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]phenyl]acetic acid **477573-76-5P**, 4-[[[3-[1-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]-3-nitrobenzoic acid **477573-77-6P**, 3-[1-(3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1-methyl-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477573-78-7P**, 5-[5-(3,5-Dibromo-2-hydroxyphenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-79-8P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-[1,2,3]triazol-1-ylethyl)amide **477573-80-1P**, 2,4-Dimethyl-5-(4-methyl-2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-81-2P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-4-methyl-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-82-3P**, 5-[5-(2-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-83-4P**, 4-[[[3-[1-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]benzoic acid methyl ester **477573-84-5P**, 5-[5-(4-Trifluoromethoxyphenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-85-6P**, 5-[2,4-Bis(trifluoromethyl)phenylmethanesulfonyl]-3-[1-(3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477573-86-7P**, 5-[5-[2,4-Bis(trifluoromethyl)phenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-87-8P**, 5-(4-Bromophenylmethanesulfonyl)-3-[1-(3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477573-88-9P**, 5-[5-(4-Bromophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-89-0P**, 5-[5-(2-Iodophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-90-3P**, 3-[1-(3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2-iodophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-91-4P**, 5-[5-(4-Cyanophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-92-5P**, 4-[[[3-[1-(3,5-Dimethyl-

4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl)methyl]benzonitrile **477573-93-6P**, 3-[[[3-[1-[4-(2-Diethylaminoethylcarbamoyl)-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl)methyl]benzoic acid methyl ester **477573-94-7P**, 3-[[[3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl)methyl]benzoic acid methyl ester **477573-95-8P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(3-trifluoromethoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-96-9P**, 2,4-Dimethyl-5-[2-oxo-5-(3-trifluoromethoxyphenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-97-0P**, 3-[[[3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl)methyl]benzonitrile **477573-98-1P**, 5-[5-(3-Cyanophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477573-99-2P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-m-tolylmethanesulfonyl-1,3-dihydroindol-2-one **477574-00-8P**, 2,4-Dimethyl-5-(2-oxo-5-m-tolylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-01-9P**, 5-(3-Chlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-02-0P**, 5-[5-(2,4-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-03-1P**, 5-(4-tert-Butylphenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-04-2P**, 5-[5-(4-tert-Butylphenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-05-3P**, 5-(2,6-Difluorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-06-4P**, 5-[5-(2,6-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-07-5P**, 5-(3-Bromophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-08-6P**, 5-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-09-7P**, 5-(2,4-Difluorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-10-0P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(4-nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-11-1P**, 2,4-Dimethyl-5-[5-(4-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-12-2P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(3-nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-13-3P**, 2,4-Dimethyl-5-[5-(3-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-14-4P**, 5-[5-(3-Bromophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-15-5P**, 5-(3,5-Difluorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-

methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-16-6P**, 5-[5-(3,5-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-17-7P**, 5-(3,4-Difluorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-18-8P**, 5-[5-(3,4-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-19-9P**, 5-[2,5-Bis(trifluoromethyl)phenylmethanesulfonyl]-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-20-2P**, 5-[5-[2,5-Bis(trifluoromethyl)phenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-21-3P**, 5-[3,5-Bis(trifluoromethyl)phenylmethanesulfonyl]-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-22-4P**, 5-[5-[3,5-Bis(trifluoromethyl)phenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-23-5P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-hydroxy-5-nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-24-6P**, 5-[5-(2-Hydroxy-5-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-25-7P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-methoxy-5-nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-26-8P**, 5-[5-(2-Methoxy-5-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-27-9P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-28-0P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-29-1P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(3-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-30-4P**, 5-[5-(3-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-31-5P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(4-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-32-6P**, 5-[5-(4-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-33-7P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(4-trifluoromethylmethoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-34-8P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-trifluoromethylphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-35-9P**, 2,4-Dimethyl-5-[2-oxo-5-(2-trifluoromethylphenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-36-0P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(3-trifluoromethylphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-37-1P**, 2,4-Dimethyl-5-[2-oxo-5-(4-

trifluoromethylphenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-38-2P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(4-trifluoromethylphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-39-3P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-pentafluorophenylmethanesulfonyl-1,3-dihydroindol-2-one **477574-40-6P**, 2,4-Dimethyl-5-(2-oxo-5-pentafluorophenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-41-7P**, 5-(2,5-Difluorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-42-8P**, 5-[5-(2,5-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-43-9P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,3,6-trifluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-44-0P**, 2,4-Dimethyl-5-[2-oxo-5-(2,3,6-trifluorophenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-45-1P**, 5-(2,3-Difluorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-46-2P**, 5-[5-(2,3-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-47-3P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-48-4P**, 5-(Biphenyl-2-ylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-49-5P**, 5-[5-(Biphenyl-2-ylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-50-8P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluoro-6-nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-51-9P**, 5-[5-(2-Fluoro-6-nitrophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-52-0P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-[2-(2-fluorophenoxy)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477574-53-1P**, 5-[5-[2-(2-Fluorophenoxy)phenylmethanesulfonyl]-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-54-2P**, 5-(2-Chlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-55-3P**, 5-[5-(4-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-56-4P**, 5-(4-Chlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-58-6P**, 4-[[[3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-2-oxo-2,3-dihydro-1H-indol-5-yl]sulfonyl]methyl]benzoic acid methyl ester **477574-59-7P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-carboxylic acid (3-diethylamino-2-hydroxypropyl)amide **477574-60-0P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl)-1,2-dihydroindol-3-(Z)-ylidenemethyl]-1H-pyrrole-3-

carboxylic acid [2-(2H-tetrazol-5-yl)ethyl]amide **477574-61-1P**,
5-Methyl-2-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide **477574-62-2P**, 5-Methyl-2-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (3-[1,2,3]triazol-1-ylpropyl)amide **477574-63-3P**,
3-[1-[(R)-[(3-Dimethylaminopyrrolidin-1-yl)carbonyl]-5-methyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477574-64-4P**, 4-Methyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-65-5P**, 2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **477574-66-6P**,
2,4-Dimethyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diisopropylaminoethyl)amide **477574-67-7P**, 5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **477574-68-8P**,
5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-69-9P**, 2-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide **477574-70-2P**,
5-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diisopropylaminoethyl)amide **477574-71-3P**, 2-[5-(2-Fluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3-[1,2,3]triazol-1-ylpropyl)amide **477574-72-4P**,
3-[1-[4-[(3R*,5S*)-3,5-Dimethylpiperazin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477574-73-5P**, 3-[1-[4-[(3R*,5S*)-3,5-Dimethylpiperazin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477574-74-6P**,
5-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-4-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477574-75-7P**, 2-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide **477574-76-8P**,
2-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3-[1,2,3]triazol-1-ylpropyl)amide **477574-77-9P**, 5-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyrrolidin-1-yl)ethyl)amide **477574-78-0P**,
5-[5-(3-Chlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diisopropylaminoethyl)amide **477574-79-1P**, 5-(3-Chlorophenylmethanesulfonyl)-3-[1-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-80-4P**,
5-(3-Chlorophenylmethanesulfonyl)-3-[1-[3-[(R)-3-dimethylaminopyrrolidin-1-yl)carbonyl]-5-methyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-81-5P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-(3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-83-7P**,
5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[5-methyl-3-[(morpholin-4-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-84-8P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[5-methyl-3-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one

477574-85-9P, 2-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid methyl(1-methylpiperidin-4-yl)amide **477574-86-0P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[5-methyl-3-(4-(pyrrolidin-1-yl)piperidin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-87-1P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(S)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-88-2P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(morpholin-4-yl)propyl)amide **477574-89-3P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-[1,2,3]triazol-1-ylpropyl)amide **477574-90-6P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3-oxopiperazin-1-yl)ethyl]amide **477574-91-7P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-94-0P**, 2-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid [2-(3-oxopiperazin-1-yl)ethyl]amide **477574-95-1P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3-[(4-hydroxypiperidin-1-yl)carbonyl]-5-methyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-96-2P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3-[(3-diethylaminopyrrolidin-1-yl)carbonyl]-5-methyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-97-3P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-98-4P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477574-99-5P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(morpholin-4-yl)methyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-00-1P**, 3-[1-[4-[(R)-2-[(Cyclopropylamino)methyl]pyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477575-04-5P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(S)-2-[(R)-3-fluoropyrrolidin-1-yl)methyl]pyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-09-0P**,
 3-[1-[4-[(4-Cyclopropylaminopiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477575-11-4P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxyethyl)amide **477575-13-6P**, 2-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-[1,2,3]triazol-1-ylpropyl)amide **477575-15-8P**,
 2-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(morpholin-4-yl)propyl)amide **477575-16-9P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid methyl(1-methylpiperidin-4-yl)amide **477575-17-0P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(3-diethylaminopyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-18-1P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3-[(3R,5S)-3,5-dimethylpiperazin-1-yl)carbonyl]-5-methyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-


1,3-dihydroindol-2-one **477575-22-7P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(3-oxopiperazin-1-yl)ethyl]acetamide **477575-23-8P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-24-9P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(2-(morpholin-4-yl)-2-oxoethyl)-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-25-0P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(R)-3-hydroxypyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-26-1P**, 3-[1-[3,5-Dimethyl-4-[(morpholin-4-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dimethylphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477575-27-2P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-((3R,5S)-3,5-dimethylpiperazin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-29-4P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-30-7P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-(4-(ethylpropylamino)piperidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-31-8P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-diethylaminoethyl)acetamide **477575-32-9P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-methyl-N-(1-methylpiperidin-4-yl)acetamide **477575-33-0P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-(3-diethylaminopyrrolidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-34-1P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-(pyrrolidin-1-yl)ethyl)acetamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and other disorders)

RN 477573-60-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-61-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2-cyanophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-62-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-63-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[[3-methoxyphenyl]methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-64-1 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[2-cyanophenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-65-2 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[[(3-methoxyphenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-66-3 HCAPLUS


CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[[(2-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-67-4 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[2-(2-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-68-5 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-69-6 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-5-[[[2-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-70-9 HCAPLUS
 CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-[(phenylmethyl)sulfonyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-71-0 HCAPLUS
 CN Benzoic acid, 4-[[[(3Z)-3-[[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-72-1 HCAPLUS

CN Benzeacetic acid, 4-[[[(3Z)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-73-2 HCAPLUS

CN Benzoic acid, 4-[[[(3Z)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]-3-nitro- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-74-3 HCAPLUS

CN Benzoic acid, 4-[[[(3E)-3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-75-4 HCAPLUS

CN Benzeneacetic acid, 4-[[[(3Z)-3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—NEt₂


RN 477573-76-5 HCAPLUS
 CN Benzoic acid, 4-[[[(3Z)-3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]-3-nitro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-77-6 HCAPLUS
 CN Piperazine, 1-[[[5-[(Z)-[1,2-dihydro-1-methyl-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-78-7 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(3,5-dibromo-2-hydroxyphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-79-8 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(1H-1,2,3-triazol-1-yl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-80-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-4-methyl-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-81-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-4-methyl-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-82-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-83-4 HCAPLUS

CN Benzoic acid, 4-[[[(3Z)-3-[[4-[[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


—NEt₂

RN 477573-84-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—NET₂


RN 477573-85-6 HCAPLUS
 CN Piperazine, 1-[[5-[(Z)-[5-[[[2,4-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-86-7 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[2,4-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-87-8 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[4-bromophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-88-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[4-bromophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477573-89-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[2-iodophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-

dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-90-3 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[[(2-iodophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-91-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(4-cyanophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-92-5 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[4-(4-cyanophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-93-6 HCAPLUS

CN Benzoic acid, 3-[[[(3Z)-3-[[4-[[2-(diethylamino)ethyl]amino]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



PAGE 1-A


PAGE 1-B

—Net₂

RN 477573-94-7 HCAPLUS


CN Benzoic acid, 3-[[[(3Z)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477573-95-8 HCAPLUS
 CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[[[3-(trifluoromethoxy)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-96-9 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[[3-(trifluoromethoxy)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—NEt₂

RN 477573-97-0 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[(3-cyanophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-98-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(3-cyanophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477573-99-2 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[[(3-methylphenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-00-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[[(3-methylphenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-01-9 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-

methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-02-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[2,4-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-03-1 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-04-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[[4-(1,1-dimethylethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-05-3 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[2,6-difluorophenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-06-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-07-5 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[(3-bromophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-08-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-09-7 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[(2,4-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-10-0 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[4-(2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]-2-oxo-3H-indol-3-ylidene]methyl]sulfonyl]-2-fluorophenyl]methyl]piperazine (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-11-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[4-(2,4-dimethyl-1H-pyrrol-3-yl)carbonyl]-2-oxo-3H-indol-3-ylidene]methyl]sulfonyl]-2-nitrophenyl]methyl]piperazine (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-12-2 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[3-(3-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-13-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[3-(3-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-14-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[3-(3-bromophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-

dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-15-5 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[3,5-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-16-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[[(3,5-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-17-7 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[(3,4-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-18-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(3,4-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-19-9 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[2,5-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-20-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[2,5-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-21-3 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-22-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-23-5 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[2-(hydroxy-5-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-24-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[2-(hydroxy-5-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-25-7 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[2-methoxy-5-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-26-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-5-[[2-methoxy-5-nitrophenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-27-9 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[2-(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-28-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[2-(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-29-1 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[3-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-30-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[3-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-31-5 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[4-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-32-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[4-(4-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-33-7 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-34-8 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-35-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-36-0 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-37-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-38-2 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[[[4-(trifluoromethyl)phenyl]methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-

Grazier 10_509633

dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-39-3 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[[pentafluorophenyl)methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-40-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[pentafluorophenyl)methyl]sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-41-7 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[2,5-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-42-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[2,5-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-43-9 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[[2,3,6-trifluorophenyl)methyl]sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-44-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[[2,3,6-trifluorophenyl)methyl]sulfonyl]-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-45-1 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[2,3-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-46-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[2,3-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-47-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-48-4 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[1,1'-biphenyl]-2-ylmethyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-49-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[1,1'-biphenyl]-2-ylmethyl)sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-50-8 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[2-fluoro-6-nitrophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-

yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-51-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[2-(2-fluoro-6-nitrophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-52-0 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[2-(2-fluorophenoxy)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-53-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[[[2-(2-fluorophenoxy)phenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-54-2 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[2-chlorophenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-55-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[4-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-56-4 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[4-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-58-6 HCAPLUS

CN Benzoic acid, 4-[[[(3Z)-3-[[3,5-dimethyl-4-[(4-methyl-1-piperazinyl)carbonyl]-1H-pyrrol-2-yl]methylene]-2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-59-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(diethylamino)-2-hydroxypropyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-60-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1H-tetrazol-5-yl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-61-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1H-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-62-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1H-

1,2,3-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-63-3 HCAPLUS

CN 1H-Pyrrole, 2-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-1-[[3-(dimethylamino)-1-pyrrolidiny]carbonyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 477574-64-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-65-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-

pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-66-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-67-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-68-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[5-[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-69-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-70-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-5-[(Z)-[5-

Grazier 10_509633

[[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-71-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1H-1,2,3-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-72-4 HCAPLUS

CN Piperazine, 1-[[[5-[(Z)-[5-[[[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)-rel]-1H-1,2,3-triazol-1-yl]propyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 477574-73-5 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 477574-74-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-75-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-76-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1H-1,2,3-triazol-1-yl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-77-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-78-0 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, N-[2-[(bis(1-methylethyl)amino)ethyl]-5-[(Z)-[5-[[3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—N(Pr-i)₂

RN 477574-79-1 HCAPLUS
 CN Piperazine, 1-[[5-[(Z)-[5-[[3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
 Double bond geometry as shown.



RN 477574-80-4 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[2-[(Z)-[5-[[3-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-81-5 HCAPLUS

CN 2H-Indol-2-one, 5-[[2-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-83-7 HCAPLUS

CN Morpholine, 4-[[2-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI)

(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-84-8 HCAPLUS

CN Piperazine, 1-[[2-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-85-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,5-dimethyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-86-0 HCAPLUS

CN Piperidine, 1-[[2-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-87-1 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-88-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-89-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-90-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-91-7 HCAPLUS

CN 4-Piperidinol, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-94-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-95-1 HCAPLUS

CN 4-Piperidinol, 1-[[2-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-96-2 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[2-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-N,N-diethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-97-3 HCAPLUS

CN Piperidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477574-98-4 HCAPLUS


CN Piperazine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477574-99-5 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-3-[[3,5-dimethyl-4-(4-morpholinylmethyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-00-1 HCAPLUS
 CN 2-Pyrrolidininemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




RN 477575-04-5 HCAPLUS
 CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[[3R)-3-fluoro-1-pyrrolidinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 477575-09-0 HCAPLUS
 CN 4-Piperidinamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-11-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2-hydroxyethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-13-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-5-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-15-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-5-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-16-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-17-0 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-N,N-diethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-18-1 HCAPLUS

CN Piperazine, 1-[[2-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 477575-22-7 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-23-8 HCAPLUS

CN 4-Piperidinol, 1-[[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-24-9 HCAPLUS

CN Morpholine, 4-[[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-25-0 HCAPLUS

CN 3-Pyrrolidinol, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-26-1 HCAPLUS

CN Morpholine, 4-[[5-[(Z)-[5-[[2,6-dimethylphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-27-2 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-3,5-dimethyl-, (3R,5S)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 477575-29-4 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-30-7 HCAPLUS

CN 4-Piperidinamine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-N-ethyl-N-propyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-31-8 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(diethylamino)ethyl]-2,4-dimethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-32-9 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl-N-(1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-33-0 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-N,N-diethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-34-1 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 477575-35-2P, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-

dimethyl-4-((S)-2-[(morpholin-4-yl)methyl]pyrrolidin-1-ylcarbonyl)-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-36-3P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-[(S)-2-[(ethylpropylamino)methyl]pyrrolidin-1-yl]-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-37-4P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-hydroxy-3-(morpholin-4-yl)propyl)acetamide **477575-38-5P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-hydroxy-3-[1,2,3]triazol-1-ylpropyl)acetamide **477575-39-6P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(R)-2-methoxymethylpyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-40-9P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(S)-2-methoxymethylpyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-41-0P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(R)-2-hydroxymethylpyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-42-1P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(S)-2-hydroxymethylpyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-43-2P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(S)-2-[(4-hydroxypiperidin-1-yl)methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-45-4P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(4-hydroxypiperidin-1-yl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-46-5P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-methoxyethyl)amide **477575-47-6P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-methoxypropyl)amide **477575-48-7P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2-hydroxyethoxy)ethyl]amide **477575-49-8P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-1-methylethyl)amide **477575-50-1P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-hydroxy-1,1-bis(hydroxymethyl)ethyl]amide **477575-51-2P**, 5-(2,6-Dimethylphenylmethanesulfonyl)-3-[1-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-52-3P**, 5-(2,6-Dimethylphenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(S)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-53-4P**, 5-(2,6-Dimethylphenylmethanesulfonyl)-3-[1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-54-5P**, 5-(2,6-Dimethylphenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(4-(pyrrolidin-1-yl)piperidin-1-ylcarbonyl)-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-55-6P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dimethylphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477575-56-7P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-57-8P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-

ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 (2-(morpholin-4-yl)ethyl)amide **477575-58-9P**,
 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 (3-(morpholin-4-yl)propyl)amide **477575-59-0P**,
 3-[1-[4-[(S)-2-((Cyclopropylamino)methyl)pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477575-62-5P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(4-(morpholin-4-yl)piperidin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-63-6P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[2-(4-(morpholin-4-yl)piperidin-1-yl)-2-oxoethyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-64-7P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylsulfanylethyl)amide **477575-65-8P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2,2,2-trifluoroethyl)amide **477575-67-0P**,
 3-[1-[4-[(S)-2-[(Cyclopropylmethyl)amino]methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477575-69-2P**,
 5-(2,3-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-70-5P**,
 5-(2,3-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(S)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-71-6P**,
 5-(2,3-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-72-7P**, 5-(2,3-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-73-8P**, 5-(2,3-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-74-9P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(R)-3-hydroxypyrrolidin-1-yl]methyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-75-0P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(3-hydroxypiperidin-1-yl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-77-2P**, 3-[1-[4-[(S)-2-[(Cyclopropylamino)methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477575-79-4P**, 3-[1-[4-[(S)-2-[(Cyclopropylamino)methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477575-80-7P**,
 5-(3,5-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-82-9P**, 5-(2,5-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-85-2P**, 5-(2,5-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477575-86-3P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-2-yl)ethyl)amide **477575-88-5P**, 3-[1-[3,5-Dimethyl-4-(2-(piperidin-1-yl)acetyl)-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-

one **477575-89-6P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-3-yl)ethyl)amide **477575-90-9P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(pyridin-4-yl)ethyl)amide **477575-91-0P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [(tetrahydrofuran-2-yl)methyl]amide **477575-92-1P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (cyclopropylmethyl)amide **477575-93-2P**, 3-[1-[3,5-Dimethyl-4-[2-oxo-2-((S)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)ethyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477575-95-4P**, 3-[1-[3,5-Dimethyl-4-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477575-97-6P**, 3-[1-[4-[2-((3R,5S)-3,5-Dimethylpiperazin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477575-99-8P**, 3-[1-[3,5-Dimethyl-4-(2-(morpholin-4-yl)-2-oxoethyl)-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477576-01-5P**, 3-[1-[4-[2-(4-Hydroxypiperidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477576-03-7P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(thiomorpholin-4-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-04-8P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-fluoroethyl)amide **477576-05-9P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-(imidazol-1-yl)propyl)amide **477576-06-0P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid methylamide **477576-07-1P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid amide **477576-08-2P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(1,1-dioxo- λ 6-thiomorpholin-4-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-09-3P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(4-acetylpiperazin-1-yl)ethyl]amide **477576-10-6P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-12-8P**, 5-(2,5-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(4-hydroxypiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-14-0P**, 5-(2,5-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(S)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-15-1P**, 5-(2,5-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-16-2P**, 5-(3,5-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-17-3P**, 5-(3,5-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-18-4P**, 5-(3,5-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(S)-2-pyrrolidin-1-

ylmethylpyrrolidin-1-yl) carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-19-5P**, 5-(3,5-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(4-methylpiperazin-1-yl) carbonyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-20-8P**, 3-[1-[4-[(4-Cyclopropylmethylpiperazin-1-yl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-22-0P**, 3-[1-[4-[2-((S)-2-[(Cyclopropylamino)methyl]pyrrolidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-23-1P**, 3-[1-[4-[(4-Acetyl piperazin-1-yl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-24-2P**, 4-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl)methyl]piperazine-1-carboxaldehyde **477576-25-3P**, 3-[1-[4-[(Cyclopropyl)methylamino]methyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-26-4P**, 3-[1-[4-[(4-Cyclopropylpiperazin-1-yl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-28-6P**, 3-[1-[4-[2-((2R,4R)-2-[(Cyclopropylamino)methyl]-4-hydroxypyrrolidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-29-7P**, 3-[1-[4-[2-((2R,3S)-2-[(Cyclopropylamino)methyl]-3-hydroxypyrrolidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-34-4P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3-acetylaminopyrrolidin-1-yl)ethyl]amide **477576-38-8P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-[4-(2-hydroxyacetyl)piperazin-1-yl]ethyl]acetamide **477576-40-2P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-((S)-2-[(R)-3-hydroxypyrrolidin-1-yl)methyl]pyrrolidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-42-4P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[2-oxo-2-((S)-3-pyrrolidin-1-ylmethylpiperidin-1-yl)ethyl]-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-44-6P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(2,2,2-trifluoroethylamino)ethyl]acetamide **477576-45-7P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(2,2,2-trifluoroethylamino)ethyl]amide **477576-47-9P**, 3-[1-[4-[(R)-2-[(Cyclopropylmethyl)amino]methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-48-0P**, (2S,4R)-1-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-hydroxypyrrolidine-2-carboxylic acid cyclopropylamide **477576-50-4P**, (2S,4R)-1-[2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-4-hydroxypyrrolidine-2-carboxylic acid cyclopropylamide **477576-51-5P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-(pyrrolidin-1-yl)propyl)amide **477576-52-6P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-cyclopropylamino-2-hydroxypropyl)amide **477576-54-8P**,

3-[1-[4-[(4-Cyclopropylpiperazin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-55-9P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid cyclopropylamide **477576-56-0P**, N-[2-(3-Acetylaminopyrrolidin-1-yl)ethyl]-2-[5-[5-(2,6-dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetamide **477576-57-1P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-[4-(2-hydroxyacetyl)piperazin-1-yl]ethyl]amide **477576-61-7P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-(2-hydroxy-3-(pyrrolidin-1-yl)propyl)acetamide **477576-62-8P**, N-(3-Cyclopropylamino-2-hydroxypropyl)-2-[5-[5-(2,6-dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetamide **477576-63-9P**, 3-[1-[4-[2-(4-Cyclopropylpiperazin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-64-0P**, 3-[1-[4-[(4-Cyclopropylmethylpiperazin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-65-1P**, 3-[1-[4-[2-(4-Cyclopropylmethylpiperazin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-66-2P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(S)-3-pyrrolidin-1-ylmethylpiperidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-67-3P**, 3-[1-[4-[(S)-2-[[[(Cyclopropyl)methylamino]methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-71-9P**, 3-[1-[4-[2-((2S,4R)-2-Cyclopropylaminomethyl-4-hydroxypyrrolidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-73-1P**, 3-[1-[4-[(2R,4R)-2-Cyclopropylaminomethyl-4-hydroxypyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-74-2P**, 3-[1-[4-[(2R,3S)-2-Cyclopropylaminomethyl-3-hydroxypyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-75-3P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(S)-2-[(R)-3-hydroxypyrrolidin-1-yl]methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-76-4P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(R)-2-[(R)-3-hydroxypyrrolidin-1-yl]methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-78-6P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-((R)-3-hydroxypyrrolidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-79-7P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-[(R)-2-[(R)-3-hydroxypyrrolidin-1-yl]methyl]pyrrolidin-1-yl]-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-81-1P**, (R)-1-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]piperidine-3-carboxylic acid cyclopropylamide **477576-83-3P**, (R)-1-[2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]piperidine-3-carboxylic acid cyclopropylamide **477576-84-4P**, 3-[1-[4-[(S)-2-[[[(Cyclopropyl)methylamino]methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl]-1,3-dihydroindol-2-

one **477576-85-5P**, 3-[1-[4-[2-((S)-3-
 [(Cyclopropylamino)methyl]piperidin-1-yl)-2-oxoethyl]-3,5-dimethyl-1H-
 pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-
 dihydroindol-2-one **477576-87-7P**, 3-[1-[4-[(S)-3-
 [(Cyclopropylamino)methyl]piperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-
 2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-
 dihydroindol-2-one **477576-88-8P**, 5-(2,6-
 Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-[(S)-2-[(R)-3-fluoropyrrolidin-
 1-yl)methyl]pyrrolidin-1-yl]-2-oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-
 (Z)-ylidene]-1,3-dihydroindol-2-one **477576-89-9P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(S)-2-[(4-fluoropiperidin-1-
 yl)methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-
 ylidene]-1,3-dihydroindol-2-one **477576-91-3P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-[(S)-2-[(4-
 fluoropiperidin-1-yl)methyl]pyrrolidin-1-yl]-2-oxoethyl]-3,5-dimethyl-1H-
 pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-92-4P**
 , 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(R)-2-[(R)-3-
 fluoropyrrolidin-1-yl)methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-
 pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-94-6P**
 , 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-[(R)-2-[(R)-3-
 fluoropyrrolidin-1-yl)methyl]pyrrolidin-1-yl]-2-oxoethyl]-3,5-dimethyl-1H-
 pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477576-95-7P**
 , 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-
 ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 [2-(4-fluoropiperidin-1-yl)ethyl]amide **477576-98-0P**,
 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-
 ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(4-fluoropiperidin-1-
 yl)ethyl]acetamide **477576-99-1P**, 3-[1-[4-[(2S,4R)-2-
 Cyclopropylaminomethyl-4-hydroxypyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-
 pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-
 dihydroindol-2-one **477577-01-8P**, 5-(2,6-
 Dichlorophenylmethanesulfonyl)-3-[1-[4-[(R)-2-[(4-fluoropiperidin-1-
 yl)methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-
 ylidene]-1,3-dihydroindol-2-one **477577-06-3P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-[(R)-2-[(4-
 fluoropiperidin-1-yl)methyl]pyrrolidin-1-yl]-2-oxoethyl]-3,5-dimethyl-1H-
 pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-07-4P**
 , 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(S)-2-[(3-fluoropiperidin-
 1-yl)methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-
 ylidene]-1,3-dihydroindol-2-one **477577-09-6P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[2-[(S)-2-[(3-
 fluoropiperidin-1-yl)methyl]pyrrolidin-1-yl]-2-oxoethyl]-3,5-dimethyl-1H-
 pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-10-9P**
 , 3-[1-[4-[2-[(S)-2-[(Cyclopropyl)methylamino)methyl]pyrrolidin-1-yl]-2-
 oxoethyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-
 dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-11-0P**
 , 3-[1-[4-[(R)-2-[(Cyclopropyl)methylamino)methyl]pyrrolidin-1-
 ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-5-(2,6-
 dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-15-4P**
 , 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(4-fluoropiperidin-1-
 yl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-
 2-one **477577-16-5P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-
 oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-
 carboxylic acid [2-(3-fluoropyrrolidin-1-yl)ethyl]amide
477577-17-6P, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-
 1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(3-
 fluoropyrrolidin-1-yl)ethyl]acetamide **477577-20-1P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[3-[(R)-2-[(R)-3-
 fluoropyrrolidin-1-yl)methyl]pyrrolidin-1-yl]-3-oxopropyl]-3,5-dimethyl-1H-
 pyrrol-2-yl)meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-21-2P**

, 5-(2,6-Difluorophenylmethanesulfonyl)-3-[1-[4-[(R)-2-[(R)-3-fluoropyrrolidin-1-yl)methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-24-5P*****,
5-(2,6-Difluorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one *477577-25-6P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[3-oxo-3-((R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)propyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-26-7P**,
 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 [2-[4-(2-amino-2-methylpropionyl)piperazin-1-yl]ethyl]amide
477577-28-9P, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[3-oxo-3-((S)-3-pyrrolidin-1-ylmethylpiperidin-1-yl)propyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-29-0P**,
 5-(2,6-Difluorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(S)-3-pyrrolidin-1-ylmethylpiperidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-30-3P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(3-(morpholin-4-yl)-3-oxopropyl)-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one
477577-31-4P, N-[2-(4-Acetylpiperazin-1-yl)ethyl]-2-[5-[5-(2,6-dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetamide **477577-33-6P**,
 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 [2-(4-hydroxypiperidin-1-yl)ethyl]amide **477577-35-8P**,
 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(4-hydroxypiperidin-1-yl)ethyl]acetamide **477577-36-9P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[3-(4-methylpiperazin-1-yl)-3-oxopropyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one
477577-37-0P, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[3-((3R,5S)-3,5-dimethylpiperazin-1-yl)-3-oxopropyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-38-1P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[3-oxo-3-((S)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl)propyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-40-5P**,
 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid
 [(1-methylpiperidin-4-yl)methyl]amide **477577-42-7P**,
 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[(1-methylpiperidin-4-yl)methyl]acetamide **477577-44-9P**, 3-[1-[4-[3-((S)-2-[(Cyclopropylamino)methyl]pyrrolidin-1-yl)-3-oxopropyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-45-0P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[3-(4-hydroxypiperidin-1-yl)-3-oxopropyl]-3,5-dimethylpyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one
477577-46-1P 477577-47-2P, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[3-[(R)-2-[(R)-3-hydroxypyrrolidin-1-yl)methyl]pyrrolidin-1-yl]-3-oxopropyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-48-3P**,
 5-(2,6-Difluorophenylmethanesulfonyl)-3-[1-[4-[(R)-3-hydroxypyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-49-4P**, 3-[1-[4-[(4-Cyclopropylaminopiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and other disorders)

RN 477575-35-2 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(4-morpholinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 477575-36-3 HCAPLUS

CN 2-Pyrrolidinemethanamine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-N-ethyl-N-propyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 477575-37-4 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(4-morpholinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-38-5 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1H-1,2,3-triazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-39-6 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(methoxymethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 477575-40-9 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(methoxymethyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 477575-41-0 HCAPLUS

CN 2-Pyrrolidinemethanol, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 477575-42-1 HCAPLUS

CN 2-Pyrrolidinemethanol, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 477575-43-2 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[(4-hydroxy-1-piperidinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-45-4 HCAPLUS

CN 2H-Indol-2-one, 5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,3-dihydro-3-[[4-[(4-hydroxy-1-piperidinyl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-46-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2-methoxyethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-47-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(3-methoxypropyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-48-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(2-hydroxyethoxy)ethyl]-

2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—OH

RN 477575-49-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-50-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-51-2 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[(2,6-dimethylphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-52-3 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-dimethylphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-53-4 HCAPLUS

CN 4-Piperidinol, 1-[[5-[(Z)-[5-[(2,6-dimethylphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-54-5 HCAPLUS

CN Piperidine, 1-[[5-[(Z)-[5-[(2,6-dimethylphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-55-6 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[(2,6-dimethylphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-56-7 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 477575-57-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-58-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-59-0 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-62-5 HCAPLUS

CN Piperidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-63-6 HCAPLUS

CN Piperidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-64-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(ethylthio)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-65-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2,2,2-trifluoroethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-67-0 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-(cyclopropylmethyl)-1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-69-2 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[(2,3-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-70-5 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,3-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-71-6 HCAPLUS

CN 4-Piperidinol, 1-[[5-[(Z)-[5-[(2,3-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-72-7 HCAPLUS


CN Piperidine, 1-[[5-[(Z)-[5-[(2,3-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-73-8 HCAPLUS
 CN Piperazine, 1-[[5-[(Z)-[5-[[[(2,3-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477575-74-9 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,3-dihydro-3-[[4-[[[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 477575-75-0 HCAPLUS

CN 2H-Indol-2-one, 5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,3-dihydro-3-[[4-[(3-hydroxy-1-piperidinyl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477575-77-2 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 477575-79-4 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[[(2,6-

difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-80-7 HCAPLUS

CN 4-Piperidinol, 1-[[5-[(Z)-[5-[[3,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-82-9 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[2,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-85-2 HCAPLUS

CN Piperidine, 1-[[5-[(Z)-[5-[[2,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-86-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-88-5 HCAPLUS

CN 2H-Indol-2-one, 3-[[3,5-dimethyl-4-(1-piperidinylacetyl)-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-[(phenylmethyl)sulfonyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-89-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-90-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-91-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-92-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-(cyclopropylmethyl)-5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-93-2 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-95-4 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477575-97-6 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477575-99-8 HCAPLUS

CN Morpholine, 4-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-01-5 HCAPLUS

CN 4-Piperidinol, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-03-7 HCAPLUS

CN Thiomorpholine, 4-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-04-8 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-(2-fluoroethyl)-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-05-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[3-(1H-imidazol-1-yl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-06-0 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-07-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N,2,4-trimethyl- (9CI) (CA INDEX NAME)

1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-08-2 HCAPLUS

CN Thiomorpholine, 4-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-09-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(4-acetyl-1-piperazinyl)ethyl]-5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-10-6 HCAPLUS

CN 2H-Indol-2-one, 5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-3-[[4-[[[(3S,5R)-3,5-dimethyl-1-piperazinyl]methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-12-8 HCAPLUS

CN 4-Piperidinol, 1-[[[5-[(Z)-[5-[[[(2,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-14-0 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[(2,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-15-1 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[(2,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-16-2 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[5-[[[(3,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-17-3 HCAPLUS

CN Piperidine, 1-[[5-[(Z)-[5-[[[(3,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-(1-pyrrolidinyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-18-4 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[3,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-19-5 HCAPLUS


CN Piperazine, 1-[[5-[(Z)-[5-[[3,5-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-20-8 HCAPLUS
 CN 2H-Indol-2-one, 3-[[4-[[4-(cyclopropylmethyl)-1-piperazinyl]methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-5-[[2,6-dichlorophenyl]methyl]sulfonyl]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477576-22-0 HCAPLUS
 CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 477576-23-1 HCAPLUS

CN Piperazine, 1-acetyl-4-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-24-2 HCAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[(2Z)-2-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]-1-(2,4-dimethyl-1H-pyrrol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-25-3 HCAPLUS

CN 2H-Indol-2-one, 3-[[4-[(cyclopropylmethylamino)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-5-[[[2,6-dichlorophenyl)methyl]sulfonyl]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-26-4 HCAPLUS

CN 2H-Indol-2-one, 3-[[4-[(4-cyclopropyl-1-piperazinyl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-5-[[[2,6-dichlorophenyl)methyl]sulfonyl]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-28-6 HCAPLUS

CN 3-Pyrrolidinol, 5-[(cyclopropylamino)methyl]-1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-29-7 HCAPLUS

CN 3-Pyrrolidinol, 2-[(cyclopropylamino)methyl]-1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-, (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-34-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[3-(acetylamino)-1-pyrrolidinyl]ethyl]-5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-38-8 HCAPLUS


CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-[4-(hydroxyacetyl)-1-piperazinyl]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 477576-40-2 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-2-[[[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-, (2S)- (9CI) (CA INDEX NAME).


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-42-4 HCAPLUS

CN Piperidine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-3-(1-pyrrolidinylmethyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-44-6 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[(2,2,2-trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-45-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-[(2,2,2-trifluoroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-47-9 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-(cyclopropylmethyl)-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-


ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 477576-48-0 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-hydroxy-, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-50-4 HCAPLUS
CN 2-Pyrrolidinecarboxamide, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-4-hydroxy-, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-51-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-52-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[3-(cyclopropylamino)-2-hydroxypropyl]-5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-54-8 HCAPLUS

CN Piperazine, 1-cyclopropyl-4-[[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX

NAME)


Double bond geometry as shown.



RN 477576-55-9 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-56-0 HCAPLUS

CN 1H-Pyrrole-3-acetamide, N-[2-[3-(acetlamino)-1-pyrrolidinyl]ethyl]-5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


—NHAc

RN 477576-57-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-[4-(hydroxyacetyl)-1-piperazinyl]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—OH

RN 477576-61-7 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-hydroxy-3-(1-pyrrolidinyl)propyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-62-8 HCAPLUS

CN 1H-Pyrrole-3-acetamide, N-[3-(cyclopropylamino)-2-hydroxypropyl]-5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-63-9 HCAPLUS

CN Piperazine, 1-cyclopropyl-4-[[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-64-0 HCAPLUS

CN Piperazine, 1-(cyclopropylmethyl)-4-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-65-1 HCAPLUS

CN Piperazine, 1-(cyclopropylmethyl)-4-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-66-2 HCAPLUS

CN Piperidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3-(1-pyrrolidinylmethyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-67-3 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-71-9 HCAPLUS

CN 3-Pyrrolidinol, 5-[(cyclopropylamino)methyl]-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-73-1 HCAPLUS

CN 3-Pyrrolidinol, 5-[(cyclopropylamino)methyl]-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R,5R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-74-2 HCAPLUS

CN 3-Pyrrolidinol, 2-[(cyclopropylamino)methyl]-1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R,3S)-rel- (9CI)
(CA INDEX NAME)


Relative stereochemistry.
Double bond geometry as shown.



RN 477576-75-3 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[[[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-76-4 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-78-6 HCAPLUS

CN 3-Pyrrolidinol, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-79-7 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-2-[[[(3R)-3-hydroxy-1-pyrrolidinyl]methyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-81-1 HCAPLUS

CN 3-Piperidinecarboxamide, N-cyclopropyl-1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-83-3 HCAPLUS

CN 3-Piperidinecarboxamide, N-cyclopropyl-1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-84-4 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(E)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-N-methyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-85-5 HCAPLUS

CN 3-Piperidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-87-7 HCAPLUS

CN 3-Piperidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-88-8 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-2-[[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-89-9 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[(4-fluoro-1-piperidinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-91-3 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-2-[(4-fluoro-1-piperidinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-92-4 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[(3R)-3-fluoro-1-pyrrolidinylmethyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-94-6 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-2-[[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477576-95-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(4-fluoro-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-98-0 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(4-fluoro-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-99-1 HCAPLUS

CN 3-Pyrrolidinol, 5-[(cyclopropylamino)methyl]-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry as shown.




RN 477577-01-8 HCAPLUS
 CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[(4-fluoro-1-piperidiny)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 477577-06-3 HCAPLUS
 CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-2-[(4-fluoro-1-piperidiny)methyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 477577-07-4 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[(3-fluoro-1-piperidinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-09-6 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-2-[(3-fluoro-1-piperidinyl)methyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-10-9 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]-N-methyl-, (2S)-(9CI)
(CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-11-0 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-N-methyl-, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-15-4 HCAPLUS

CN 2H-Indol-2-one, 5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-3-[[4-[(4-fluoro-1-piperidinyl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-16-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(3-fluoro-1-pyrrolidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-17-6 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(3-fluoro-1-pyrrolidiny]ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477577-20-1 HCAPLUS

CN Pyrrolidine, 1-[3-[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-2-[[[(3R)-3-fluoro-1-pyrrolidiny]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

F

RN 477577-21-2 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[[[(3R)-3-fluoro-1-pyrrolidinyl]methyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-24-5 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-25-6 HCAPLUS

CN Pyrrolidine, 1-[3-[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 477577-26-7 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[4-(2-amino-2-methyl-1-oxopropyl)-1-piperazinyl]ethyl]-5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


—NH₂


RN 477577-28-9 HCAPLUS

CN Piperidine, 1-[3-[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-3-(1-pyrrolidinylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A






RN 477577-29-0 HCAPLUS

CN Piperidine, 1-[[5-[(Z)-[5-[[[(2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-3-(1-pyrrolidinylmethyl)-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-30-3 HCAPLUS

CN Morpholine, 4-[3-[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-31-4 HCAPLUS

CN 1H-Pyrrole-3-acetamide, N-[2-(4-acetyl-1-piperazinyl)ethyl]-5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-33-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(4-hydroxy-1-piperidiny)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477577-35-8 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(4-hydroxy-1-piperidiny)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B

—OH


RN 477577-36-9 HCAPLUS
 CN Piperazine, 1-[3-[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-37-0 HCAPLUS
 CN Piperazine, 1-[3-[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-3,5-dimethyl-, (3R,5S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.



RN 477577-38-1 HCAPLUS

CN Pyrrolidine, 1-[3-[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-40-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-42-7 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[(1-methyl-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477577-44-9 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[3-[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-, (2S)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 477577-45-0 HCAPLUS

CN 4-Piperidinol, 1-[3-[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477577-46-1 HCAPLUS

CN 3-Pyrrolidinol, 1-[3-[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 477577-47-2 HCAPLUS

CN Pyrrolidine, 1-[3-[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]-2-[[3-(3R)-3-hydroxy-1-pyrrolidinyl)methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




PAGE 1-A




RN 477577-48-3 HCAPLUS
 CN 3-Pyrrolidinol, 1-[[5-[(Z)-[5-[[2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 477577-49-4 HCAPLUS
 CN 4-Piperidinamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 477577-50-7P, 3-[1-[4-[3-(4-Cyclopropylaminopiperidin-1-yl)-3-oxopropyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one 477577-51-8P, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[5-methyl-3-[(S)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-

ylidene]-1,3-dihydroindol-2-one **477577-52-9P**,
 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(S)-2-[(S)-3-fluoropyrrolidin-1-yl)methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-54-1P**,
 3-[1-[4-[(Cyclopropyl)methylamino]methyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-[2-(2-(morpholin-4-yl)ethoxy)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477577-55-2P**, 3-[1-[4-[(R)-3-Hydroxypyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-[2-(2-(morpholin-4-yl)ethoxy)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477577-57-4P**, 3-[1-[3,5-Dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-[2-(2-(morpholin-4-yl)ethoxy)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477577-58-5P**, 3-[1-[3,5-Dimethyl-4-[(R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-[2-(2-(morpholin-4-yl)ethoxy)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477577-60-9P**, 3-[1-[4-[(4-Cyclopropylaminopiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(3,5-dimethoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-61-0P**, 3-[1-[4-[(R)-2-[(Cyclopropylamino)methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(3,5-dimethoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-62-1P**, 3-[1-[4-[(R)-2-[(Cyclopropylmethyl)amino]methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(3,5-dimethoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-63-2P**, 5-(3,5-Dimethoxyphenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-64-3P**, 3-[1-[3,5-Dimethyl-4-[(R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477577-65-4P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid cyclopropyl((R)-1-pyrrolidin-2-ylmethyl)amide **477577-66-5P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (cyclopropylmethyl)((R)-1-pyrrolidin-2-ylmethyl)amide **477577-67-6P**, 5-(2,6-Dimethoxyphenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-68-7P**, 3-[1-[4-[(R)-2-[(Cyclopropylmethyl)amino]methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-69-8P**, 3-[1-[4-[(R)-2-[(Cyclopropylamino)methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-70-1P**, 3-[1-[4-[(R)-2-[(Cyclopropylamino)methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-71-2P**, 3-[1-[4-[(R)-2-[(Cyclopropylmethyl)amino]methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-72-3P**, 3-[1-[3,5-Dimethyl-4-[(R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-73-4P**, 5-(2-Chlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[(R)-2-pyrrolidin-1-ylmethylpyrrolidin-1-yl]carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-74-5P**, 5-(2-Chlorophenylmethanesulfonyl)-3-[1-[4-[(R)-2-[(cyclopropylamino)methyl]pyrrolidin-1-yl]carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-75-6P**, 5-(2-Chlorophenylmethanesulfonyl)-3-[1-[4-[(R)-2-

[[(cyclopropylmethyl)amino]methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-76-7P**
 , 5-(2-Chlorophenylmethanesulfonyl)-3-[1-[4-[(4-cyclopropylaminopiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-77-8P**, 3-[1-[4-[(4-Cyclopropylaminopiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-78-9P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[4-[(R)-2-[(S)-2-hydroxymethylpyrrolidin-1-yl)methyl]pyrrolidin-1-ylcarbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477577-79-0P**, 3-[1-[4-[(4-Aminopiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-80-3P**
 , 3-[1-[4-[(4-Aminopiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-81-4P**, 3-[1-[4-[(4-Aminopiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-82-5P**
 , 3-[1-[4-[(4-Aminopiperidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-chlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-83-6P**, 3-[1-[4-[(S)-3-Aminopyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-84-7P**
 , 3-[1-[4-[(S)-3-Aminopyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-chlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-85-8P**, 3-[1-[4-[(S)-3-Aminopyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-86-9P**
 , 3-[1-[4-[(S)-3-Aminopyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-87-0P**, 3-[1-[4-[(R)-3-Aminopyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-88-1P**
 , 3-[1-[4-[(R)-3-Aminopyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2,6-dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-89-2P**, 3-[1-[4-[(R)-3-Aminopyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-chlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-90-5P**
 , 3-[1-[4-[(R)-3-Aminopyrrolidin-1-yl)carbonyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-(2-fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477577-91-6P**, 3-[1-(5-Methyl-3H-imidazol-4-yl)meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477577-92-7P**, 3-[1-[3-[(3-Dimethylaminopyrrolidin-1-yl)carbonyl]-5-methyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477577-93-8P**, 3-[5-Ethyl-2-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid **477577-94-9P**, 3-[4-Methyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid **477577-95-0P**, 3-[1-[3-Methyl-5-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477577-96-1P**, 4-(4-Fluorophenyl)-2-methyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477577-97-2P**, 4-[5-Methyl-2-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrol-3-yl]benzoic acid **477577-98-3P**, 3-[1-(4-Morpholin-4-yl)phenyl)meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477577-99-4P**, 4-(2-Carboxyethyl)-3-methyl-5-(2-oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrole-2-carboxylic acid ethyl ester **477578-00-0P**, 3-[2,4-Dimethyl-5-(2-

oxo-5-phenylmethanesulfonyl-1,2-dihydroindol-3-(Z)-ylidenemethyl)-1H-pyrrol-3-yl]propionic acid **477578-01-1P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide **477578-02-2P**, 2-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (3-(pyrrolidin-1-yl)propyl)amide **477578-03-3P**, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [2-(3-fluoropiperidin-1-yl)ethyl]amide **477578-04-4P**, 2-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-5-methyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide **477578-05-5P**, 3-[1-[4-[(3R,5S)-3,5-dimethylpiperazin-1-yl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]meth-(Z)-ylidene]-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477578-06-6P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(1-methylpiperidin-4-yl)-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477578-07-7P**, 2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]-N-[2-(3-fluoropiperidin-1-yl)ethyl]acetamide **477578-08-8P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-(4-[(morpholin-4-yl)methyl]phenyl)-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477578-09-9P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[4-(cyclopropylamino)piperidin-1-ylmethyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one **477578-10-2P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-3-[1-[3,5-dimethyl-4-[4-(pyrrolidin-1-yl)piperidin-1-ylmethyl]-1H-pyrrol-2-yl]meth-(Z)-ylidene]-1,3-dihydroindol-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and other disorders)

RN 477577-50-7 HCAPLUS

CN 4-Piperidinamine, N-cyclopropyl-1-[3-[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A






RN 477577-51-8 HCAPLUS

CN Pyrrolidine, 1-[[2-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-52-9 HCAPLUS


CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[[3S)-3-fluoro-1-pyrrolidinyl]methyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 477577-54-1 HCAPLUS
CN 2H-Indol-2-one, 3-[[4-[(cyclopropylmethylamino)methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-1,3-dihydro-5-[[[2-[2-(4-morpholinyl)ethoxy]phenyl]methyl]sulfonyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN	477577-55-2	HCAPLUS	
CN	3-Pyrrolidinol, 1-[[5-[(Z)-[1,2-dihydro-5-[[[2-[2-(4-morpholinyl)ethoxy]phenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R)- (9CI) (CA INDEX NAME)		

Absolute stereochemistry.
Double bond geometry as shown.



RN	477577-57-4	HCAPLUS	
CN	Piperazine, 1-[[5-[(Z)-[1,2-dihydro-5-[[2-[2-(4-morpholinyl)ethoxy]phenyl)methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)		

Double bond geometry as shown.




RN 477577-58-5 HCAPLUS


CN Pyrrolidine, 1-[[5-[(Z)-[1,2-dihydro-5-[[[2-[2-(4-morpholinyl)ethoxy]phenyl]methyl]sulfonyl]-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 477577-60-9 HCAPLUS

CN 4-Piperidinamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[[3,5-dimethoxyphenyl]methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-61-0 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[(3,5-dimethoxyphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 477577-62-1 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-(cyclopropylmethyl)-1-[[5-[(Z)-[5-[(3,5-dimethoxyphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 477577-63-2 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[[(3,5-dimethoxyphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 477577-64-3 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 477577-65-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-cyclopropyl-5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-66-5 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-(cyclopropylmethyl)-5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[(2R)-2-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-67-6 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dimethoxyphenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-68-7 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-(cyclopropylmethyl)-1-[[5-[(Z)-[5-[[2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-69-8 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[[2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-70-1 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-cyclopropyl-1-[[5-[(Z)-[5-[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-71-2 HCAPLUS

CN 2-Pyrrolidinemethanamine, N-(cyclopropylmethyl)-1-[[5-[(Z)-[5-[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-72-3 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-73-4 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-(1-pyrrolidinylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-74-5 HCAPLUS

CN 2-Pyrrolidinemethanamine, 1-[[5-[(Z)-[5-[[[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-N-cyclopropyl-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-75-6 HCAPLUS

CN 2-Pyrrolidinemethanamine, 1-[[5-[(Z)-[5-[[[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-N-(cyclopropylmethyl)-, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-76-7 HCAPLUS

CN 4-Piperidinamine, 1-[[5-[(Z)-[5-[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-77-8 HCAPLUS

CN 4-Piperidinamine, N-cyclopropyl-1-[[5-[(Z)-[5-[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-78-9 HCAPLUS

CN Pyrrolidine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-2-[[2S)-2-(hydroxymethyl)-1-pyrrolidinyl)methyl]-, (2R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-79-0 HCAPLUS

CN 4-Piperidinamine, 1-[[5-[(Z)-[5-[[2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-80-3 HCAPLUS

CN 4-Piperidinamine, 1-[[5-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-81-4 HCAPLUS

CN 4-Piperidinamine, 1-[[5-[(Z)-[5-[[2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-82-5 HCAPLUS

4-Piperidinamine, 1-[[5-[(Z)-[5-[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477577-83-6 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[[2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 477577-84-7 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-85-8 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-86-9 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[(2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-87-0 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[[[(2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-88-1 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-89-2 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[[[(2-chlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-90-5 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[5-[(Z)-[5-[(2-fluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 477577-91-6 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methylene]-5-[(phenylmethyl)sulfonyl]-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-92-7 HCAPLUS

CN 3-Pyrrolidinamine, 1-[[2-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]carbonyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-93-8 HCAPLUS

CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-5-ethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-94-9 HCAPLUS

CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-95-0 HCAPLUS

CN Piperazine, 1-[[5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-4-methyl-1H-pyrrol-2-yl]carbonyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-96-1 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-(diethylamino)ethyl]-5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-4-(4-fluorophenyl)-2-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-97-2 HCAPLUS

CN Benzoic acid, 4-[2-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-5-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-98-3 HCAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-3-[[4-(4-morpholinyl)phenyl]methylene]-5-[(phenylmethyl)sulfonyl]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477577-99-4 HCAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 2-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-5-(ethoxycarbonyl)-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477578-00-0 HCAPLUS
 CN 1H-Pyrrole-3-propanoic acid, 5-[(Z)-[1,2-dihydro-2-oxo-5-[(phenylmethyl)sulfonyl]-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477578-01-1 HCAPLUS
 CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477578-02-2 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-5-methyl-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477578-03-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(3-fluoro-1-piperidiny)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477578-04-4 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 2-[(Z)-[5-[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-N-[2-(diethylamino)ethyl]-5-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477578-05-5 HCAPLUS

CN 2H-Indol-2-one, 3-[[4-[[3,5-dimethyl-1-piperazinyl)methyl]-3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-5-[(phenylmethyl)sulfonyl]-, (3Z)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


Double bond geometry as shown.



RN 477578-06-6 HCAPLUS

CN 2H-Indol-2-one, 5-[[2,6-dichlorophenyl)methyl]sulfonyl]-3-[[3,5-dimethyl-4-(1-methyl-4-piperidinyl)-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477578-07-7 HCAPLUS

CN 1H-Pyrrole-3-acetamide, 5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-N-[2-(3-fluoro-1-piperidinyl)ethyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477578-08-8 HCAPLUS

CN 2H-Indol-2-one, 5-[(2,6-dichlorophenyl)methyl]sulfonyl]-3-[[3,5-dimethyl-4-[4-(4-morpholinylmethyl)phenyl]-1H-pyrrol-2-yl]methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477578-09-9 HCAPLUS

CN 2H-Indol-2-one, 3-[[4-[[4-(cyclopropylamino)-1-piperidinyl]methyl]-3,5-dimethyl-1H-pyrrol-2-yl]methylene]-5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477578-10-2 HCAPLUS

CN 2H-Indol-2-one, 5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-3-[[3,5-dimethyl-4-[[4-(1-pyrrolidinyl)-1-piperidinyl]methyl]-1H-pyrrol-2-yl]methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 477575-84-1, 5-[(2,5-Dichlorobenzyl)sulfonyl]-1,3-dihydroindol-2-one 477575-87-4, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid [1,2,3]triazolo[4,5-b]pyridin-3-yl ester 477576-13-9, 5-[5-(2,5-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 2,5-dioxopyrrolidin-1-yl ester 477577-22-3, 5-[5-(2,6-Difluorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid 477577-53-0, 5-(3,5-Dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aralkylsulfonyl- and pyrrolylmethylidene-substituted
 indolinones as kinase inhibitors useful against cancers and other
 disorders)

RN 477575-84-1 HCAPLUS


CN 2H-Indol-2-one, 5-[[[(2,5-dichlorophenyl)methyl]sulfonyl]-1,3-dihydro-
 (9CI) (CA INDEX NAME)



RN 477575-87-4 HCAPLUS

CN 2H-Indol-2-one, 5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-3-[[[3,5-dimethyl-
 4-[[[3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)carbonyl]-1H-pyrrol-2-
 yl]methylene]-1,3-dihydro-, (3Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477576-13-9 HCAPLUS

CN 2,5-Pyrrolidinedione, 1-[[[5-[(Z)-[5-[[[(2,5-dichlorophenyl)methyl]sulfonyl]
]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-
 yl]carbonyl]oxy]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 477577-22-3 HCAPLUS


CN 1H-Pyrrole-3-carboxylic acid, 5-[(Z)-[5-[(2,6-difluorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 477577-53-0 HCAPLUS

CN 2H-Indol-2-one, 5-[[[(3,5-dichlorophenyl)methyl]sulfonyl]-1,3-dihydroindol-2-one (9CI) (CA INDEX NAME)



IT 477573-04-9P, 5-(2-Trifluoromethylphenylmethanesulfonyl)-1,3-dihydroindol-2-one 477573-05-0P, 5-(4-

Nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one 477573-06-1P, 3-[[[(2-Oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl]methyl]benzonitrile

477573-07-2P, 5-(2,4-Difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one 477573-08-3P, 5-Phenylmethanesulfonyl-1,3-dihydroindol-2-one 477573-09-4P, 5-(2,6-


Dimethylphenylmethanesulfonyl)-1,3-dihydroindol-2-one 477573-10-7P

, 5-(2,3-Dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one
477573-11-8P, 5-(2,6-Dimethoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-12-9P**, 5-[2-(2-(Morpholin-4-yl)ethoxy)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477573-13-0P**, 5-(3-Methoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-14-1P**, 5-(3-Nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-15-2P**, 5-(2-Nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-16-3P**, 5-(3-Trifluoromethoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-17-4P**, 5-(3-Bromophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-18-5P**, 5-(2,6-Difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-19-6P**, 5-(3,5-Difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-20-9P**, 5-(3,4-Difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-21-0P**, 5-[2,4-Bis(trifluoromethyl)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477573-22-1P**, 5-[3,5-Bis(trifluoromethyl)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477573-23-2P**, 5-(2-Hydroxy-5-nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-24-3P**, 5-(2-Methoxy-5-nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-26-5P**, 5-(2-Fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-27-6P**, 5-(3-Fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-28-7P**, 5-(4-Fluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-29-8P**, 5-(4-Trifluoromethoxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-30-1P**, 5-(3-Trifluoromethylphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-31-2P**, 5-(4-Trifluoromethylphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-32-3P**, 4-[[[(2-Oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl]methyl]benzoic acid **477573-33-4P**, [4-[[[(2-Oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl]methyl]phenyl]acetic acid **477573-34-5P**, 3-Nitro-4-[[[(2-oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl]methyl]benzoic acid **477573-35-6P**, 5-Pentafluorophenylmethanesulfonyl-1,3-dihydroindol-2-one **477573-36-7P**, 5-(2,5-Difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-37-8P**, 5-(2,3,6-Trifluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-38-9P**, 5-(2,3-Difluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-39-0P**, 5-(2,6-Dichlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-40-3P**, 5-(Biphenyl-2-ylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-41-4P**, 5-(2-Fluoro-6-nitrophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-42-5P**, 5-[3-(4-Fluorophenoxy)phenylmethanesulfonyl]-1,3-dihydroindol-2-one **477573-43-6P**, 5-(3,5-Dibromo-2-hydroxyphenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-44-7P**, 5-(2,3,5-Trifluorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-45-8P**, 4-Methyl-5-phenylmethanesulfonyl-1,3-dihydroindol-2-one **477573-46-9P**, 5-(2-Fluorophenylmethanesulfonyl)-4-methyl-1,3-dihydroindol-2-one **477573-47-0P**, 2-[[[(2-Oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl]methyl]benzonitrile **477573-48-1P**, 5-(3-Chlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477573-49-2P**, 4-[[[(2-Oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl]methyl]benzoic acid methyl ester **477573-50-5P**, 3-[[[(2-Oxo-2,3-dihydro-1H-indol-5-yl)sulfonyl]methyl]benzoic acid methyl ester **477573-51-6P**, 5-(2-Chlorophenylmethanesulfonyl)-1,3-dihydroindol-2-one **477576-37-7P**, 4-[2-[[2-[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]amino]ethyl]piperazine-1-carboxylic acid tert-butyl ester **477576-39-9P**, Acetic acid

2-[4-[2-[[2-[5-[5-(2,6-dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]amino]ethyl]piperazin-1-yl]-2-oxoethyl ester
477576-58-2P, 4-[2-[[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]piperazine-1-carboxylic acid tert-butyl ester
477576-59-3P, 5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-(piperazin-1-yl)ethyl)amide **477576-60-6P**, Acetic acid
 2-[4-[2-[[5-[5-(2,6-dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]piperazin-1-yl]-2-oxoethyl ester
477577-27-8P, [2-[4-[2-[[5-[5-(2,6-Dichlorophenylmethanesulfonyl)-2-oxo-1,2-dihydroindol-3-(Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]piperazin-1-yl]-1,1-dimethyl-2-oxoethyl]carbamic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aralkylsulfonyl- and pyrrolylmethylidene-substituted indolinones as kinase inhibitors useful against cancers and other disorders)


RN 477573-04-9 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[[2-(trifluoromethyl)phenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-05-0 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[[4-nitrophenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-06-1 HCAPLUS

CN Benzonitrile, 3-[[[2,3-dihydro-2-oxo-1H-indol-5-yl]sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 477573-07-2 HCAPLUS


CN 2H-Indol-2-one, 5-[[[2,4-difluorophenyl]methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-08-3 HCAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-09-4 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[(2,6-dimethylphenyl)methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 477573-10-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[(2,3-dichlorophenyl)methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-11-8 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[(2,6-dimethoxyphenyl)methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-12-9 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[[2-(4-morpholinyl)ethoxy]phenyl)methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-13-0 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[[3-methoxyphenyl)methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-14-1 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[[3-nitrophenyl)methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-15-2 HCAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[[2-nitrophenyl)methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-16-3 HCAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-5-[[[3-(trifluoromethoxy)phenyl]methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-17-4 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[3-bromophenyl]methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-18-5 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[2,6-difluorophenyl]methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-19-6 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[3,5-difluorophenyl]methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-20-9 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[3,4-difluorophenyl]methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-21-0 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[2,4-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-22-1 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]sulfonyl]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 477573-23-2 HCAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-5-[[[(2-hydroxy-5-nitrophenyl)methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-24-3 HCAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-5-[[[(2-methoxy-5-nitrophenyl)methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-26-5 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[(2-fluorophenyl)methyl]sulfonyl]-1,3-dihydro- (9CI)
 (CA INDEX NAME)




RN 477573-27-6 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[(3-fluorophenyl)methyl]sulfonyl]-1,3-dihydro- (9CI)
 (CA INDEX NAME)



RN 477573-28-7 HCAPLUS
 CN 2H-Indol-2-one, 5-[[[(4-fluorophenyl)methyl]sulfonyl]-1,3-dihydro- (9CI)
 (CA INDEX NAME)




RN 477573-29-8 HCAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-5-[[[4-(trifluoromethoxy)phenyl]methyl]sulfonyl]-1- (9CI) (CA INDEX NAME)




RN 477573-30-1 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[[3-(trifluoromethyl)phenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-31-2 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[[4-(trifluoromethyl)phenyl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-32-3 HCAPLUS

CN Benzoic acid, 4-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 477573-33-4 HCAPLUS

CN Benzeneacetic acid, 4-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 477573-34-5 HCAPLUS


CN Benzoic acid, 4-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]methyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 477573-35-6 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[pentafluorophenyl)methyl]sulfonyl] - (9CI)
(CA INDEX NAME)


RN 477573-36-7 HCAPLUS

CN 2H-Indol-2-one, 5-[[2,5-difluorophenyl)methyl]sulfonyl] -1,3-dihydro-
(9CI) (CA INDEX NAME)

RN 477573-37-8 HCAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-5-[[2,3,6-trifluorophenyl)methyl]sulfonyl] -
(9CI) (CA INDEX NAME)

RN 477573-38-9 HCAPLUS

CN 2H-Indol-2-one, 5-[[2,3-difluorophenyl)methyl]sulfonyl] -1,3-dihydro-
(9CI) (CA INDEX NAME)


RN 477573-39-0 HCAPLUS

CN 2H-Indol-2-one, 5-[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 477573-40-3 HCAPLUS

CN 2H-Indol-2-one, 5-[[(1,1'-biphenyl)-2-ylmethyl]sulfonyl]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 477573-41-4 HCAPLUS

CN 2H-Indol-2-one, 5-[[(2-fluoro-6-nitrophenyl)methyl]sulfonyl]-1,3-dihydro-
(9CI) (CA INDEX NAME)




RN 477573-42-5 HCAPLUS

CN 2H-Indol-2-one, 5-[[[3-(4-fluorophenoxy)phenyl]methyl]sulfonyl]-1,3-
dihydro- (9CI) (CA INDEX NAME)




RN 477573-43-6 HCAPLUS

CN 2H-Indol-2-one, 5-[[(3,5-dibromo-2-hydroxyphenyl)methyl]sulfonyl]-1,3-
dihydro- (9CI) (CA INDEX NAME)




RN 477573-44-7 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[2,3,5-trifluorophenyl)methyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-45-8 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-methyl-5-[(phenylmethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 477573-46-9 HCAPLUS

CN 2H-Indol-2-one, 5-[[2-fluorophenyl)methyl]sulfonyl]-1,3-dihydro-4-methyl- (9CI) (CA INDEX NAME)




RN 477573-47-0 HCAPLUS

CN Benzonitrile, 2-[[2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]methyl]- (9CI) (CA INDEX NAME)




RN 477573-48-1 HCAPLUS

CN 2H-Indol-2-one, 5-[[[(3-chlorophenyl)methyl]sulfonyl]-1,3-dihydro- (9CI)
(CA INDEX NAME)




RN 477573-49-2 HCAPLUS

CN Benzoic acid, 4-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 477573-50-5 HCAPLUS

CN Benzoic acid, 3-[[[(2,3-dihydro-2-oxo-1H-indol-5-yl)sulfonyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 477573-51-6 HCAPLUS

CN 2H-Indol-2-one, 5-[[[(2-chlorophenyl)methyl]sulfonyl]-1,3-dihydro- (9CI)
(CA INDEX NAME)




RN 477576-37-7 HCAPLUS

CN 1-Piperazinecarboxylic acid, 4-[2-[[[5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]acetyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B


/OBu-t

RN 477576-39-9 HCAPLUS


CN 1H-Pyrrole-3-acetamide, N-[2-[4-[(acetyloxy)acetyl]-1-piperazinyl]ethyl]-5-[(Z)-[5-[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B




RN 477576-58-2 HCAPLUS


CN 1-Piperazinecarboxylic acid, 4-[2-[[[5-[(Z)-[5-[[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



RN 477576-59-3 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, 5-[(Z)-[5-[[[2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 477576-60-6 HCAPLUS

CN 1H-Pyrrole-3-carboxamide, N-[2-[4-[(acetyloxy)acetyl]-1-piperazinyl]ethyl]-5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

—OAc


RN 477577-27-8 HCAPLUS

CN Carbamic acid, [2-[4-[2-[[[5-[(Z)-[5-[[[(2,6-dichlorophenyl)methyl]sulfonyl]-1,2-dihydro-2-oxo-3H-indol-3-ylidene]methyl]-2,4-dimethyl-1H-pyrrol-3-yl]carbonyl]amino]ethyl]-1-piperazinyl]-1,1-dimethyl-2-oxoethyl]-,


1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 1-B



L18 ANSWER 13 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:906195 HCAPLUS
 DOCUMENT NUMBER: 138:4618
 TITLE: Preparation of 3-quinoline-2(1H)-ylideneindolin-2-one derivatives as vascular endothelial growth factor (VEGF) inhibitors
 INVENTOR(S): Samizu, Kiyohiro; Hisamichi, Hiroyuki; Matsuhisa, Akira; Kinoyama, Isao; Hayakawa, Masahiko; Taniguchi, Nobuaki; Ideyama, Yukitaka; Kuromitsu, Sadao; Yahiro, Kiyoshi; Okada, Minoru
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002094809	A1	20021128	WO 2002-JP5014	20020523 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2448076 AA 20021128 CA 2002-2448076 20020523 <--
 EP 1396490 A1 20040310 EP 2002-728131 20020523 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 CN 1511151 A 20040707 CN 2002-810534 20020523 <--
 US 2005090498 A1 20050428 US 2003-478504 20020523
 PRIORITY APPLN. INFO.: JP 2001-155761 A 20010524
 WO 2002-JP5014 W 20020523
 OTHER SOURCE(S): MARPAT 138:4618
 GI



AB Novel 3-(1,2-dihydroquinolin-2-ylidene)indolin-2-one derivs. represented by the following general formula (I) or salts thereof [wherein A, B, E, G, J= N, CH; R1, R2 = lower alkyl, alkenyl, or alkynyl, Ra, X-(C1-8 alkylene optionally substituted by ORb)-Ra, X-C1-8 alkenylene-Ra, X-C1-8 alkynylene-Ra, provided that R1 and R2 are not substituted on N atom; X = O, CO, CO2, O2C, S, SO, SO2, NRb, NRbSO2, SO2NRb, CONRb, NRbCO, NRbCONRb, NRbCO2, O2CNRb, a single bond; wherein Ra = halo-lower alkyl, halo, NO2, cyano, ORb, O-lower alkylene-NRbRc, CO2Rb, CORb, CONRbRc, NRbRc, NRd-lower alkylene-NRbRc, etc.; Rb, Rc, Rd = H, lower alkyl, lower alkylene-RIN; RIN = (un)substituted saturated heterocyclyl, cycloalkyl, aryl, or heteroaryl; n, m = an integer of 0-4; provided that when A, B, E, G, and J are simultaneously C, they are not simultaneously N] are prepared. These compds. have excellent effects of inhibiting VEGF and **angiogenesis** and an antitumor effect and, therefore, are useful as appropriate VEGF inhibitors, **angiogenesis** inhibitors and anticancer agents. They are useful as remedies for diseases in which **angiogenesis** participates, e.g. solid tumors and diabetic retinopathy. Thus, 0.3 mL benzoyl chloride was added to a solution of 510 mg 6-[2-(1H-1,2,3-triazol-1-yl)ethoxy]quinoline N-oxide in 25 mL CHCl3 under ice-cooling and stirred at the same temperature for 30 min, followed by adding 265 mg indolidin-2-one, and the resulting mixture was refluxed at 90° for 8 h to give 3-[6-[2-(1H-1,2,3-triazol-1-yl)ethoxy]quinolin-2(1H)-ylidene]isoindolin-2-one (II). II and 5-fluoro-3-(quinolin-2(1H)-ylidene)isoindolin-2-one showed IC50 of 0.14 and 0.00097 μM, resp., for inhibiting the human recombinant VEGF-promoted uptake of [3H]thymidine in human umbilical vein endothelial cells (HUVEC).


IT 476656-85-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 3-quinoline-2(1H)-ylideneindolin-2-one derivs. as vascular endothelial growth factor (VEGF) inhibitors, **angiogenesis** inhibitors, and antitumor agents)

RN 476656-85-6 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-(phenylmethoxy)-3-(2(1H)-quinolinylidene)-
 (9CI) (CA INDEX NAME)




IT 476657-67-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-quinoline-2(1H)-ylideneindolin-2-one derivs. as vascular endothelial growth factor (VEGF) inhibitors, **angiogenesis** inhibitors, and antitumor agents)

RN 476657-67-7 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(phenylmethoxy)-3-(2(1H)-quinolinylidene)-
 (9CI) (CA INDEX NAME)




IT 458526-10-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-quinoline-2(1H)-ylideneindolin-2-one derivs. as vascular endothelial growth factor (VEGF) inhibitors, **angiogenesis** inhibitors, and antitumor agents)

RN 458526-10-8 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:


45

THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L18 ANSWER 14 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:814851 HCAPLUS
 DOCUMENT NUMBER: 137:310930
 TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties
 INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: U.S. Pat. Appl. Publ., 426 pp., Cont.-in-part of U.S. Ser. No. 663,780.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002156081	A1	20021024	US 2001-815310	20010322 <--
US 6921763	B2	20050726		
US 6660744	B1	20031209	US 2000-663780	20000915 <--
CA 2440724	AA	20021017	CA 2002-2440724	20020322 <--
WO 2002080926	A1	20021017	WO 2002-US9104	20020322 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1385524	A1	20040204	EP 2002-746301	20020322 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CN 1520298	A	20040811	CN 2002-810250	20020322 <--
JP 2004531513	T2	20041014	JP 2002-578965	20020322
BR 2002005889	A	20041109	BR 2002-5889	20020322
ZA 2003006886	A	20040716	ZA 2003-6886	20030903 <--
NO 2003004176	A	20031121	NO 2003-4176	20030919 <--
BG 108269	A	20041230	BG 2003-108269	20031014
PRIORITY APPLN. INFO.:			US 1999-154620P	P 19990917
			US 2000-663780	A2 20000915
			US 2001-815310	A 20010322
			WO 2002-US9104	W 20020322
OTHER SOURCE(S):		MARPAT 137:310930		
GI				




- AB Title compds. I [wherein G = (un)substituted 5-6 membered (azahetero)aryl; R² = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or C₆H₄-4-CH₂E; E = (un)substituted alkyl-OR, alkyl-CO₂R, alkylheteroaryl, alkylheterocycloalkyl, or alkyl-NR²; R = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); R³ = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prepared For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. Treatment of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh₃)₄, and Na₂CO₃ in H₂O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addition of morpholine to the benzaldehyde in the presence of Na(AcO)₃BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concentration of ≤ 50 μM. Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of ≤ 50 μM. Thus, I are useful for the treatment of a wide variety of disease states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no data).
- IT **461702-74-9**, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(benzyloxy)-1H-2-indolecarboxamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
- RN **461702-74-9** HCAPLUS
- CN 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidiny1)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



IT **461702-75-0P**, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate **461702-83-0P**, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protein kinase inhibitor; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
 RN 461702-75-0 HCAPLUS
 CN 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate (9CI)
 (CA INDEX NAME)
 CM 1
 CRN 461702-74-9
 CMF C33 H32 N8 O3



CM 2
 CRN 64-19-7
 CMF C2 H4 O2




RN 461702-83-0 HCAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 461702-82-9


CMF C33 H32 N8 O3



CM 2

CRN 64-19-7

CMF C2 H4 O2



L18 ANSWER 15 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:793426 HCAPLUS

DOCUMENT NUMBER: 137:310925

TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties

INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.

PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany

SOURCE: PCT Int. Appl., 867 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080926	A1	20021017	WO 2002-US9104	20020322 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2002156081	A1	20021024	US 2001-815310	20010322 <--
US 6921763	B2	20050726		
CA 2440724	AA	20021017	CA 2002-2440724	20020322 <--
EP 1385524	A1	20040204	EP 2002-746301	20020322 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004531513	T2	20041014	JP 2002-578965	20020322
BR 2002005889	A	20041109	BR 2002-5889	20020322
NO 2003004176	A	20031121	NO 2003-4176	20030919 <--
PRIORITY APPLN. INFO.:			US 2001-815310	A 20010322
			US 1999-154620P	P 19990917
			US 2000-663780	A2 20000915
			WO 2002-US9104	W 20020322
OTHER SOURCE(S):	MARPAT 137:310925			
GI				



AB Title compds. I [wherein G = (un)substituted 5-6 membered (azahetero)aryl; R2 = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or C6H4-4-CH2E; E = (un)substituted alkyl-OR, alkyl-CO2R, alkylheteroaryl,

alkylheterocycloalkyl, or alkyl-NR₂; R = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); R₃ = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prepared For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. Treatment of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh₃)₄, and Na₂CO₃ in H₂O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addition of morpholine to the benzaldehyde in the presence of Na(AcO)₃BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concentration of ≤ 50 μM. Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of ≤ 50 μM. Thus, I are useful for the treatment of a wide variety of disease states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no data).

- IT **461702-74-9**, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(benzyloxy)-1H-2-indolecarboxamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
- RN 461702-74-9 HCAPLUS
- CN 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)




- IT **461702-75-0P**, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate **461702-83-0P**, 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protein kinase inhibitor; preparation of [(hetero)aryl]pyrazolo[3,4-d]pyrimidinamines as protein kinase inhibitors with antiangiogenic properties)
- RN 461702-75-0 HCAPLUS
- CN 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate (9CI)

(CA INDEX NAME)

CM 1

CRN 461702-74-9


CMF C33 H32 N8 O3



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 461702-83-0 HCAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidiny1)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate (9CI)
(CA INDEX NAME)


CM 1

CRN 461702-82-9

CMF C33 H32 N8 O3



CM 2

CRN 64-19-7
CMF C2 H4 O2

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 16 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:777727 HCAPLUS
DOCUMENT NUMBER: 137:288985
TITLE: Inhibitors of prenyl-protein transferase
INVENTOR(S): Desolms, S. Jane; Shaw, Anthony W.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078702	A1	20021010	WO 2002-US9208	20020326 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-280610P	P 20010330

OTHER SOURCE(S): MARPAT 137:288985


AB The present invention is directed to compds. which inhibit a prenyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The compds. of the present invention comprise non-prodrug, non-thiol compds. that contain a spirocyclic pyrrolidinyl moiety. The invention is further directed to chemotherapeutic compns. containing the compds. of this invention and methods for inhibiting a prenyl-protein transferase and the prenylation of the oncogene protein Ras.

IT 467424-14-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors of prenyl-protein transferase)

RN 467424-14-2 HCAPLUS

CN Benzonitrile, 2-(1H-indol-7-yloxy)-4-[2-(1-methyl-1H-imidazol-5-yl)-2-pyrrolidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 17 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:754390 HCAPLUS

DOCUMENT NUMBER: 137:263056

TITLE: Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties

INVENTOR(S): Hirst, Gavin C.; Rafferty, Paul; Ritter, Kurt; Calderwood, David; Wishart, Neil; Arnold, Lee D.; Friedman, Michael M.

PATENT ASSIGNEE(S): Abbott GmbH & Co. KG, Germany

SOURCE: PCT Int. Appl., 440 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076986	A1	20021003	WO 2002-US8996	20020322 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2440714	AA	20021003	CA 2002-2440714	20020322 <--
EP 1379528	A1	20040114	EP 2002-728546	20020322 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002005890	A	20040629	BR 2002-5890	20020322 <--
JP 2005501811	T2	20050120	JP 2002-576244	20020322
US 2004006083	A1	20040108	US 2002-104140	20020719 <--
ZA 2003006887	A	20040913	ZA 2003-6887	20030903 <--
NO 2003004177	A	20031121	NO 2003-4177	20030919 <--
BG 108268	A	20050430	BG 2003-108268	20031014
PRIORITY APPLN. INFO.:			US 2001-278047P	P 20010322

OTHER SOURCE(S) :
GI

MARPAT 137:263056



AB Title compds. I [wherein G = (un)substituted 5-6 membered (azahetero)aryl; R^2 = H or (un)substituted trityl, cycloalkenyl, azaheteroaryl, or $C_6H_4-4-CH_2E$; E = (un)substituted alkyl-OR, alkyl-CO $2R$, alkylheteroaryl, alkylheterocycloalkyl, or alkyl-NR 2 ; R = independently H or (un)substituted (cyclo)alkyl, or aryl(alkyl); R^3 = independently H, OH, or (un)substituted alkyl, alkyl-CO, (hetero)aryl-CO, or alkoxy; or racemic diastereomeric mixts., optical isomers, pharmaceutically acceptable salts, prodrugs, and/or biol. active metabolites thereof] were prepared For example, 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine was coupled with 4-fluorobenzaldehyde in the presence of NaH in DMF to give 4-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)benzaldehyde. Treatment of the 3-iodopyrazolopyrimidine with N-[2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-fluoro-4-(trifluoromethyl)benzamide, Pd(PPh $_3$) $_4$, and Na $_2$ CO $_3$ in H $_2$ O afforded the N-[4-(pyrazolopyrimidin-3-yl)phenyl]benzamide. Addition of morpholine to the benzaldehyde in the presence of Na(AcO) $_3$ BH in dichloroethane produced II. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concentration of ≤ 50 μ M. Certain compds. of the invention also significantly inhibited cdc2 or cellular VEGF-induced KDR tyrosine kinase phosphorylation at concns. of ≤ 50 μ M. Thus, I are useful for the treatment of a wide variety of disease states ameliorated by the inhibition of protein tyrosine kinase activity essential for angiogenic processes (no data).

IT **461702-75-0P 461702-83-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties)


RN 461702-75-0 HCAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)-, monoacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 461702-74-9


CMF C33 H32 N8 O3



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 461702-83-0 HCAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-4-(phenylmethoxy)-, monoacetate (9CI)
(CA INDEX NAME)

CM 1

CRN 461702-82-9


CMF C33 H32 N8 O3



CM 2

CRN 64-19-7


CMF C2 H4 O2



IT **461702-74-9**, N-[4-[4-Amino-1-(4-piperidyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(benzyloxy)-1H-indole-2-carboxamide
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of (azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties)

RN 461702-74-9 HCAPLUS

CN 1H-Indole-2-carboxamide, N-[4-[4-amino-1-(4-piperidinyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl]-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 18 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:695948 HCAPLUS
 DOCUMENT NUMBER: 137:232556


TITLE: Preparation of indolones as **angiogenesis** inhibitors.
 INVENTOR(S): Arnould, Jean Claude
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
 SOURCE: PCT Int. Appl., 65 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070478	A1	20020912	WO 2002-GB947	20020304 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1370527	A1	20031217	EP 2002-702529	20020304 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529110	T2	20040924	JP 2002-569798	20020304 <--
US 2004147589	A1	20040729	US 2004-469834	20040116 <--
PRIORITY APPLN. INFO.:			EP 2001-400583	A 20010306
			WO 2002-GB947	W 20020304
OTHER SOURCE(S):			MARPAT 137:232556	
GI				




AB Use of title compds. [I; X = O, S, SO, SO₂, NR₅, CO, CONR₅, SO₂NR₅; R₁ = amino, halo, OH, OPO₃H₂, alkyl, alkoxy, wherein the amino group is optionally substituted by an amino acid residue and the OH group is optionally esterified; R₂ = H, alkyl; R₃ = H, halo, OH, hydroxyalkyl, cyano, cyanoalkyl, carboxy, carboxyalkyl, alkanoyl, alkanoylalkyl, carbamoyl, carbamoylalkyl, alkoxy, alkoxy-carbonyl, alkoxy-carbonylalkyl, alkoxy-carbonylamino, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, ureido, alkylureylene; R₄ = alkyl, alkoxy, halo; R₅ = H, alkyl; n = 0, 1; p = 0-3; q = 0-2] for manufacture of a medicament for treatment of **angiogenesis**-associated disease is claimed (no data). Thus, 2-NO₂-5-(phenylthio)phenylacetic acid (preparation given) was heated at 100° for 10 h with Zn, H₂SO₄, and EtOH to give 31% 5-(phenylthio)-1,3-dihydro-2H-indol-2-one.


IT 458525-84-3P, 5-(Phenylsulfanyl)-1,3-dihydro-2H-indol-2-one
 458525-85-4P, 5-(4-Aminophenoxy)-1,3-dihydro-2H-indol-2-one
 458525-86-5P, 5-(4-Aminophenylsulfanyl)-1,3-dihydro-2H-indol-2-one
 458525-87-6P, 5-(4-Hydroxyphenylsulfanyl)-1,3-dihydro-2H-indol-2-one
 458525-88-7P, 6-(3-Aminobenzyloxy)-1,3-dihydro-2H-indol-2-one
 458525-89-8P 458525-90-1P 458525-91-2P
 458525-92-3P 458525-93-4P 458525-94-5P
 458526-08-4P 458526-09-5P 458526-10-8P
 458526-11-9P 458526-12-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of indolones as **angiogenesis** inhibitors)
 RN 458525-84-3 HCAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-5-(phenylthio)- (9CI) (CA INDEX NAME)




RN 458525-85-4 HCAPLUS
 CN 2H-Indol-2-one, 5-(4-aminophenoxy)-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 458525-86-5 HCAPLUS
 CN 2H-Indol-2-one, 5-[(4-aminophenyl)thio]-1,3-dihydro- (9CI) (CA INDEX NAME)




RN 458525-87-6 HCAPLUS
 CN 2H-Indol-2-one, 5-[(4-hydroxyphenyl)thio]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 458525-88-7 HCAPLUS
 CN 2H-Indol-2-one, 6-[(3-aminophenyl)methoxy]-1,3-dihydro- (9CI) (CA INDEX NAME)


NAME)



RN 458525-89-8 HCAPLUS

CN Pentanoic acid, 4-amino-5-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)oxy]phenyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 458525-90-1 HCAPLUS


CN Propanamide, 2-amino-N-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)oxy]phenyl]-3-hydroxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 458525-91-2 HCAPLUS


CN Acetamide, 2-amino-N-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)oxy]phenyl]- (9CI) (CA INDEX NAME)



RN 458525-92-3 HCAPLUS

CN Pentanoic acid, 4-amino-5-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)thio]phenyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 458525-93-4 HCAPLUS


CN Pentanoic acid, 4-amino-5-[[3-[[[(2,3-dihydro-2-oxo-1H-indol-6-yl)oxy]methyl]phenyl]amino]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 458525-94-5 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-[[4-(phosphonooxy)phenyl]thio]- (9CI) (CA INDEX NAME)




RN 458526-08-4 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 458526-09-5 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-1-methyl-6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 458526-10-8 HCAPLUS
 CN 2H-Indol-2-one, 1,3-dihydro-4-(phenylmethoxy) - (9CI) (CA INDEX NAME)



RN 458526-11-9 HCAPLUS
 CN Pentanoic acid, 4-amino-5-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)oxy]phenyl]amino]-5-oxo-, hydrochloride (20:19), (4S) - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●19/20 HCl

RN 458526-12-0 HCAPLUS
 CN Pentanoic acid, 4-amino-5-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)thio]phenyl]amino]-5-oxo-, hydrochloride (10:9), (4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●9/10 HCl

IT 458525-99-0P 458526-00-6P 458526-01-7P
 458526-02-8P 458526-05-1P 458526-06-2P
 458526-07-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of indolones as **angiogenesis** inhibitors)
 RN 458525-99-0 HCAPLUS
 CN Pentanoic acid, 4-amino-5-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-

yl)oxy]phenyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 458526-00-6 HCAPLUS


CN Carbamic acid, [(1S)-2-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)oxy]phenyl]amino]-1-(hydroxymethyl)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 458526-01-7 HCAPLUS


CN Carbamic acid, [2-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)oxy]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 458526-02-8 HCAPLUS


CN Pentanoic acid, 4-amino-5-[[4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)thio]phenyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 458526-05-1 HCAPLUS


CN 2H-Indol-2-one, 1,3-dihydro-6-[(3-nitrophenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 458526-06-2 HCAPLUS


CN Pentanoic acid, 4-amino-5-[[3-[[[(2,3-dihydro-2-oxo-1H-indol-6-yl)oxy]methyl]phenyl]amino]-5-oxo-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 458526-07-3 HCAPLUS

CN Phosphoric acid, 4-[(2,3-dihydro-2-oxo-1H-indol-5-yl)thiol]phenyl bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 19 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN



ACCESSION NUMBER: 2002:637636 HCAPLUS

DOCUMENT NUMBER: 137:185515

TITLE: Preparation of acylated indanyl amines and their use as remedies in upregulation of endothelial nitric

INVENTOR(S) : oxide synthase
 Strobel, Hartmut; Wohlfart, Paulus; Safarova, Alena;
 Walser, Armin; Suzuki, Teri; Dharanipragada, Ramalinga
 M.
 PATENT ASSIGNEE(S) : Aventis Pharma Deutschland GmbH, Germany
 SOURCE: PCT Int. Appl., 137 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064545	A1	20020822	WO 2002-EP1444	20020212 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437944	AA	20020822	CA 2002-2437944	20020212 <--
EE 200300369	A	20031015	EE 2003-369	20020212 <--
EP 1373191	A1	20040102	EP 2002-722067	20020212 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2002007211	A	20040127	BR 2002-7211	20020212 <--
CN 1491207	A	20040421	CN 2002-804836	20020212 <--
JP 2004518719	T2	20040624	JP 2002-564478	20020212 <--
NZ 527470	A	20050429	NZ 2002-527470	20020212
US 2003055093	A1	20030320	US 2002-73160	20020213 <--
ZA 2003005413	A	20040428	ZA 2003-5413	20030714 <--
BG 108076	A	20050531	BG 2003-108076	20030807
NO 2003003565	A	20031013	NO 2003-3565	20030812 <--
PRIORITY APPLN. INFO.:			EP 2001-102850	A 20010213
			WO 2002-EP1444	W 20020212
OTHER SOURCE(S) : GI	MARPAT 137:185515			



AB Title compds. [I; R1-R4 =; A = CH₂, CHOH, CH(C1-C3-alkyl); B = CH₂, CH(C1-C3-alkyl); R5 = aryl, heteroaryl] are prepared and are useful in the upregulation of endothelial nitric oxide synthase (eNOS). Title compds. I may therefore be useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA (percutaneous trans-luminal coronary angioplasty), hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes or diabetes complications, nephropathy or retinopathy, **angiogenesis**, asthma bronchial, chronic renal failure, cirrhosis of the liver, osteoporosis, restricted memory performance, a restricted ability to learn, or for the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives. Thus, the title compound II was prepared from 2-amino-4-methylindane and 4-fluorobenzoyl chloride, purified by HPLC and was in vitro tested on human umbilical vein cord endothelial cells for activation effect of eNOS transcription with EC-50 (μM) = 6.0 and TIR(max) = 2.80.


IT **450353-75-0P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation method of acylated indanyl amines and use as remedies in upregulation of endothelial nitric oxide synthase)

RN 450353-75-0 HCAPLUS

CN 1H-Indole-2-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-5-(phenylmethoxy)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 20 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:514276 HCAPLUS

DOCUMENT NUMBER: 137:63079

TITLE: Preparation of aminobenzoic acids and their use as vascular endothelial growth factor (VEGF) receptor antagonists

INVENTOR(S): Wada, Hisaya; Asanuma, Hajime; Takayama, Tetsuo; Sato, Masakazu; Yamagishi, Takehiro; Shibuya, Masashi

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent




LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002193923	A2	20020710	JP 2000-395413	20001226 <--
PRIORITY APPLN. INFO.:			JP 2000-395413	20001226
OTHER SOURCE(S):	MARPAT	137:63079		

GI



AB Title compds. I [R1 = H, C1-6 alkyl; R2 = C1-6 alkylthio, carboxyphenoxy, alkoxy-carbonylphenoxy; R3 = H, C1-6 alkyl; R4 = C14-20 alkyl; X = Q1, Q2; Y = O, NH, :N; A = O, (C1-6 alkyl-substituted) amide group; n = 0, 1] or

their medically acceptable salts, useful for treatment of diabetic retinopathy, rheumatoid arthritis, solid tumor, etc., are prepared Thus, amidation of Me 5-amino-2-methylthiobenzoate with 6-(octadecyloxy)-2-naphthoic acid gave I (R1 = Me, R2 = MeS, R3 = H, XAR4 = 6-(octadecyloxy)-2-naphthyl, n = 0], which was hydrolyzed to give the corresponding carboxylic acid derivative The product inhibited binding of VEGF to its receptor with IC50 of 0.87 μ M.


IT 1215-59-4, 5-Benzyloxyindole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of aminobenzoic acids as vascular endothelial growth factor receptor antagonists)

RN 1215-59-4 HCAPLUS

CN 1H-Indole, 5-(phenylmethoxy)- (9CI) (CA INDEX NAME)




IT 402933-28-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of aminobenzoic acids as vascular endothelial growth factor receptor antagonists)

RN 402933-28-2 HCAPLUS

CN 1H-Indole-1-acetic acid, 5-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)



L18 ANSWER 21 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:353460 HCAPLUS

DOCUMENT NUMBER: 136:355230

TITLE: Preparation of tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles, hexahydrocyclohept[b]indoles, and related compounds with cytotoxic and antiangiogenic activity.

INVENTOR(S): Giannini, Giuseppe; Marzi, Mauro; Tinti, Maria Ornella; Pisano, Claudio

PATENT ASSIGNEE(S): Sigma-Tau Industrie Farmaceutiche Riunite S.P.A., Italy

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2002036597 A1 20020510 WO 2001-IT526 20011016 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,
PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
IT 1317926 B1 20030715 IT 2000-RM570 20001103 <--
CA 2427568 AA 20020510 CA 2001-2427568 20011016 <--
AU 2002015186 A5 20020515 AU 2002-15186 20011016 <--
EP 1343789 A1 20030917 EP 2001-983768 20011016 <--
EP 1343789 B1 20050824
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
BR 2001015119 A 20030930 BR 2001-15119 20011016 <--
JP 2004513130 T2 20040430 JP 2002-539355 20011016 <--
AT 302780 E 20050915 AT 2001-983768 20011016
US 2004034052 A1 20040219 US 2003-415896 20030828 <--
US 6887892 B2 20050503
US 2005124647 A1 20050609 US 2005-32068 20050111
PRIORITY APPLN. INFO.: IT 2000-RM570 A 20001103
WO 2001-IT526 W 20011016
OTHER SOURCE(S): MARPAT 136:355230
GI




AB Title compds. [I; X = CH, N; X1 = O, S, N, CH; R, R1 = H, OH, OR5, NO2,
amino, CO2H, alkoxy carbonyl; RR1 = aliphatic or aromatic cyclic group having
5-6
atoms; R5 = alkyl, benzyl; 2 vicinal R5 = CH2; when X1 = N, CH, then R2 =
H, Ph, PhCH2, alkyl; n = 0-4; R3, R4 = H, OH, OR6; R6 = alkyl; when R3 =
R4 = vicinal OR6, then R6 = isopropylidene; A = Q1, A1 = H; or A1 = Q1, A
= H, R7; R7 = CHO, CH:NOH, (HO-, R6O-substituted) alkyl], were prepared
Thus, 1-(indol-3-yl)-2,3-O-isopropylidene-4-(2,3-O-
isopropylideneethyl)tetrahydrocarbazole (preparation outlined) showed IC50 =
21.1 μ M against MCF-7 cells.
IT **422323-85-1P 422323-87-3P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(preparation of tetrahydrocyclopentindoles, tetrahydrocarbazoles,
hexahydrocycloheptindoles, and related compds. with cytotoxic and
antiangiogenic activity)
RN 422323-85-1 HCAPLUS
CN Cyclohept[b]indole, 5,6,7,8,9,10-hexahydro-2-(phenylmethoxy)-6-[5-

(phenylmethoxy)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



RN 422323-87-3 HCAPLUS

CN Cyclohept[b]indole, 5,6,7,8,9,10-hexahydro-2-(phenylmethoxy)-10-[5-(phenylmethoxy)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 22 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:886064 HCAPLUS

DOCUMENT NUMBER: 136:20012

TITLE: Synthetic preparation of indole derivatives with potential vascular damaging activity

INVENTOR(S): Arnould, Jean-Claude; Bird, Thomas Geoffrey; Boyle, Francis Thomas; Blakey, David Charles

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Ltd.

SOURCE: PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001092224	A1	20011206	WO 2001-GB2335	20010525 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				

*Copied
from
to Amines*

BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2406979	AA	20011206	CA 2001-2406979	20010525 <--
EP 1289952	A1	20030312	EP 2001-931944	20010525 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001011230	A	20030610	BR 2001-11230	20010525 <--
JP 2003535078	T2	20031125	JP 2002-500839	20010525 <--
NZ 522074	A	20040625	NZ 2001-522074	20010525 <--
ZA 2002008938	A	20040204	ZA 2002-8938	20021104 <--
US 2003216356	A1	20031120	US 2002-276347	20021113 <--
NO 2002005696	A	20021127	NO 2002-5696	20021127 <--
PRIORITY APPLN. INFO.:			EP 2000-401551	A 20000531
			EP 2000-402956	A 20001025
			WO 2001-GB2335	W 20010525
OTHER SOURCE(S):	MARPAT 136:20012			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides a compound of formula I [R1, R2 = independently H, halogen, CN, hydrocarbyl group or a group of formula II: wherein W = aryl or heterocyclic group, R4 = independently H, halogen, OH, amino, alkanoylamino, OPO3H2, or hydrocarbyl group, wherein the amino group is optionally substituted by an amino acid residue and the hydroxy group is optionally esterified or two R4 groups together form an optionally substituted cyclic or heterocyclic group; X = S, O, S(O), S(O2), or NH; p = 0,1,2,3 or 4; q = 1,2,3 or 4; R3, R10 = independently H, lower alkyl or a group of formula III: wherein Y = NH, O or a bond; Z = NH, O, C(O) or a bond; r = 0,1,2,3 or 4; t = 0 or 1; R6 = H, hydrocarbyl group or a group of formula IV: wherein n = 1,2,3,4,5 or 6; R7, R8 = independently H or hydrocarbyl group; R11 = H or lower alkyl; or a salt or solvate thereof; provided that: when R1 = unsubstituted Sph, R2,R10, and R11 = H then R3 is neither H nor- C(O)OEt; and R1, R2 and R3 are not all H.]. Thus, 5-(4-hydroxyphenylsulphanyl)-2-amino-1H-indole-3-carbonitrile (V) was produced from 4-(4-hydroxyphenylsulphanyl)-2-chloro-nitrobenzene and malononitrile in 62% yield. Such compds. are predicted to cause the selective destruction of tumor vasculature and they may therefore be used to inhibit and/or reverse, and/or alleviate symptoms of **angiogenesis** and/or any disease state associated with **angiogenesis**. For example, V has an activity of 36% in the colchicine binding site competitive assay at 10 μ M and 55% in the cell detachment assay at 100 μ M and 6-methyl-5-fluoro-2-amino-1H-indole-3-carbonitrile (VI) has an activity of 31% in the colchicine binding site competitive assay at 10 μ M and 34% in the cell detachment assay at 100 μ M.


IT 378236-89-6P 378236-96-5P 378236-97-6P
 378237-07-1P 378237-10-6P 378237-12-8P
 378237-15-1P 378237-25-3P 378237-30-0P
 378237-31-1P 378237-32-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (indole derivs. with potential vascular damaging activity)

RN 378236-89-6 HCAPLUS


CN 1H-Indole-3-carbonitrile, 2-amino-5-(3,4,5-trimethoxyphenoxy)- (9CI) (CA INDEX NAME)




RN 378236-96-5 HCAPLUS
CN Acetamide, N-[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl] - (9CI) (CA INDEX NAME)




RN 378236-97-6 HCAPLUS
CN 1H-Indole-3-carbonitrile, 2-amino-5-(4-aminophenoxy) - (9CI) (CA INDEX NAME)




RN 378237-07-1 HCAPLUS
CN 1H-Indole-3-carbonitrile, 2-amino-6-(phenylmethoxy) - (9CI) (CA INDEX NAME)




RN 378237-10-6 HCAPLUS
CN 1H-Indole-3-carbonitrile, 2-amino-5-[4-(phenylmethoxy)phenoxy] - (9CI) (CA INDEX NAME)




RN 378237-12-8 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 2-amino-5-(4-hydroxyphenoxy) - (9CI) (CA INDEX NAME)




RN 378237-15-1 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 2-amino-5-[(3-aminophenyl)methoxy]-1-methyl- (9CI) (CA INDEX NAME)




RN 378237-25-3 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 2-amino-5-(4-hydroxyphenoxy)-1-methyl- (9CI) (CA INDEX NAME)




RN 378237-30-0 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 2-amino-1-methyl-5-(3,4,5-trimethoxyphenoxy) - (9CI) (CA INDEX NAME)




RN 378237-31-1 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 2-amino-5-(4-hydroxy-3,5-dimethoxyphenoxy)-1-methyl- (9CI) (CA INDEX NAME)




RN 378237-32-2 HCAPLUS
 CN 1H-Indole-1-acetamide, 2-amino-3-cyano-5-(3,4,5-trimethoxyphenoxy)- (9CI)
 (CA INDEX NAME)




IT 378236-69-2P 378236-71-6P 378236-73-8P
 378236-76-1P 378236-78-3P 378236-85-2P
 378236-87-4P 378236-93-2P 378236-94-3P
 378236-99-8P 378237-01-5P 378237-03-7P
 378237-05-9P 378237-08-2P 378237-13-9P
 378237-20-8P 378237-22-0P 378237-27-5P
 378237-28-6P 378237-29-7P 378237-33-3P
 378237-35-5P 378237-36-6P 378245-38-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (indole derivs. with potential vascular damaging activity)
 RN 378236-69-2 HCAPLUS
 CN Carbamic acid, [3-cyano-5-(phenylthio)-1H-indol-2-yl]-, phenyl ester (9CI)
 (CA INDEX NAME)




RN 378236-71-6 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 2-amino-5-[(4-hydroxyphenyl)thio]- (9CI) (CA
 INDEX NAME)




RN 378236-73-8 HCAPLUS
CN 1H-Indole-3-carbonitrile, 2-amino-5-[(3,4-dimethoxyphenyl)thio]- (9CI)
(CA INDEX NAME)




RN 378236-76-1 HCAPLUS
CN 1H-Indole-3-carbonitrile, 2-amino-5-[(3-methoxyphenyl)thio]- (9CI) (CA
INDEX NAME)




RN 378236-78-3 HCAPLUS
CN 1H-Indole-3-carbonitrile, 2-amino-5-[(4-fluorophenyl)thio]- (9CI) (CA
INDEX NAME)




RN 378236-85-2 HCAPLUS
CN 1H-Indole-3-carbonitrile, 2-amino-5-(4-methoxyphenoxy)- (9CI) (CA INDEX
NAME)



RN 378236-87-4 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 2-amino-5-[(2,5-dimethoxyphenyl)thio]- (9CI)
 (CA INDEX NAME)




RN 378236-93-2 HCAPLUS
 CN Carbamic acid, [3-cyano-5-(phenylthio)-1H-indol-2-yl]-, 3-(4-methyl-1-piperazinyl)propyl ester, hydrochloride (5:2) (9CI) (CA INDEX NAME)



●2/5 HCl


RN 378236-94-3 HCAPLUS
 CN 1H-Indole-1-carboxylic acid, 2-amino-3-cyano-5-(phenylthio)-, 3-(4-methyl-1-piperazinyl)propyl ester, hydrochloride (10:47) (9CI) (CA INDEX NAME)



●47/10 HCl

RN 378236-99-8 HCAPLUS


CN Acetamide, 2-amino-N-[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl]- (9CI)
(CA INDEX NAME)



RN 378237-01-5 HCAPLUS

CN Propanamide, 2-amino-N-[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378237-03-7 HCAPLUS

CN Pentanoic acid, 4-amino-5-[[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl]amino]-5-oxo-, hydrochloride (20:23), (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●23/20 HCl

RN 378237-05-9 HCAPLUS

CN Propanamide, 2-amino-N-[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl]-3-hydroxy-, hydrochloride (5:7), (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●7/5 HCl

RN 378237-08-2 HCAPLUS

CN 1-Piperazinebutanamide, N-[3-cyano-6-(phenylmethoxy)-1H-indol-2-yl]-4-methyl-γ-oxo-, hydrochloride (10:11) (9CI) (CA INDEX NAME)




●11/10 HCl

RN 378237-13-9 HCAPLUS


CN 1-Piperazinebutanoic acid, 4-methyl-γ-oxo-, 4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl ester (9CI) (CA INDEX NAME)

Grazier 10_509633



RN 378237-20-8 HCAPLUS

CN Acetamide, 2-amino-N-[3-[[2-amino-3-cyano-1-methyl-1H-indol-5-yl]oxy]methyl]phenyl]-, hydrochloride (10:19) (9CI) (CA INDEX NAME)




●19/10 HCl

RN 378237-22-0 HCAPLUS

CN Propanamide, 2-amino-N-[3-[[2-amino-3-cyano-1-methyl-1H-indol-5-yl]oxy]methyl]phenyl]-3-hydroxy-, hydrochloride (5:7), (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●7/5 HCl


RN 378237-27-5 HCAPLUS

CN 1H-Indole-3-carbonitrile, 2-amino-1-methyl-5-[4-(phosphonooxy)phenoxy]- (9CI) (CA INDEX NAME)




RN 378237-28-6 HCAPLUS

CN 1H-Indole-1-acetamide, 2-amino-3-cyano-5-(phenylmethoxy) - (9CI) (CA INDEX NAME)




RN 378237-29-7 HCAPLUS

CN 1H-Indole-3-carbonitrile, 2-amino-5-(4-hydroxy-3,5-dimethoxyphenoxy) - (9CI) (CA INDEX NAME)




RN 378237-33-3 HCAPLUS

CN 1H-Indole-1-acetamide, 2-amino-3-cyano-5-(4-hydroxy-3,5-dimethoxyphenoxy) - (9CI) (CA INDEX NAME)




RN 378237-35-5 HCAPLUS

CN 1H-Indole-3-carbonitrile, 2-amino-5-[3,5-dimethoxy-4-(phosphonoxy)phenoxy] -1-methyl - (9CI) (CA INDEX NAME)



RN 378237-36-6 HCAPLUS


CN 1H-Indole-3-carbonitrile, 2-amino-5-[4-(phosphonooxy)phenoxy]- (9CI) (CA INDEX NAME)



RN 378245-38-6 HCAPLUS

CN 1H-Indole-3-carbonitrile, 2-amino-5-[[3-[(2S)-2-amino-3-hydroxy-1-oxopropyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 91531-98-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(indole derivs. with potential vascular damaging activity)

RN 91531-98-5 HCAPLUS

CN 1H-Indole-3-carbonitrile, 2-amino-5-(phenylthio)- (9CI) (CA INDEX NAME)



IT 378236-98-7P 378237-00-4P 378237-02-6P

378237-04-8P 378237-06-0P 378237-14-0P

378237-16-2P 378237-17-3P 378237-19-5P

378237-21-9P 378237-23-1P 378237-24-2P


378237-26-4P 378237-34-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(indole derivs. with potential vascular damaging activity)

RN 378236-98-7 HCAPLUS


CN Carbamic acid, [2-[[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl]amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 378237-00-4 HCAPLUS

CN Carbamic acid, [(1S)-2-[[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl]amino]-1-methyl-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378237-02-6 HCAPLUS

CN Pentanoic acid, 5-[[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl]amino]-4-[[[(1,1-dimethylethoxy)carbonyl]amino]-5-oxo]-, 1,1-dimethylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 378237-04-8 HCAPLUS

CN Propanamide, 2-amino-N-[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl]-3-

Grazier 10_509633

(1,1-dimethylethoxy)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 378237-06-0 HCAPLUS


CN Carbamic acid, [(1S)-2-[[4-[(2-amino-3-cyano-1H-indol-5-yl)oxy]phenyl]amino]-1-[(1,1-dimethylethoxy)methyl]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 378237-14-0 HCAPLUS

CN 1H-Indole-3-carbonitrile, 2-amino-1-methyl-5-[(3-nitrophenyl)methoxy] - (9CI) (CA INDEX NAME)




RN 378237-16-2 HCAPLUS

CN 1H-Indole-3-carbonitrile, 2-amino-5-(phenylmethoxy) - (9CI) (CA INDEX NAME)




RN 378237-17-3 HCAPLUS

CN 1H-Indole-3-carbonitrile, 2-amino-1-methyl-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 378237-19-5 HCAPLUS


CN Carbamic acid, [2-[[3-[[[(2-amino-3-cyano-1-methyl-1H-indol-5-yl)oxy)methyl]phenyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 378237-21-9 HCAPLUS

CN Propanamide, 2-amino-N-[3-[[[(2-amino-3-cyano-1-methyl-1H-indol-5-yl)oxy)methyl]phenyl]-3-(1,1-dimethylethoxy)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 378237-23-1 HCAPLUS

CN Carbamic acid, [(1S)-2-[[3-[[[(2-amino-3-cyano-1-methyl-1H-indol-5-yl)oxy)methyl]phenyl]amino]-1-[(1,1-dimethylethoxy)methyl]-2-oxoethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 378237-24-2 HCAPLUS
 CN 1H-Indole-3-carbonitrile, 2-amino-1-methyl-5-[4-(phenylmethoxy)phenoxy]-(9CI) (CA INDEX NAME)



RN 378237-26-4 HCAPLUS
 CN Phosphoric acid, 4-[(2-amino-3-cyano-1-methyl-1H-indol-5-yl)oxy]phenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 378237-34-4 HCAPLUS
 CN Phosphoric acid, 4-[(2-amino-3-cyano-1-methyl-1H-indol-5-yl)oxy]-2,6-dimethoxyphenyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 23 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:836852 HCAPLUS

DOCUMENT NUMBER: 136:112229

TITLE: Synthetic 2-Aroylindole Derivatives as a New Class of Potent Tubulin-Inhibitory, Antimitotic Agents

AUTHOR(S): Mahboobi, Siavosh; Pongratz, Herwig; Hufsky, Harald; Hockemeyer, Joerg; Frieser, Markus; Lyssenko, Alexei; Paper, Dietrich H.; Buergermeister, Jutta; Boehmer, Frank-D.; Fiebig, Heinz-Herbert; Burger, Angelika M.; Baasner, Silke; Beckers, Thomas

CORPORATE SOURCE: Faculty of Chemistry and Pharmacy Institute of Pharmacy, University of Regensburg, Regensburg, D-93040, Germany

SOURCE: Journal of Medicinal Chemistry (2001), 44(26), 4535-4553

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:112229

AB A new class of simple synthetic antimitotic compds. based on 2-aryloindoles was discovered. (5-Methoxy-1H-2-indolyl)-phenylmethanone (I) as well as analogous 3-fluorophenyl- and 3-methoxyphenyl derivs. displayed high cytotoxicity of IC50 = 20 to 75 nM against the human HeLa/KB cervical, SK-OV-3 ovarian, and U373 astrocytoma carcinoma cell lines. The inhibition of proliferation correlated with the arrest in the G2/M phase of the cell cycle. In in vitro assays with tubulin isolated from bovine brain, in general antiproliferative activity correlated with inhibition of tubulin polymerization. Thus, the antimitotic activity of 2-aryloindoles is explained by interference with the mitotic spindle apparatus and destabilization of microtubules. In contrast to colchicine, vincristine, nocodazole, or taxol, I did not significantly affect the GTPase activity of β -tubulin. Interestingly, selected compds. inhibited **angiogenesis** in the chorioallantoic membrane (CAM) assay. In xenograft expts., I was highly active after oral administration at 200 mg/kg against the human amelanocytic melanoma MEXF 989 in athymic nude mice. We conclude, that 2-aryloindoles constitute an interesting new class of antitubulin agents with the potential to be clin. developed for cancer treatment.


IT 170147-26-9P 370581-40-1P 370581-41-2P
370581-42-3P 370581-43-4P 370581-44-5P
370581-45-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of aroylindoles as tubulin-inhibitory antimitotic agents)


RN 170147-26-9 HCAPLUS

CN Methanone, phenyl [5-(phenylmethoxy)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 370581-40-1 HCAPLUS

CN Methanone, (3-chlorophenyl) [5-(phenylmethoxy)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 370581-41-2 HCAPLUS

CN Methanone, (4-chlorophenyl) [5-(phenylmethoxy)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 370581-42-3 HCAPLUS

CN Methanone, (4-methoxyphenyl) [5-(phenylmethoxy)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




RN 370581-43-4 HCAPLUS


CN Methanone, [5-(phenylmethoxy)-1H-indol-2-yl] (3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 370581-44-5 HCAPLUS
 CN Methanone, (2-methoxyphenyl) [5-(phenylmethoxy)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)



RN 370581-45-6 HCAPLUS
 CN Methanone, (3-methoxyphenyl) [5-(phenylmethoxy)-1H-indol-2-yl]- (9CI) (CA INDEX NAME)




IT 170147-24-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of aroylindoles as tubulin-inhibitory antimitotic agents)
 RN 170147-24-7 HCAPLUS
 CN 1H-Indole, 5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




IT 370580-70-4P 370580-71-5P 370580-74-8P
 370580-77-1P 370580-78-2P 370580-81-7P
 370580-83-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aroylindoles as tubulin-inhibitory antimitotic agents)
 RN 370580-70-4 HCAPLUS

CN 1H-Indole, 2-benzoyl-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 370580-71-5 HCAPLUS

CN 1H-Indole, 2-(3-chlorobenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 370580-74-8 HCAPLUS

CN 1H-Indole, 2-(4-chlorobenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 370580-77-1 HCAPLUS


CN 1H-Indole, 2-(4-methoxybenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 370580-78-2 HCAPLUS
 CN 1H-Indole, 5-(phenylmethoxy)-1-(phenylsulfonyl)-2-(3,4,5-trimethoxybenzoyl)- (9CI) (CA INDEX NAME)



RN 370580-81-7 HCAPLUS
 CN 1H-Indole, 2-(2-methoxybenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 370580-83-9 HCAPLUS
 CN 1H-Indole, 2-(3-methoxybenzoyl)-5-(phenylmethoxy)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 24 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:597980 HCAPLUS

DOCUMENT NUMBER: 135:180700

TITLE: Preparation of indol-3-ylpropionates as integrin inhibitors.

INVENTOR(S): Goodman, Simon; Gottschlich, Rudolf; Wiesner, Matthias

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058893	A2	20010816	WO 2001-EP84	20010105 <--
WO 2001058893	A3	20020418		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10006139	A1	20010816	DE 2000-10006139	20000211 <--
CA 2399813	AA	20010816	CA 2001-2399813	20010105 <--
AU 2001031664	A5	20010820	AU 2001-31664	20010105 <--
EP 1254133	A2	20021106	EP 2001-903624	20010105 <--
EP 1254133	B1	20050420		
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008154	A	20030121	BR 2001-8154	20010105 <--
JP 2003530319	T2	20031014	JP 2001-558443	20010105 <--
NZ 521260	A	20040227	NZ 2001-521260	20010105 <--
AT 293620	E	20050515	AT 2001-903624	20010105
RU 2257380	C2	20050727	RU 2002-123332	20010105
PT 1254133	T	20050930	PT 2001-903624	20010105
ES 2240400	T3	20051016	ES 2001-1903624	20010105
NO 2002003770	A	20020809	NO 2002-3770	20020809 <--
US 2003045728	A1	20030306	US 2002-203406	20020809 <--
US 6743810	B2	20040601		
ZA 2002007273	A	20031210	ZA 2002-7273	20020910 <--
US 2004138284	A1	20040715	US 2004-750879	20040105 <--
PRIORITY APPLN. INFO.:			DE 2000-10006139	A 20000211
			WO 2001-EP84	W 20010105
			US 2002-203406	A2 20020809
OTHER SOURCE(S):	MARPAT	135:180700		
GI				



AB Title compds. [I; A, B = O, S, NH, NR7, CO, CONH, bond; X = (substituted) alkylene; R1 = H, Z, (CH2)oAr; R2 = H, R7, COZ; R3 = NHR6, NR6C(:NR6)NHR6, Het; R4, R5 = H, O, R7, (CH2)oAr, OAr, etc.; R6 = H, COR7, COAr, R7, CO2R7, SO2R7, etc.; R7 = alkyl, cycloalkyl; Z = alkyl; Ar = (substituted) aryl; Het = (unsatd.) (substituted) mono- or bicyclic N-heterocyclyl; m = 0-6; n, o = 0-2], were prepared as integrin inhibitors useful for combating thrombosis, myocardial infarcts, coronary heart disease, arteriosclerosis, inflammation, tumors, osteoporosis, rheumatic arthritis, macular degenerative diseases, diabetic retinopathy, infections, restenosis after angioplasty, and pathol. conditions which are maintained or propagated by **angiogenesis** (no data). Thus, 6-benzyloxyindole, PhCHO, Meldrum's acid, and L-proline were stirred 3 h in MeCN to give 5-[phenyl-(6-O-benzylindol-3-yl)methyl]-2,2-dimethyl-1,3-dioxane-4,6-dione. The latter was refluxed with Cu powder in pyridine/EtOH to give Et 3-phenyl-3-(6-O-benzylindol-3-yl)propionate, which was hydrogenated in EtOH over Pd/C to give Et 3-phenyl-3-(6-hydroxyindol-3-yl)propionate. This was converted to 3-phenyl-3-[6-[3-(pyridin-2-ylamino)propoxy]indol-3-yl]propionic acid in several steps.


IT 1215-59-4, 5-Benzyloxyindole 15903-94-3,
6-Benzyloxyindole

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of indolylpropionates as integrin inhibitors)


RN 1215-59-4 HCAPLUS

CN 1H-Indole, 5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 15903-94-3 HCAPLUS

CN 1H-Indole, 6-(phenylmethoxy)- (9CI) (CA INDEX NAME)




IT 354822-51-8P 354822-52-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of indolylpropionates as integrin inhibitors)

RN 354822-51-8 HCAPLUS

CN 1,3-Dioxane-4,6-dione, 2,2-dimethyl-5-[phenyl[6-(phenylmethoxy)-1H-indol-3-yl]methyl]- (9CI) (CA INDEX NAME)



RN 354822-52-9 HCAPLUS

CN 1H-Indole-3-propanoic acid, β -phenyl-6-(phenylmethoxy)-, ethyl ester (9CI) (CA INDEX NAME)

L18 ANSWER 25 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:338524 HCAPLUS

DOCUMENT NUMBER: 134:340503

TITLE: Preparation of heterocyclylpyrazolinones as protein kinase inhibitors

INVENTOR(S): Singh, Jasbir; Tripathy, Rabindranath

PATENT ASSIGNEE(S): Cephalon, Inc., USA

SOURCE: PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032653	A1	20010510	WO 2000-US30226	20001101 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6455525	B1	20020924	US 2000-702191	20001031 <--
CA 2389807	AA	20010510	CA 2000-2389807	20001101 <--
EP 1226141	A1	20020731	EP 2000-978338	20001101 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

Grazier 10_509633

TR 200201225	T2	20020821	TR 2002-200201225	20001101	<--
JP 2003513091	T2	20030408	JP 2001-534804	20001101	<--
BR 2000015568	A	20030610	BR 2000-15568	20001101	<--
NO 2002002095	A	20020611	NO 2002-2095	20020502	<--
ZA 2002003492	A	20030804	ZA 2002-3492	20020502	<--
BG 106771	A	20030331	BG 2002-106771	20020604	<--
US 2003162775	A1	20030828	US 2002-225670	20020822	<--
US 6831075	B2	20041214			
PRIORITY APPLN. INFO.:			US 1999-163377P	P	19991104
			US 2000-702191	A	20001031
			WO 2000-US30226	W	20001101
OTHER SOURCE(S):					
GI			MARPAT 134:340503		




AB Title compds. e.g., I [R = (un)substituted heterocyclyl or -heteroaryl; R1 = H, (un)substituted alkyl, NH2, acyl, etc.; R2,R3 = H, (un)substituted alkyl, acyl, heterocyclyl, etc.] were prepared Thus, 2-acetylthiazole was condensed with CO(OEt)2 and the product cyclocondensed with H2NNH2 to give 3-(2-thiazolyl)-2-pyrazolin-5-one which was condensed with indole-3-carboxaldehyde to give I (R = 2-thiazolyl, R1 = R2 = H, R3 = 3-indolyl). Data for biol. activity of I were given.

IT 338753-21-2P 338753-27-8P 338753-44-9P
338753-68-7P 338753-70-1P 338756-22-2P
338756-30-2P 338756-32-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclylpyrazolinones as protein kinase inhibitors)


RN 338753-21-2 HCAPLUS

CN 3H-Pyrazol-3-one, 5-(3-furanyl)-2,4-dihydro-4-[[4-(phenylmethoxy)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 338753-27-8 HCAPLUS

CN 3H-Pyrazol-3-one, 5-(3-furanyl)-2,4-dihydro-4-[[5-(phenylmethoxy)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 338753-44-9 HCAPLUS

CN 3H-Pyrazol-3-one, 2,4-dihydro-5-(1-methyl-1H-pyrrol-3-yl)-4-[[4-(phenylmethoxy)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 338753-68-7 HCAPLUS

CN 3H-Pyrazol-3-one, 5-(2-furanyl)-2,4-dihydro-4-[[5-(phenylmethoxy)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 338753-70-1 HCAPLUS


CN 3H-Pyrazol-3-one, 5-(2-furanyl)-2,4-dihydro-4-[[4-(phenylmethoxy)-1H-indol-3-yl]methylene]- (9CI) (CA INDEX NAME)




RN 338756-22-2 HCAPLUS
 CN 3H-Pyrazol-3-one, 2,4-dihydro-4-[[1-methyl-4-(phenylmethoxy)-1H-indol-3-yl]methylene]-5-pyrazinyl- (9CI) (CA INDEX NAME)



RN 338756-30-2 HCAPLUS
 CN 3H-Pyrazol-3-one, 2,4-dihydro-4-[[1-methyl-5-(phenylmethoxy)-1H-indol-3-yl]methylene]-5-pyrazinyl- (9CI) (CA INDEX NAME)



RN 338756-32-4 HCAPLUS
 CN 3H-Pyrazol-3-one, 2,4-dihydro-4-[[1-methyl-5-(phenylmethoxy)-1H-indol-3-yl]methylene]-5-(2-thiazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 26 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:265404 HCAPLUS

DOCUMENT NUMBER: 134:295842

TITLE: Preparation of triazine kinase inhibitors

INVENTOR(S): Armistead, David M.; Bemis, Jean E.; Buchanan, John L.; Dipietro, Lucian V.; Elbaum, Daniel; Habgood, Gregory J.; Kim, Joseph L.; Marshall, Teresa L.; Geuns-Meyer, Stephanie D.; Novak, Perry M.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.; Zhu, Xiaotian

PATENT ASSIGNEE(S): Kinetix Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 376 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025220	A1	20010412	WO 2000-US27811	20001006 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2386218	AA	20010412	CA 2000-2386218	20001006 <--
EP 1218360	A1	20020703	EP 2000-972036	20001006 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511378	T2	20030325	JP 2001-528166	20001006 <--
AU 770600	B2	20040226	AU 2001-10754	20001006 <--
PRIORITY APPLN. INFO.:				
			US 1999-158176P	P 19991007
			US 1999-166978P	P 19991123
			US 1999-170378P	P 19991213
			US 2000-183263P	P 20000217
			US 2000-215576P	P 20000630
			US 2000-219801P	P 20000720
			WO 2000-US27811	W 20001006

OTHER SOURCE(S):
GI

MARPAT 134:295842




AB Title triazine compds. (I) [wherein R¹ and R² = independently R³, R⁸, NHR³, NHR⁵, NHR⁶, NR⁵R⁵, NR⁵R⁶, SR⁵, SR⁶, SR³, OR⁵, OR⁶, OR³, COR³, or (un)substituted heterocyclyl or alkyl; R³ = independently aryl or (un)substituted Ph or heteroaryl; R⁵ = independently H, (un)substituted (cyclo)alkyl or alkenyl, alkynyl, cycloalkenyl, aryl, or haloalkyl; R⁶ = independently COR⁵, CO₂R⁵, CONR⁵R⁵, C(NR⁵)NR⁵R⁵, or SOnR⁵; R⁸ = independently (un)substituted mono-, di-, or tricyclic ring system comprising 1-3, 1-6, or 1-9 heteroatoms, resp.; n = 1-2] were prepared as inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer. For example, amination of 2,4-dichloro-1,3,5-triazine (preparation given) with 3,4,5-trimethoxyaniline in DMF, followed by a second amination with 4-aminoveratrole in the presence of diisopropylethylamine in EtOH, yielded II. In kinase inhibition studies, II gave IC₅₀ values of < 0.4 µg/mL for KDR-1, PDGFRB-1, and Flt-1; 0.4 to 2.4 µg/mL for Lck-1; 3.5 to 4.5 µg/mL for EGFR-1, Tek-1, and EPGB4-1; and > 4.5 µg/mL for IGFR-1, AKT3-1, Met-1, Zap-1, Itk-1, FGFR1-1, and Fyn-1. I and compns. comprising them are useful for the treatment of disease or disease symptoms related to kinase inhibition, such as **angiogenesis** or vasculogenesis (no data).

IT 333727-64-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of triazine kinase inhibitors for inhibiting **angiogenesis** or vasculogenesis)

RN 333727-64-3 HCAPLUS

CN 1,3,5-Triazin-2-amine, 4-[5-(phenylmethoxy)-1H-indol-1-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 27 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:137023 HCAPLUS


DOCUMENT NUMBER: 134:178552

TITLE: 3(5)-Acylaminopyrazole derivatives, process for their preparation and their use as antitumor agents

INVENTOR(S): Pevarello, Paolo; Orsini, Paolo; Traquandi, Gabriella;

PATENT ASSIGNEE(S): Varasi, Mario; Fritzen, Edward L.; Warpehoski, Martha A.; Pierce, Betsy S.; Brasca, Maria Grabriella
 SOURCE: Pharmacia & Upjohn S.p.A., Italy; Pharmacia & Upjohn Company
 DOCUMENT TYPE: PCT Int. Appl., 123 pp.
 LANGUAGE: CODEN: PIXXD2
 Patent
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION: English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012189	A1	20010222	WO 2000-US6699	20000505 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2383555	AA	20010222	CA 2000-2383555	20000505 <--
AU 2000049714	A5	20010313	AU 2000-49714	20000505 <--
EP 1202733	A1	20020508	EP 2000-931906	20000505 <--
EP 1202733	B1	20051005		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000013143	A	20020611	BR 2000-13143	20000505 <--
JP 2003507329	T2	20030225	JP 2001-516535	20000505 <--
EE 200200065	A	20030415	EE 2002-65	20000505 <--
NZ 517237	A	20040227	NZ 2000-517237	20000505 <--
US 6218418	B1	20010417	US 2000-667603	20000922 <--
NO 2002000684	A	20020403	NO 2002-684	20020211 <--
HR 2002000128	A1	20030430	HR 2002-128	20020212 <--
ZA 2002001511	A	20030311	ZA 2002-1511	20020222 <--
BG 106480	A	20020930	BG 2002-106480	20020305 <--
PRIORITY APPLN. INFO.:			US 1999-372831	A 19990812
			US 2000-560400	A1 20000428
			WO 2000-US6699	W 20000505
OTHER SOURCE(S):		MARPAT 134:178552		
GI				



AB Compds. which are 3-acylaminopyrazole derivs. (I; e.g. N-(5-cyclopropyl-1H-pyrazol-3-yl)-2,2-diphenylacetamide) wherein R is C3-C6 cycloalkyl group optionally substituted by a straight or branched C1-C6 alkyl or arylalkyl group; R1 is a straight or branched C1-C6 alkyl, C2-C4 alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl or arylalkenyl group, each of which may be optionally further substituted as indicated in the description; or a pharmaceutically acceptable salt thereof, processes for their preparation and their therapeutic uses. The compds. are useful for the treatment of

cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases, but no quant. test results are presented. The cancer is selected from carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoacanthoma, thyroid follicular cancer and Kaposi's sarcoma. The cell proliferative disorder is selected from benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis. The method of treatment provides tumor **angiogenesis** and metastasis inhibition, cell cycle inhibition or cdk/cyclin dependent inhibition, and treatment or prevention of radiotherapy-induced or chemotherapy-induced alopecia. A process for preparing the 3-aminopyrazole derivative or the pharmaceutically acceptable

salt

thereof, comprising: (a) reacting RCO_2R_2 ($\text{R}_2 = \text{alkyl}$), with MeCN in the presence of a basic agent, to obtain $\text{RC(O)CH}_2\text{CN}$; (b) reacting $\text{RC(O)CH}_2\text{CN}$ with hydrazine hydrate to obtain an 3-amino-5-R-1H-pyrazole; (c) oxidizing the 3-amino-5-R-1H-pyrazole to obtain the nitro analog; (d) reacting the nitro compound with tert-butoxycarbonyl anhydride (Boc₂O) to obtain the N-Boc derivative; (e) reducing this BOC derivative to obtain the amino analog;

(f)

reacting this amino compound with $\text{R}_1\text{C(O)X}$ ($\text{X} = \text{OH}$ or a suitable leaving group) to obtain the N1-Boc-protected I; and (g) hydrolyzing this intermediate in an acidic medium to obtain I. Other methods of preparation are also claimed.


IT 326824-40-2P, 2-[5-(Benzyloxy)-1H-indol-3-yl]-N-(5-cyclopropyl-1H-pyrazol-3-yl)acetamide

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(acylaminopyrazole derivs., process for preparation and use as antitumor agents)

RN 326824-40-2 HCAPLUS

CN 1H-Indole-3-acetamide, N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-(phenylmethoxy)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 28 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:900841 HCAPLUS

DOCUMENT NUMBER: 134:37031

TITLE: FVIIA/TF activity inhibiting compounds


INVENTOR(S): Jakobsen, Palle; Persson, Egon

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 25 pp.


DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000077246	A2	20001221	WO 2000-DK316	20000613 <--
WO 2000077246	A3	20010222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1192270	A2	20020403	EP 2000-934951	20000613 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003530819	T2	20031021	JP 2001-503687	20000613 <--
US 6238878	B1	20010529	US 2000-616010	20000713 <--
US 6444434	B1	20020903	US 2001-844828	20010427 <--
PRIORITY APPLN. INFO.:				
			DK 1999-840	A 19990614
			US 1999-139714P	P 19990617
			DK 1999-910	A 19990625
			US 1999-141416P	P 19990629
			DK 1999-1241	A 19990903
			US 1999-152863P	P 19990908
			WO 2000-DK316	W 20000613
			US 2000-616010	A1 20000713
AB	The invention relates to compds. inhibiting the activation of FX to FXa by TF/FVIIa. The compds. are anticoagulants. The invention also relates to a method of identifying a drug candidate.			
IT	313236-56-5 313236-57-6 313236-59-8 313236-60-1			
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(FVIIA/TF activity inhibiting compds.)			
RN	313236-56-5 HCAPLUS			
CN	1,3-Propanediamine, N-[[6-chloro-1-[(3,4-dichlorophenyl)methyl]-5-(phenylmethoxy)-1H-indol-3-yl]methyl]-N,N',N'-trimethyl- (9CI) (CA INDEX NAME)			




RN 313236-57-6 HCAPLUS
 CN 4-Piperidinamine, N,N-dimethyl-1-[[5-(phenylmethoxy)-1H-indol-3-yl]methyl]-

(9CI) (CA INDEX NAME)




RN 313236-59-8 HCAPLUS

CN 1H-Indole-3-carboxamide, 1-[(3,4-dichlorophenyl)methyl]-N-[3-(dimethylamino)propyl]-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 313236-60-1 HCAPLUS

CN 1H-Indole-3-ethanamine, 6-chloro-1-[(3,4-dichlorophenyl)methyl]-N,N-dimethyl-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L18 ANSWER 29 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:688234 HCAPLUS

DOCUMENT NUMBER: 133:266589

TITLE: Preparation of heterocyclic derivatives as chemokine receptor antagonists effective against HIV, tumor, and allergy

INVENTOR(S): Bridger, Gary; Skerlj, Renato; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor R.; Crawford, Jason; McEachern, Ernest J.; Atsma, Bem; Nan, Siqiao; Zhou, Yuanxi; Schols, Dominique

PATENT ASSIGNEE(S): Anormed Inc., Can.

SOURCE: PCT Int. Appl., 274 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056729	A1	20000928	WO 2000-CA321	20000324 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG




CA 2368047	AA	20000928	CA 2000-2368047	20000324 <--
EP 1163238	A1	20011219	EP 2000-913979	20000324 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000010655	A	20020213	BR 2000-10655	20000324 <--
TR 200102799	T2	20020722	TR 2001-200102799	20000324 <--
NZ 514709	A	20030328	NZ 2000-514709	20000324 <--
JP 2003524620	T2	20030819	JP 2000-606590	20000324 <--
US 6750348	B1	20040615	US 2000-535314	20000324 <--
AU 775123	B2	20040715	AU 2000-35460	20000324 <--
NO 2001004593	A	20011029	NO 2001-4593	20010921 <--
US 2004235823	A1	20041125	US 2004-837467	20040430

PRIORITY APPLN. INFO.:

US 1999-125823P	P	19990324
US 2000-535314	A3	20000324
WO 2000-CA321	W	20000324

OTHER SOURCE(S): MARPAT 133:266589

GI



AB Title compds. [YW(X)(Z)(CR1R2)nArCR3R4N(R5)(CR6R7)qR8; W = N, Y is void; WY = CH; R1 to R7 may be the same or different and are independently selected from H, straight, branched or cyclic C1-6 alkyl; R8 = substituted heterocyclic group or a substituted aromatic group; Ar = aromatic or heteroarom.

ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and q are

independently = 0-2; X = Q, Q1; A = optionally substituted, saturated or unsatd. 5 or 6-membered ring; P = optionally substituted carbon atom, optionally substituted nitrogen atom, sulfur or oxygen atom; B = optionally substituted 5 to 7-membered ring; Ring A and Ring B in the above formula can be connected to the group W from any position via the group V; V = bond, (CH₂)_m, CO; m = 0-2; Z = H, optionally substituted C1-6 alkyl group, C0-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, optionally substituted C0-6 alkylamino, C3-7 cycloalkylamino group, optionally substituted carbonyl group or sulfonyl], pharmaceutically acceptable acid addition, salts, metal complexes, stereoisomers, isomer mixts., and pharmaceutical composition are prepared

Title


comps. are having protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5 and inhibiting the subsequent binding of their natural ligands. Thus, the title compound I was prepared and tested for inhibition of HIV-1 NL4.3 or IIIB replication in MT-4 cells and exhibited EC₅₀'s of less than 20µg/mL.

IT 297770-83-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)

RN 297770-83-3 HCAPLUS

CN 1,4-Benzenedimethanamine, N-[[5-(phenylmethoxy)-1H-indol-3-yl]methyl]-N,N'-bis(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 30 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:608722 HCAPLUS

DOCUMENT NUMBER: 133:193079

TITLE: Preparation of arylsulfonylheterocyclylhydroxamic acids and related compounds as matrix metalloprotease inhibitors


INVENTOR(S): Barta, Thomas E.; Becker, Daniel P.; Bedell, Louis J.; Boehm, Terri L.; Carroll, Jeffery N.; De Crescenzo, Gary A.; Fobian, Yvette M.; Freskos, John N.; Getman, Daniel P.; McDonald, Joseph J.; Hanson, Gunnar J.; Hockerman, Susan L.; Howard, Susan C.; Kolodziej, Steve A.; Li, Hui; Mischke, Deborah A.; Rico, Joseph G.; Stehle, Nathan W.; Tollefson, Michael B.; Vernier, William F.; Villamil, Clara I.; Rao, Shashidhar N.

PATENT ASSIGNEE(S): G.D. Searle and Co., USA

SOURCE: PCT Int. Appl., 851 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050396	A1	20000831	WO 2000-US2518	20000222 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2001039287	A1	20011108	US 1999-256948	19990224 <--
CA 2371876	AA	20000831	CA 2000-2371876	20000222 <--
AU 2000034785	A5	20000914	AU 2000-34785	20000222 <--
EP 1230219	A1	20020814	EP 2000-913317	20000222 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000008491	A	20020917	BR 2000-8491	20000222 <--
JP 2002537378	T2	20021105	JP 2000-600979	20000222 <--
NZ 513648	A	20040227	NZ 2000-513648	20000222 <--
NO 2001003963	A	20011023	NO 2001-3963	20010815 <--
ZA 2001006780	A	20020816	ZA 2001-6780	20010816 <--
US 2002177588	A1	20021128	US 2001-954451	20010917 <--
US 6750233	B2	20040615		
PRIORITY APPLN. INFO.:			US 1999-256948	A 19990224
			US 1997-66007P	P 19971114
			US 1998-95347P	P 19980804
			US 1998-95501P	P 19980806
			US 1998-101080P	P 19980918
			WO 2000-US2518	W 20000222
OTHER SOURCE(S):			MARPAT 133:193079	
GI				



I

AB A process for treating conditions associated with pathol. matrix metalloproteinase (MMP) activity comprises administration of compds. having inhibitory activity against >1 of MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition of MMP-1. The compds. are of the form HONHCOCR1R2SO2R3 [R1, R2 = H; R1R2 = atoms to form a 5-8 membered ring containing 1-3 heteroatoms; R3 = (substituted) aryl, heteroaryl]. Thus, 4-PhOC6H4SH was heated in Me2SO to give the disulfide dimer, which in THF was added to a mixture of Et N-tert-butoxycarbonylisonipecotate (preparation

given) and LDA in THF at -60° to room temperature to give 40% sulfide, which was oxidized with m-ClC₆H₄CO(OOH) to give 59% sulfone. The Et ester was saponified with NaOH in EtOH/H₂O to give 100% acid, which in DMF was treated with hydroxybenzotriazole, EDC, 4-methylmorpholine, and aqueous NH₂OH to give title compound I. I inhibited MMP-2 with IC₅₀ = 0.2 nM. Pharmacol., pharmacokinetic, and toxicol. data are given for selected compds.

IT 226390-30-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonylheterocyclhydroxamic acids and related compds. as matrix metalloprotease inhibitors)


RN 226390-30-3 HCAPLUS

CN 1H-Indole-2-carboxamide, N,N-dimethyl-6-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenoxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226390-29-0


CMF C23 H25 N3 O7 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 226399-13-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonylheterocyclhydroxamic acids and related compds. as matrix metalloprotease inhibitors)

RN 226399-13-9 HCAPLUS

CN 1H-Indole-2-carboxamide, N,N-dimethyl-6-[4-[[tetrahydro-4-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2H-pyran-4-yl]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 31 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:592560 HCAPLUS

DOCUMENT NUMBER: 133:198575

TITLE: Compositions and methods for use in targeting vascular destruction

INVENTOR(S): Pero, Ronald W.; Sherris, David

PATENT ASSIGNEE(S): Oxigene, Inc., USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048606	A1	20000824	WO 2000-US3996	20000216 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2358925	AA	20000824	CA 2000-2358925	20000216 <--
CA 2455956	AA	20000824	CA 2000-2455956	20000216 <--
EP 1152764	A1	20011114	EP 2000-914606	20000216 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002537262	T2	20021105	JP 2000-599398	20000216 <--
US 6538038	B1	20030325	US 2000-505402	20000216 <--
AU 776511	B2	20040909	AU 2000-35973	20000216 <--
EP 1547603	A2	20050629	EP 2004-76582	20000216
EP 1547603	A3	20050727		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 2003109500	A1	20030612	US 2002-218833	20020814 <--
US 6956054	B2	20051018		

PRIORITY APPLN. INFO.: US 1999-120478P P 19990218
 CA 2000-2358925 A3 20000216
 EP 2000-914606 A3 20000216
 US 2000-505402 A1 20000216
 WO 2000-US3996 W 20000216

OTHER SOURCE(S): MARPAT 133:198575


AB Treatment of warm-blooded animals having a tumor or non-malignant hypervascularization, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.

IT 91531-98-5D, Amphetamine, derivs.

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (prodrugs for use in targeting vascular destruction)

RN 91531-98-5 HCAPLUS

CN 1H-Indole-3-carbonitrile, 2-amino-5-(phenylthio)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 32 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:573671 HCAPLUS

DOCUMENT NUMBER: 133:177183

TITLE: Preparation of quinazoline derivatives as **angiogenesis** inhibitors

INVENTOR(S): Hennequin, Laurent Francois Andre; Ple, Patrick; Stokes, Elaine Sophie Elizabeth; Mckerrecher, Darren

PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK; Zeneca-Pharma S.A.

SOURCE: PCT Int. Appl., 346 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047212	A1	20000817	WO 2000-GB373	20000208 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2362715	AA	20000817	CA 2000-2362715	20000208 <--
EP 1154774	A1	20011121	EP 2000-902730	20000208 <--

EP 1154774 B1 20050622
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

TR 200102314	T2	20020121	TR 2001-200102314	20000208	<--
BR 2000008128	A	20020213	BR 2000-8128	20000208	<--
JP 2002536414	T2	20021029	JP 2000-598164	20000208	<--
EE 200100409	A	20021216	EE 2001-409	20000208	<--
AU 763618	B2	20030731	AU 2000-24475	20000208	<--
NZ 513204	A	20040430	NZ 2000-513204	20000208	<--
TR 200500745	T2	20050523	TR 2005-200500745	20000208	
NZ 530832	A	20050527	NZ 2000-530832	20000208	
EP 1553097	A1	20050713	EP 2005-4285	20000208	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
AT 298237	E	20050715	AT 2000-902730	20000208	
RU 2262935	C2	20051027	RU 2001-124816	20000208	
ZA 2001006340	A	20021101	ZA 2001-6340	20010801	<--
NO 2001003882	A	20011009	NO 2001-3882	20010809	<--
NO 2005002773	A	20011009	NO 2005-2773	20050608	<--
PRIORITY APPLN. INFO.:			EP 1999-400305	A	19990210
			EP 2000-902730	A3	20000208
			WO 2000-GB373	W	20000208


OTHER SOURCE(S): MARPAT 133:177183
 GI




AB The title compds. (I) [wherein A = an 8-, 9-, 10-, 12- or 13-membered bicyclic or tricyclic ring optionally containing 1-3 O, N, and/or S heteroatoms; Z = O, NH, S, CH₂, or a bond; n = 0-5; m = 0-3; R₂ = H, OH, halo, CN, NO₂, CF₃, alkyl(sulfanyl), alkoxy, NR₃N₄, or R₅X₁; R₃ and R₄ = independently H or alkyl; X₁ = a bond, O, CH₂, OC(O), CO, S, SO, SO₂, NR₆CO, CONR₇, SO₂R₈, NR₉SO₂, or NR₁₀; R₅ = H or (un)substituted alkyl, alkenyl, alkynyl, or heterocyclyl, etc.; R₆-R₁₀ = independently H or (alkoxy)alkyl] were prepared for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. For instance, II was synthesized in a 9-step sequence starting with the cyclization of 2-amino-4-benzyloxy-5-methoxybenzamide using Gold's reagent

in dioxane to form 7-benzyloxy-6-methoxy-3,4-dihydroquinazolin-4-one (84%). I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis (no data).

IT 2439-68-1, 5-Benzyloxy-1-methylindole 4790-04-9,
5-Benzyloxy-6-methoxyindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; preparation of quinazolines as **angiogenesis**
inhibitors by cyclization of 2-aminobenzamides and subsequent
derivatization)
RN 2439-68-1 HCAPLUS
CN 1H-Indole, 1-methyl-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 4790-04-9 HCAPLUS
CN 1H-Indole, 6-methoxy-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 33 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:383910 HCAPLUS

DOCUMENT NUMBER: 133:26859

TITLE: Methods of reducing serum glucose and triglyceride
levels and for inhibiting **angiogenesis** using
substituted indole-alkanoic acids

INVENTOR(S): Sredy, Janet; Jacot, Jorge

PATENT ASSIGNEE(S): The Institutes for Pharmaceutical Discovery, Inc., USA

SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032180	A2	20000608	WO 1999-US28483	19991201 <--
WO 2000032180	A3	20001116		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN,
IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,

SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2385845	AA	20000608	CA 1999-2385845	19991201 <--
BR 9915882	A	20010821	BR 1999-15882	19991201 <--
EP 1135124	A2	20010926	EP 1999-965955	19991201 <--
EP 1135124	B1	20040428		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

TR 200101539	T2	20011221	TR 2001-200101539	19991201 <--
JP 2002531398	T2	20020924	JP 2000-584876	19991201 <--
EE 200100296	A	20030217	EE 2001-296	19991201 <--
US 6555568	B1	20030429	US 1999-452252	19991201 <--
AU 770925	B2	20040311	AU 2000-21616	19991201 <--
AT 265210	E	20040515	AT 1999-965955	19991201 <--
TW 584560	B	20040421	TW 1999-88120912	20000201 <--
ZA 2001004126	A	20020521	ZA 2001-4126	20010521 <--
BG 105531	A	20011231	BG 2001-105531	20010522 <--
NO 2001002690	A	20010727	NO 2001-2690	20010531 <--
US 2003216452	A1	20031120	US 2003-397140	20030326 <--
US 6964980	B2	20051115		

PRIORITY APPLN. INFO.:

US 1998-110395P	P	19981201
US 1999-452252	A1	19991201
WO 1999-US28483	W	19991201

OTHER SOURCE(S): MARPAT 133:26859

AB Methods are disclosed for reducing serum glucose and triglyceride levels and for inhibiting **angiogenesis**, the methods comprising administration of substituted indole-alkanoic acids to patients in need of such treatment. Also disclosed are such compds. useful in the treatment of **angiogenesis**, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compns. containing the compds. Preparation of the compds. of the invention is included.


IT 245116-96-5P 245117-09-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(indole-alkanoic acid derivative preparation for reducing serum glucose and triglyceride levels and for inhibiting **angiogenesis**)


RN 245116-96-5 HCAPLUS

CN 1H-Indole-1-acetic acid, 5-(phenylmethoxy)-3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]- (9CI) (CA INDEX NAME)




RN 245117-09-3 HCAPLUS


CN 1H-Indole-1-acetic acid, 5-phenoxy-3-[(4,5,7-trifluoro-2-benzothiazolyl)methyl]- (9CI) (CA INDEX NAME)



IT 78304-53-7P, 5-Phenoxyindole
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction; indole-alkanoic acid derivative preparation for
 reducing serum glucose and triglyceride levels and for inhibiting
 angiogenesis)
 RN 78304-53-7 HCAPLUS
 CN 1H-Indole, 5-phenoxy- (9CI) (CA INDEX NAME)



IT 1215-59-4, 5-Benzyloxyindole
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reaction; indole-alkanoic acid derivative preparation for reducing serum
 glucose and triglyceride levels and for inhibiting angiogenesis
)
 RN 1215-59-4 HCAPLUS
 CN 1H-Indole, 5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



L18 ANSWER 34 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:350651 HCAPLUS
 DOCUMENT NUMBER: 131:18929
 TITLE: Preparation of arylsulfonylheterocyclylhydroxamic
 acids and related compounds as matrix metalloprotease
 inhibitors
 INVENTOR(S): Barta, Thomas E.; Becker, Daniel P.; Boehm, Terri L.;
 De Crescenzo, Gary A.; Villamil, Clara I.; McDonald,
 Joseph J.; Freskos, John N.; Getman, Daniel P.
 PATENT ASSIGNEE(S): G.D. Searle and Co., USA
 SOURCE: PCT Int. Appl., 840 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English


FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925687	A1	19990527	WO 1998-US23242	19981112 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2306460	AA	19990527	CA 1998-2306460	19981112 <--
AU 9913732	A1	19990607	AU 1999-13732	19981112 <--
AU 756150	B2	20030102		
BR 9814643	A	20001003	BR 1998-14643	19981112 <--
EP 1042290	A1	20001011	EP 1998-957485	19981112 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2001523662	T2	20011127	JP 2000-521071	19981112 <--
NZ 503485	A	20021025	NZ 1998-503485	19981112 <--
RU 2250105	C2	20050420	RU 2000-115948	19981112
ZA 9810412	A	19991209	ZA 1998-10412	19981113 <--
US 2001014688	A1	20010816	US 1998-191129	19981113 <--
NO 2000002469	A	20000712	NO 2000-2469	20000512 <--
US 6541489	B1	20030401	US 2000-554082	20000731 <--
US 2002177588	A1	20021128	US 2001-954451	20010917 <--
US 6750233	B2	20040615		
US 2004048852	A1	20040311	US 2003-337942	20030107 <--
US 6890937	B2	20050510		

PRIORITY APPLN. INFO.:

US 1997-66007P	P	19971114
US 1998-95347P	P	19980804
US 1998-95501P	P	19980806
US 1998-101080P	P	19980918
WO 1998-US23242	W	19981112
US 1999-256948	B3	19990224
US 2000-554082	A3	20000731

OTHER SOURCE(S): MARPAT 131:18929
GI

I

AB A process for treating conditions associated with pathol. matrix metalloproteinase (MMP) activity comprises administration of compds. having inhibitory activity against >1 of MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition of MMP-1. The compds. are of the form HONHCOCR₁R₂SO₂R₃ [R₁, R₂ = H; R₁R₂ = atoms to form a 5-8 membered ring containing 1-3 heteroatoms; R₃ = (substituted) aryl, heteroaryl]. Thus, 4-PhOC₆H₄SH was heated in Me₂SO to give the disulfide dimer, which in THF

was added to a mixture of Et N-tert-butoxycarbonylisonipecotate (preparation given) and LDA in THF at -60° to room temperature to give 405 sulfide, which was oxidized with m-ClC₆H₄CO(OOH) to give 59% sulfone. The Et ester was saponified with NaOH in EtOH/H₂O to give 100% acid, which in DMF was treated with hydroxybenzotriazole, EDC, 4-methylmorpholine, and aqueous NH₂OH to give title compound (I). I inhibited MMP-2 with IC₅₀ = 0.2 nM.

IT 226390-30-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonylheterocyclhydroxamic acids and related compds. as matrix metalloprotease inhibitors)


RN 226390-30-3 HCAPLUS

CN 1H-Indole-2-carboxamide, N,N-dimethyl-6-[4-[[tetrahydro-4-[(hydroxyamino)carbonyl]-2H-pyran-4-yl]sulfonyl]phenoxy]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 226390-29-0


CMF C23 H25 N3 O7 S



CM 2

CRN 76-05-1

CMF C2 H F3 O2




IT 226399-13-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonylheterocyclhydroxamic acids and related compds. as matrix metalloprotease inhibitors)

RN 226399-13-9 HCAPLUS

CN 1H-Indole-2-carboxamide, N,N-dimethyl-6-[4-[[tetrahydro-4-[[[(tetrahydro-2H-pyran-2-yl)oxy]amino]carbonyl]-2H-pyran-4-yl]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 35 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:271331 HCAPLUS

DOCUMENT NUMBER: 130:311803

TITLE: Preparation of aminobutanoic acid derivatives as inhibitors of matrix metalloproteinases

INVENTOR(S): Takahashi, Kanji; Sugiura, Tsuneyuki

PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 557 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9919296	A1	19990422	WO 1998-JP4529	19980907 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1024134	A1	20000802	EP 1998-947771	19980907 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
JP 3155536	B2	20010409	JP 2000-515869	19980907 <--
ZA 9809113	A	19990414	ZA 1998-9113	19981006 <--
CA 2305463	AA	19990422	CA 1998-2305463	19981007 <--
AU 9894580	A1	19990503	AU 1998-94580	19981007 <--
AU 760181	B2	20030508		
BR 9812807	A	20001017	BR 1998-12807	19981007 <--
TR 200001732	T2	20010122	TR 2000-200001732	19981007 <--
JP 2001172245	A2	20010626	JP 2000-322746	19981007 <--
JP 3470692	B2	20031125		
TR 200101019	T2	20020621	TR 2001-200101019	19981007 <--
TR 200101020	T2	20020621	TR 2001-200101020	19981007 <--
NZ 503789	A	20021126	NZ 1998-503789	19981007 <--
JP 2003212831	A2	20030730	JP 2002-344969	19981007 <--

RU 2215735	C2	20031110	RU 2000-111472	19981007 <--
TW 568897	B	20040101	TW 1998-87116686	19981009 <--
NO 2000001813	A	20000609	NO 2000-1813	20000407 <--
MX 200003465	A	20001113	MX 2000-3465	20000407 <--
US 6420427	B1	20020716	US 2000-529056	20000407 <--
PRIORITY APPLN. INFO.:			JP 1997-291834	A 19971009
			JP 1998-28533	A 19980210
			JP 2000-515869	A3 19980907
			WO 1998-JP4529	W 19980907
			JP 2000-322746	A3 19981007
OTHER SOURCE(S):			MARPAT 130:311803	
GI				




AB Aminobutanoic acid derivs. represented by general formula (I) and salts thereof [wherein R1 = CO₂R₁₀, CONHOR₁₀, CONHNHR₁₀, (CH₂)_nSR₅₀, Y-P(:O)(OR₅₁)₂; R₁₀ = H, C1-8 alkyl, Ph, phenyl- or C1-8 alkoxy-C1-8 alkyl, PhO₂C, PhCH₂O₂C, C1-8 alkoxy-carbonyl; wherein n = 0-3; R₅₀ = H, C1-8 alkyl, C1-8-alkyl-carbonyl, PhCO, SH, C1-8 alkylthio, SPh; R₅₁ = H, C1-8 alkyl, Ph; Y = single bond, CH₂, O; R₂-R₇ = H, C2-8 alkenyl, (un)substituted SH, OH, or NH₂, CO₂H, C1-8 alkyl-carbonyl, C1-8 alkoxy-carbonyl, (un)substituted carbocyclyl or heterocyclyl, (un)substituted C1-8 alkyl or C2-8 alkenyl; or R₃ and R₄ or R₅ and R₆ together represents C1-8 alkylene; or R₂ and R₃, R₄ and R₅, or R₆ and R₇ together represent C2-8 alkylene; when R₈ = H, (un)substituted C1-8 alkyl, or C1-8 alkoxy-carbonyl, R₉ = (un)substituted carbocyclyl; or when R₈ = (un)substituted carbocyclyl or heterocyclyl, R₉ = (un)substituted C1-8 alkyl or C1-8 alkoxy, (un)substituted carbocyclyl; M = C1-8 alkylene; J = single bond, O, S, NH, C1-8 alkyl-N] are prepared and claimed. Also claimed are matrix metalloproteinases containing I as the active ingredients and drugs containing I as the active ingredients for the prevention and/or treatment of rheumatism, osteoarthritis, pathol. bone resorption, osteoporosis, periodontal diseases, interstitial nephritis, arteriosclerosis, pulmonary emphysema, hepatic cirrhosis, corneal injury, diseases due to metastasis and infiltration of cancer cells or proliferation thereof, autoimmune diseases (such as Crohn's disease and Sjogren's disease), diseases due to transmigration of white blood cells or infiltration thereof, neovascularization, multiple sclerosis, aortic aneurysm, or endometritis. For example, the title compound (II) showed IC₅₀ of 26 nM against human stromelysin. A table and an ampule formulation containing II were described.

IT 223466-05-5P 223466-31-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aminobutanoic acid derivs. as inhibitors of matrix metalloproteinases for prevention and treatment of diseases)


RN 223466-05-5 HCAPLUS

CN Butanoic acid, 4-[[[5-(phenylmethoxy)-1H-indol-2-yl]carbonyl]amino]- (9CI)
 (CA INDEX NAME)



RN 223466-31-7 HCAPLUS

CN 1H-Indole-2-carboxamide, N-[4-(hydroxyamino)-4-oxobutyl]-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 36 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:222914 HCAPLUS

DOCUMENT NUMBER: 130:267341

TITLE: Preparation of oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors.

INVENTOR(S): Davis, Stephen Thomas; Dickerson, Scott Howard; Frye, Stephen Vernon; Harris, Philip Anthony; Hunter, Robert Neil, III; Kuyper, Lee Frederick; Lackey, Karey Elizabeth; Luzzio, Michael Joseph; Veal, James Marvin; Walker, Duncan Herrick

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 133 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9915500	A1	19990401	WO 1998-EP5559	19980903 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

TW 520358	B	20030211	TW 1998-87113993	19980825 <--
CA 2302572	AA	19990401	CA 1998-2302572	19980903 <--
AU 9897407	A1	19990412	AU 1998-97407	19980903 <--
AU 747506	B2	20020516		
ZA 9808078	A	20000322	ZA 1998-8078	19980903 <--
EP 1009738	A1	20000621	EP 1998-951342	19980903 <--
EP 1009738	B1	20040519		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

TR 200001174	T2	20000821	TR 2000-200001174	19980903 <--
BR 9812048	A	20000926	BR 1998-12048	19980903 <--
EE 200000117	A	20001215	EE 2000-200000117	19980903 <--
JP 2001517652	T2	20011009	JP 2000-512809	19980903 <--
AT 267170	E	20040615	AT 1998-951342	19980903 <--
ES 2221211	T3	20041216	ES 1998-951342	19980903
US 6369086	B1	20020409	US 1999-262351	19990304 <--
MX 200002254	A	20001030	MX 2000-2254	20000303 <--
US 6387919	B1	20020514	US 2000-486960	20000606 <--
US 2003004351	A1	20030102	US 2001-924431	20010808 <--
US 6541503	B2	20030401		
US 2003069430	A1	20030410	US 2001-999331	20011130 <--

PRIORITY APPLN. INFO.:

GB 1997-18913	A	19970905
WO 1998-EP5559	W	19980903
US 1999-262351	A3	19990304
US 2000-486960	A3	20000606

OTHER SOURCE(S): MARPAT 130:267341
 GI



AB Title compds. [I; X = N, CH, CCF3, CA; A = aliphatic; R1 = H, SH, OH, HOA, heterocyclyl, AHN, A2N, A2NCO, halo, cyano, NO2, etc.; R2 = H, A, HONA, alkoxy, HOA, heterocyclyl, A2NSO2, halo, NO2, OH, ASO2, etc.; R3 = H, A, OH, HOA, A2N, aryl, aryloxy, hydroxyaryl, heterocyclyl, hydroxyheterocyclyl, etc.; R4 = SO3H, SO2A, A2N, A2NCO, heterocyclylamino, heterocyclylsulfonyl, etc.; R5 = H; R1R2, R4R5 = fused ring], were prepared. Thus, (Z)-N-(3-hydroxy-2,2-dimethylpropyl)-4-[(7-oxo-6,7-dihydro-1-thia-3,6-diaza-as-indacen-8-ylidenemethyl)amino]benzenesulfonamide [prepared from 8-ethoxymethylene-6,8-dihydro-1-thia-3,6-diaza-as-indacen-7-one and 4-amino-N-(3-hydroxy-2,2-dimethylpropyl)benzenesulfonamide] inhibited protein kinases CDK1, CDK2, and UL97 with IC50 = 1-10 nM.


IT 222034-96-0P 222035-48-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oxindoles as protein tyrosine kinase and protein
 serine/threonine kinase inhibitors)

RN 222034-96-0 HCAPLUS


CN Benzenesulfonamide, 4-[(1,2-dihydro-2-oxo-4-phenoxy-3H-indol-3-ylidene)hydrazino]- (9CI) (CA INDEX NAME)



RN 222035-48-5 HCAPLUS

CN Benzenesulfonamide, 4-[(2Z)-(1,2-dihydro-2-oxo-6-phenoxy-3H-indol-3-ylidene)hydrazino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 222036-24-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of oxindoles as protein tyrosine kinase and protein
 serine/threonine kinase inhibitors)

RN 222036-24-0 HCAPLUS

CN 1H-Indole-2,3-dione, 6-phenoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L18 ANSWER 37 OF 37 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1997:756964 HCAPLUS

DOCUMENT NUMBER: 128:22920

TITLE: Oxindolylquinazoline derivatives as **angiogenesis** inhibitors
 INVENTOR(S): Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Lohmann, Jean-jacques Marcel; Ple, Patrick
 PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca Pharma S.A.; Thomas, Andrew Peter; Hennequin, Laurent Francois Andre; Lohmann, Jean-Jacques Marcel; Ple, Patrick
 SOURCE: PCT Int. Appl., 164 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9742187	A1	19971113	WO 1997-GB1211	19970502 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9726475	A1	19971126	AU 1997-26475	19970502 <--
EP 912557	A1	19990506	EP 1997-918293	19970502 <--
EP 912557	B1	20030709		
R: CH, DE, FR, GB, IT, LI				
JP 2000510115	T2	20000808	JP 1997-539644	19970502 <--
ZA 9703844	A	19971106	ZA 1997-3844	19970505 <--
US 6265411	B1	20010724	US 1998-180310	19981106 <--
PRIORITY APPLN. INFO.:			EP 1996-400956	A 19960506
			EP 1996-400957	A 19960506
			EP 1996-402762	A 19961217
			EP 1996-402763	A 19961217
			WO 1997-GB1211	W 19970502
OTHER SOURCE(S):			MARPAT 128:22920	
GI				



AB Title compds. I [R = H, alkyl, alkoxymethyl, dialkoxymethyl, alkanoyl and the benzene rings may be further substituted] were prepared for use in inhibiting **angiogenesis** and reducing vascular permeability (no data). Thus, 4,5-dimethoxyanthranilic acid was converted to 6,7-dimethoxyquinazoline by treatment with HCONH₂ and was treated with

1-methyloxindole to give 6,7-dimethoxy-4-(1-methyl-3-oxindolyl)quinazoline.


IT 74864-80-5 156232-24-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of oxindolylquinazoline derivs. as **angiogenesis** and vascular permeability inhibitors)


RN 74864-80-5 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-(methylthio)-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 156232-24-5 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)



IT 74864-81-6P 199327-49-6P 199327-51-0P


199327-57-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of oxindolylquinazoline derivs. as **angiogenesis** and vascular permeability inhibitors)


RN 74864-81-6 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 199327-49-6 HCAPLUS

CN 2H-Indol-2-one, 1-(diethoxymethyl)-1,3-dihydro-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-5-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 199327-51-0 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-5-(phenylmethoxy)-1-(diethoxymethyl)- (9CI)
(CA INDEX NAME)




RN 199327-57-6 HCAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-3-[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinazolinyl]-7-(phenylmethoxy)- (9CI) (CA INDEX NAME)




=> => d stat que l23
L3 STR



REP G1=(0-1) CH2
 VAR G2=O/S
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17


STEREO ATTRIBUTES: NONE
 L5 STR



REP G1=(0-1) CH2
 VAR G2=O/S
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 17


```
STEREO ATTRIBUTES: NONE
L7                      STR
```




```

REP G1=(0-1) CH2
VAR G2=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

```
STEREO ATTRIBUTES: NONE
L9                STR
```




```

REP G1=(0-1) CH2
VAR G2=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

```
STEREO ATTRIBUTES: NONE
L12      11678 SEA FILE=REGISTRY SSS FUL L3 OR L5 OR L7 OR L9
L13      STR
```



REP G1=(0-1) CH2
 VAR G2=O/S
 VAR G3=10/11/14/15

NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC I
 NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L14 7996 SEA FILE=REGISTRY SUB=L12 SSS FUL L13
 L15 1916 SEA FILE=HCAPLUS ABB=ON PLU=ON L14
 L16 30199 SEA FILE=HCAPLUS ABB=ON PLU=ON ANGIOGENESIS/CV OR ?ANGIOGENE?

 L17 44 SEA FILE=HCAPLUS ABB=ON PLU=ON L15 AND L16
 L18 37 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND PD=<SEPTEMBER 29, 2004
 L19 41 SEA FILE=HCAPLUS ABB=ON PLU=ON ("ARNOULD J"/AU OR "ARNOULD J C"/AU) OR ("ARNOULD JEAN"/AU OR "ARNOULD JEAN C"/AU OR "ARNOULD JEAN CLAUDE"/AU)
 L20 3 SEA FILE=HCAPLUS ABB=ON PLU=ON L19 AND L15
 L21 0 SEA FILE=HCAPLUS ABB=ON PLU=ON L20 NOT L18
 L22 38 SEA FILE=HCAPLUS ABB=ON PLU=ON L19 NOT L18
 L23 38 SEA FILE=HCAPLUS ABB=ON PLU=ON L21 OR L22

=>

=> d ibib abs hitstr l23 1-38

L23 ANSWER 1 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:1170531 HCAPLUS

DOCUMENT NUMBER: 143:440254

TITLE: Preparation of 3,4-disubstituted maleimides derivatives as vascular damaging agents

INVENTOR(S): **Arnould, Jean-Claude**; Harris, Craig Steven; Boyle, Francis Thomas; Gibson, Keith Hopkinson

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

 WO 2005102997 A1 20051103 WO 2005-GB1553 20050422
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
 NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
 SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
 ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
 GI

EP 2004-291074

A 20040426



AB Title compds. represented by the formula I [wherein Ar1 = (un)substituted Ph, heteroaryl or heterocyclyl; Ar2 = (un)substituted Ph or heteroaryl; Ar3 = (un)substituted heteroaryl; R1 = H, Me, carboxy, alkyl, etc.; R10 = H or alkyl; and their salts thereof] were prepared as vascular damaging agents. For example, reaction of (preparation given) with 3-chloro-4-phenylpyrrole-2,5-dione provided II in 91% yield. II showed inhibition of colchicine binding by 80% at a concentration of 10 μ M. Thus, I and their pharmaceutical compns. are useful as vascular damaging agents for the treatment of angiogenesis or disease states associated with angiogenesis.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:962266 HCAPLUS

DOCUMENT NUMBER: 143:266908

TITLE: Preparation of substituted thieno[2,3-b]pyrroles as antagonists of GnRH

INVENTOR(S): Arnould, Jean-Claude; Harris, Craig Steven; Jones, Paul

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 98 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080402	A1	20050901	WO 2005-GB568	20050217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			EP 2004-290466	A 20040220
OTHER SOURCE(S):	MARPAT 143:266908			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, alkyl, aryl, etc.; R2 = H, alkyl, etc.; R3 = alkyl, alkylamino, etc.; R4 = H, alkyl, halo; R5 = alkylcarboxamido, carboxamido, acyl, etc.] are prepared For instance, II is prepared in 3 steps from III, 3-benzhydrylazetid-3-carboxylic acid and 2-formylthiophene. Compds. of the invention have GnRH activity at a concentration of 1 nM to 5 μ M. I are useful for treating a sex hormone related condition.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:792784 HCAPLUS

TITLE: Apparatus for supporting and bending glass-sheets and application for making curved tempered glass-sheets

INVENTOR(S): Arnould, Jean; Pommera, Christian

PATENT ASSIGNEE(S): Saint-Gobain Vitrage International, Fr.

SOURCE: Eur. Pat. Appl., No pp. given

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 452206	A1	19911016	EP 1991-400947	19910409
EP 452206	B1	19941012		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
CA 2039957	AA	19911014	CA 1991-2039957	19910408
CA 2039957	C	20020402		
ES 2064935	T3	19950201	ES 1991-400947	19910409
US 5292357	A	19940308	US 1991-684376	19910412

Grazier 10_509633

JP 04228434 A2 19920818 JP 1991-171568 19910415
PRIORITY APPLN. INFO.: FR 1990-4806 A 19900413
AB Unavailable

L23 ANSWER 4 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:182888 HCAPLUS

DOCUMENT NUMBER: 140:235695

TITLE: Preparation of 6H-thieno[2,3-b]pyrrole derivatives as
antagonists of gonadotropin-releasing hormone (GnRh)
for treating sex hormone related conditions

INVENTOR(S): Foote, Kevin Michael; Matusiak, Zbigniew; Dossetter,
Alexander Graham; Arnould, Jean Claude;
Lamorlette, Maryannick Andree; Delouvrie, Benedicte;
Hamon, Annie

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 215 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018480	A1	20040304	WO 2003-GB3631	20030819
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1543012	A1	20050622	EP 2003-792485	20030819
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, LT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			

PRIORITY APPLN. INFO.: EP 2002-292074 A 20020821
WO 2003-GB3631 W 20030819

OTHER SOURCE(S): MARPAT 140:235695

GI



II

AB Title compds. I [R1 = H, (un)substituted-alkyl, -alkanoyl, -aryl, or -arylalkyl; R2 = (un)substituted mono or bicyclic aromatic ring; R3 = arylalkylaminoalkyl, arylheterocyclylalkyl, heterocyclylheterocyclylalkyl, etc.; R4 = H, (un)substituted-alkyl, -aryl, CN, halo, etc.; R5 = heterocyclylcarbonylalkyl, halo, H, etc.] and their pharmaceutically acceptable salts are prepared and disclosed as gonadotropin releasing hormone antagonists. Thus, e.g., II, was prepared in a multistep synthesis from Et thiophen-2-ylacetate. In test assays, I possessed activity at concns. from 1nM to 5 μ M.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:182887 HCAPLUS

DOCUMENT NUMBER: 140:235694

TITLE: Preparation of thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone

INVENTOR(S): Arnould, Jean Claude

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 74 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004018479	A1	20040304	WO 2003-GB3603	20030818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,				

Grazier 10_509633

PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1532154 A1 20050525 EP 2003-748242 20030818
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
PRIORITY APPLN. INFO.: EP 2002-292076 A 20020821
WO 2003-GB3603 W 20030818
OTHER SOURCE(S): MARPAT 140:235694
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [A = bond or (un)substituted alkylene; R1 = H,
(un)substituted alkyl, cycloalkyl, or cycloalkylalkyl; R2 =
(un)substituted mono- or bicyclic aromatic ring structure; R4 = H; R5 =
(un)substituted heterocyclic ring containing 1-4 heteroatoms selected from O,
N and S, hydroxyalkyl, alkylcarbonyl, etc.; R3 and R3a = independently H,
(un)substituted alkyl or together represent a carbonyl; R7 = H or
(un)substituted alkyl; R8 and X = when X represents CH, R8 represents NO2,
when X represents N, R8 is selected from CN, OH, H, alkoxy, etc., or the
combination XR8 equals CO] are prepared and disclosed as compds. useful as
gonadotropin releasing hormone antagonists. Thus, e.g., II was prepared via
condensation of 2-[2-(1,1-dimethyl-2-oxo-2-pyrrolidin-1-ylethyl)-5-(3,5-
dimethylphenyl)-6H-thieno[2,3-b]pyrrol-4-yl]ethylamine (preparation given) with
diphenyl-N-cyanocarbonimidate and subsequent substitution with
3-(pyridin-4-yl)pyrrolidine. I have activity at a concentration from 1nM to
5µM. The invention also relates to pharmaceutical formulations of said
compds., methods of treatment using said compds. and to processes for the
preparation of said compds.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:90033 HCAPLUS

DOCUMENT NUMBER: 136:151337

TITLE: Preparation of colchinel derivatives as angiogenesis
inhibitors

INVENTOR(S): Arnould, Jean Claude

PATENT ASSIGNEE(S): Angiogene Pharmaceuticals Limited, UK

SOURCE: PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008213	A1	20020131	WO 2001-GB2964	20010704
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,			


RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2410562	AA	20020131	CA 2001-2410562	20010704
EP 1301498	A1	20030416	EP 2001-943701	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012225	A	20030506	BR 2001-12225	20010704
JP 2004504391	T2	20040212	JP 2002-514119	20010704
NZ 522661	A	20040730	NZ 2001-522661	20010704
EE 200300015	A	20041015	EE 2003-15	20010704
ZA 2002009778	A	20040302	ZA 2002-9778	20021202
NO 2003000055	A	20030106	NO 2003-55	20030106
US 2003195173	A1	20031016	US 2003-332271	20030107
US 6720323	B2	20040413		
US 2004142909	A1	20040722	US 2003-705198	20031112
US 6846925	B2	20050125		


PRIORITY APPLN. INFO.:

EP 2000-401976	A	20000707
EP 2000-401977	A	20000707
WO 2001-GB2964	W	20010704
US 2003-332271	A1	20030107

OTHER SOURCE(S): MARPAT 136:151337
 GI



I



II

AB Colchicinol derivs., such as I [R1-R3 = OH, phosphoryloxy, alkoxy, ester; R4-R6 = alkoxy; R = N(R7)-A-[CH(Ra)]a-B-[CH(Rb)]b-D; A = CO, ester, CONR8; R8 = H, alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl; a = an integer from 1 to 4 inclusive; Ra, Rb = H, OH, amino; B = O, CO, N(R9)CO, CON(R9), N(R9)C(O)O, N(R9)CON(R10), N(R9)SO2, SO2N(R9), a direct single bond; R7, R9, R10 = H, alkyl, alkoxyalkyl, aminoalkyl, hydroxyalkyl; b = 0 or an integer from 1 to 4 inclusive; D = carboxy, sulfo, tetrazolyl, imidazolyl, phosphoryloxy, hydroxy, amino, N-(alkyl)amino, N,N-di(alkyl)amino, etc.], and pharmaceutically acceptable salt, solvate or pro-drug thereof, were prepared for their use as vascular damaging agents. Thus, reaction between colchicinol I [R1-R3, R5 = OMe; R4, R6 = H; R = NH2] and 2[2-(tert-butoxycarbonylamino)acetylamin]acetic acid yielded II (R = BOC) which on treatment with TFA afforded colchicinol derivative II (R = H). The prepared colchicinol derivs. were tested against s.c. CaNT tumors.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN



ACCESSION NUMBER: 2002:51447 HCAPLUS

DOCUMENT NUMBER: 136:102557

TITLE: Preparation of colchicinol derivatives as vascular

damaging agents
 INVENTOR(S): **Arnould, Jean Claude**; Lamorlette, Maryannick
 Andree
 PATENT ASSIGNEE(S): Angiogene Pharmaceuticals Limited, UK
 SOURCE: PCT Int. Appl., 82 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002004434	A1	20020117	WO 2001-GB2966	20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2411160	AA	20020117	CA 2001-2411160	20010704
EP 1301497	A1	20030416	EP 2001-943702	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012224	A	20030610	BR 2001-12224	20010704
JP 2004502766	T2	20040129	JP 2002-509300	20010704
NZ 522861	A	20040730	NZ 2001-522861	20010704
ZA 2002009776	A	20040302	ZA 2002-9776	20021202
NO 2003000056	A	20030106	NO 2003-56	20030106
PRIORITY APPLN. INFO.:			EP 2000-401978	A 20000707
			WO 2001-GB2966	W 20010704
OTHER SOURCE(S):		MARPAT 136:102557		
GI				



AB Colchicinol derivs., such as I [R1 - R3 = OH, phosphoryloxy, alkoxy; R4 = R6 = H, NO2, NH2, alkylamino, OH, F, alkoxy, alkyl; R5 = A-X-Y-B; A = alkylene, (CH2)_p-Q; p = 1-2; Q = phenylene, thienylene; X = O, CO, ester, amide, amino, etc.; Y = alkylene; B = carboxy, sulfo, phosphoryloxy, hydroxy, amino, heterocyclic group, etc.; R8 = CO, ester, amino, amide, SO2, etc.; R9 = H, alkyl], and pharmaceutically acceptable salt, solvate or pro-drug thereof, were prepared for their use as vascular damaging agents in a warm blooded animal. Thus, reaction between glutaric anhydride and N-acetylpiperazine yielded 5-(4-acetylpiperazin-1-yl)-5-oxopentanoic acid which on condensation with N-acetyl colchicinol afforded colchicinol derivative II

(R = 4-acetylpiperazin-1-yl). The prepared colchinel derivs. were tested against s.c. CaNT tumors.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:475616 HCAPLUS

DOCUMENT NUMBER: 133:89673

TITLE: Preparation of colchinel derivatives for use as vascular damaging agents

INVENTOR(S): Davis, Peter David; Arnould, Jean-Claude; Boyle, Francis Thomas

PATENT ASSIGNEE(S): Angiogene Pharmaceuticals Ltd., UK

SOURCE: PCT Int. Appl., 136 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040529	A1	20000713	WO 1999-GB4436	19991224
W:				
AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2355302	AA	20000713	CA 1999-2355302	19991224
EP 1140745	A1	20011010	EP 1999-962468	19991224
EP 1140745	B1	20031022		
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9916790	A	20011204	BR 1999-16790	19991224
JP 2002534400	T2	20021015	JP 2000-592241	19991224
AU 760830	B2	20030522	AU 2000-18823	19991224
AT 252529	E	20031115	AT 1999-962468	19991224
NZ 512398	A	20031128	NZ 1999-512398	19991224
PT 1140745	T	20040331	PT 1999-962468	19991224
ES 2211206	T3	20040701	ES 1999-962468	19991224
ZA 2001005065	A	20020920	ZA 2001-5065	20010620
NO 2001003367	A	20010905	NO 2001-3367	20010706
PRIORITY APPLN. INFO.:			GB 1999-334	A 19990107
			WO 1999-GB4436	W 19991224
OTHER SOURCE(S):	MARPAT	133:89673		
GI				



I



II

AB Colchicinol derivs., such as I [X = CO, CS, C:NOH, CHR7, etc.; R1, R2, R3 = H, phosphate, sulfate, alkyl, etc.; R4, R5, R6 = H, OH, NO2, NH2, phosphate, phosphonate, halogen, carboxy, carbamoyl, acyl, etc.; R7 = H, OH, alkoxy, amino, acylamino, etc.] were prepared and formulated for use as vascular damaging agents in the treatment of a number of disease states including cancer and rheumatoid arthritis. Thus, colchicinol derivative II [R5 = OCO(CH2)2NHCOC2NH2] was prepared starting from N-acetylcolchicinol, β -alanine Et ester hydrochloride, and N-(tert-butoxycarbonyl)glycine. Pharmaceutical compns. containing the prepared colchicinol derivs. were also presented.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 9 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:282206 HCAPLUS

DOCUMENT NUMBER: 130:325147

TITLE: Imidazole amine derivatives and their use as farnesyl protein transferase inhibitors

INVENTOR(S): Arnould, Jean-Claude

PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca Pharma S.A.

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920612	A1	19990429	WO 1998-GB3115	19981019
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9894529	A1	19990510	AU 1998-94529	19981019
EP 1025089	A1	20000809	EP 1998-947692	19981019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001520222	T2	20011030	JP 2000-516954	19981019
US 6410539	B1	20020625	US 2000-509476	20000324
PRIORITY APPLN. INFO.:			EP 1997-402503	A 19971022
			EP 1997-402504	A 19971022
			WO 1998-GB3115	W 19981019

OTHER SOURCE(S): MARPAT 130:325147
GI





AB The invention relates to compds. I [Ar1 = certain (un)substituted 1H-imidazol-1-yl, -2-yl, or -5-yl subunits; R1 = H, C1-4 alkyl or alkanoyl; R12, R13 = H or C1-4 alkyl; Ar2 = Ph or heteroaryl; p = 0 or 1; Ar3 = (un)substituted Ph or certain 6-membered N heterocycles with 1 or 2 N atoms, and bearing groups R2 and -(CH2)nR3 which are attached to ring carbon atoms; R2 = CONHCR7R8COR9 or γ -butyrolacton-2-ylaminocarbonyl; n = 0, 1, or 2; R3 = Ph or heteroaryl; R7 = H or C1-4 alkyl; R8 = (CH2)qR10 where q = 0-4 and R10 = OH, alkylsulfanyl, alkoxy, (un)substituted carbamoyl, Ph, thienyl, etc.; R9 = OH, alkoxy, alkylsulfonylamino, etc.; with provisos] and their pharmaceutically-acceptable salts, prodrugs, or solvates. Also disclosed are processes for their preparation, their use as therapeutic agents, and pharmaceutical compns. containing them. As inhibitors of the farnesylation of ras proteins by farnesyl protein transferase (FPTase), I are particularly useful in cancer therapy. Over 20 synthetic examples are given. For instance, Me 4-amino-2-(4-fluorophenyl)benzoate underwent imine condensation with 1-(4-fluorophenyl)-2-(imidazol-1-yl)ethanone in the presence of TiCl4, followed by reduction with NaBH3CN (52%), hydrolysis of the Me ester (95%), and amidation with L-methionine Me ester HCl (80%), to give title compound II. Compds. I inhibited FPTase in vitro with IC50 values generally in the range of 0.0005-50 μ M.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 10 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:282205 HCAPLUS
DOCUMENT NUMBER: 130:325146
TITLE: Imidazole ether derivatives and their use as farnesyl protein transferase inhibitors

INVENTOR(S): Arnould, Jean-Claude
 PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca-Pharma S.A.
 SOURCE: PCT Int. Appl., 114 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9920611	A1	19990429	WO 1998-GB3117	19981019
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9894530	A1	19990510	AU 1998-94530	19981019
EP 1025088	A1	20000809	EP 1998-947694	19981019
EP 1025088	B1	20010905		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 205195	E	20010915	AT 1998-947694	19981019
JP 2001524455	T2	20011204	JP 2000-516953	19981019
ES 2163295	T3	20020116	ES 1998-947694	19981019
PT 1025088	T	20020130	PT 1998-947694	19981019
US 6342765	B1	20020129	US 2000-509210	20000324
US 2002052376	A1	20020502	US 2001-955994	20010920
US 2002058665	A1	20020516	US 2001-956005	20010920
PRIORITY APPLN. INFO.:			EP 1997-402502	A 19971022
			EP 1997-402505	A 19971022
			WO 1998-GB3117	W 19981019
			US 2000-509210	A3 20000324
OTHER SOURCE(S):			MARPAT 130:325146	
GI				



AB The invention relates to compds. I [wherein Ar1 = (un)substituted imidazol-1-yl, -2-yl, or -5-yl; R12 and R13 are independently H or C1-4 alkyl; Ar2 = Ph or heteroaryl; p = 0 or 1; Ar3 = Ph, pyridinyl, pyridazinyl, pyrimidyl or pyrazynyl, with the ring being substituted on ring C atoms by R2 and -(CH2)nR3, and with Ar3 being attached via a ring C atom; R2 = -CONHCR7R8COR9, or a γ -butyrolacton-2-ylaminocarbonyl group; n = 0, 1 or 2; R3 = Ph or heteroaryl] and the pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also disclosed are processes for their preparation, their use as therapeutic agents, and pharmaceutical compns. containing them. As inhibitors of farnesyl protein transferase (FPTase), and particularly as inhibitors of the farnesylation of the protein ras, I are useful in cancer therapy. Approx. 90 compds. I were prepared. For instance, 2-(4-fluorophenyl)-4-[[2-(imidazol-1-yl)-1-((4-fluorophenyl)ethoxy)methyl]benzoyl]benzoic acid (preparation in 5 steps given) was amidated with L-methionine Me ester hydrochloride using EDC, HOBT, and N-methylmorpholine in CH2Cl2 (75% yield), followed by hydrolysis of the Me ester using aqueous NaOH in MeOH (65%), to give title compound II. As inhibitors of FPTase, I in general had IC50 values in the range of 0.0005 to 50 μ M, and II had an IC50 of 0.001 μ M.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 11 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:527321 HCAPLUS

DOCUMENT NUMBER: 129:161561

TITLE: Preparation of [(imidazolylalkenyl)benzamido]alkanoic acids and their analogs and derivatives as inhibitors of farnesyl protein transferase

INVENTOR(S): Arnould, Jean-Claude; Boyle, Francis Thomas; Davies, Gareth Morse; Wardleworth, James Michael

PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca Pharma S.A.



SOURCE: PCT Int. Appl., 128 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832741	A1	19980730	WO 1998-GB230	19980127
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9857726	A1	19980818	AU 1998-57726	19980127
EP 975603	A1	20000202	EP 1998-901389	19980127
R: CH, DE, FR, GB, IT, LI, SE				
JP 2001509156	T2	20010710	JP 1998-531747	19980127
ZA 9800702	A	19980729	ZA 1998-702	19980128
US 6414145	B1	20020702	US 1999-355440	19990728
US 2003220495	A1	20031127	US 2002-71098	20020211
PRIORITY APPLN. INFO.:			EP 1997-400207	A 19970129
			WO 1998-GB230	W 19980127
			US 1999-355440	A1 19990728
OTHER SOURCE(S):			MARPAT 129:161561	
GI				



AB The invention relates to inhibitors of ras farnesylation, having formula I [wherein T = (un)substituted imidazolyl; A, B = aryl, heteroaryl; X, Y = H; or XY = pi bond; R1 = (carboxyalkyl)carbamoyl or derivs., having L or D

configuration at the chiral alpha carbon in the corresponding free amino acid; R2 = H, aryl, heteroaryl; Z = bond, CH2, CH2CH2, C:CH2, O, CH2O, or OCH2; and R3 = H, alkyl, halo, OH, alkoxy, alkanoyl, (un)substituted amino, etc.; p, q = 0-3; R4 = H, alkyl], and their pharmaceutically acceptable salts, prodrugs, and solvates. Processes for their preparation, their use as therapeutic agents (especially for cancer), and pharmaceutical compns. containing them are also disclosed. For example, Wittig reaction of [(4-cyanophenyl)methyl]triphenylphosphonium chloride with 2-(imidazol-1-yl)propiophenone, followed by acid hydrolysis of the cyano group, amidation with L-methionine Me ester-HCl, and alkaline ester hydrolysis, gave title compound II. In an assay against farnesylation of Kras using human placental farnesyl protein transferase in vitro, IC50 values ranged from 0.0005 to 50 μ M, with that of II being 0.15 μ M.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 12 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:673301 HCAPLUS

DOCUMENT NUMBER: 126:44808

TITLE: Synthesis and antibacterial activity of lipophilic carbapenems with anti-MRSA activity

AUTHOR(S): **Arnould, Jean Claude**; Illingworth, Ruth N.; Nichols, Wright W.; Wilson, R. Geoffrey

CORPORATE SOURCE: Zeneca Pharma Centre Recherches, Reims, 51689, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(20), 2449-2454
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of S- and C-linked lipophilic carbapenems was prepared and evaluated for antibacterial activity in vitro and in vivo and for affinity for penicillin-binding protein (PBP) 2' of Staphylococcus aureus. Potent activity in vitro against methicillin-resistant S. aureus and methicillin-resistant coagulase-neg. staphylococci was observed despite IC50 values for PBP2' being higher than the MIC.

L23 ANSWER 13 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:397515 HCAPLUS

DOCUMENT NUMBER: 125:194695

TITLE: Convenient synthesis of aromatic thiols from phenols

AUTHOR(S): **Arnould, Jean Claude**; Didelot, Myriam;

Cadilhac, Caroline; Pasquet, Marie Jeanne

CORPORATE SOURCE: Centre Recherches, Zeneca Pharma, Reims, 51689, Fr.

SOURCE: Tetrahedron Letters (1996), 37(26), 4523-4524

CODEN: TELEAY; ISSN: 0040-4039


PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 125:194695

GI



AB Aromatic thiols were prepared from phenols in good yield and under mild conditions by reaction of the corresponding triflates with sodium triisopropylsilanethiolate (NaSTIPS) and subsequent deprotection. For example, the treatment of 4-hydroxyacetophenone with triflic anhydride and sodium triisopropylsilanethiolate followed by deprotection gave the disulfide I. Also, 6-hydroxy-1-indanone was converted into 2,3-dihydro-6-mercapto-1H-inden-1-one.

L23 ANSWER 14 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:256100 HCAPLUS

DOCUMENT NUMBER: 124:316867

TITLE: Carbapenem derivatives containing a bicyclic substituent

INVENTOR(S): Arnould, Jean-Claude

PATENT ASSIGNEE(S): Zeneca Limited, UK; Zeneca-Pharma

SOURCE: Eur. Pat. Appl., 27 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 695753	A1	19960207	EP 1995-305428	19950803
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
US 5607928	A	19970304	US 1995-508698	19950728
CA 2155493	AA	19960206	CA 1995-2155493	19950804
JP 08059664	A2	19960305	JP 1995-201126	19950807
PRIORITY APPLN. INFO.:			EP 1994-401814	A 19940805
OTHER SOURCE(S):		MARPAT 124:316867		

GI



AB Bactericidal (no data) carbapenems I [R = aryl, heteroaryl; R¹ = CH₂OH, CHMeOH, CHMeF; R² = H, C1-4 alkyl; X = O, S] and pharmaceutically acceptable salts or in vivo hydrolyzable esters thereof, were prepared. Thus, (3S,4R,1'R,1''R)-1-(allyloxycarbonyltriphenylphosphoranylidene)methyl)-3-(1-hydroxyethyl)-4-[1-(hydroxymethylcarbonyl)ethyl]azetidin-2-one was treated with 5-hydroxy-1-tetralone, followed by ester hydrolysis to give the carbapenem II.

L23 ANSWER 15 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:190505 HCAPLUS

DOCUMENT NUMBER: 124:275460

TITLE: Effects of annealing in oxygen and nitrogen atmosphere


on float-zone silicon wafers
 AUTHOR(S): Gay, N.; Floret, F.; Martinuzzi, S.; Roux, L.;
Arnould, J.; Mathieu, G.
 CORPORATE SOURCE: Laboratoire Photoelectricite des semi-conducteurs,
 Faculte des Sciences et Techniques, Marseille, 13397,
 Fr.
 SOURCE: Materials Science & Engineering, B: Solid-State
 Materials for Advanced Technology (1996), B36(1-3),
 125-08
 CODEN: MSBTEK; ISSN: 0921-5107
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Float-zone silicon wafers were submitted to high temperature annealings during long times in oxygen and in nitrogen atmospheric in order to reproduce the same treatments which are necessary to develop power and high voltage transistors or diodes. It is shown by elec. techniques (microwave detected photocond. decay and surface photovoltage) and by revelation techniques (scanning IR microscope, x-ray topog., Fourier transformed IR spectroscopy, chemical etching) that annealings in nitrogen added to annealings in oxygen have a deleterious effect on the lifetime of minority carriers and can create dislocations and ppts.

L23 ANSWER 16 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:605125 HCAPLUS
 DOCUMENT NUMBER: 121:205125
 TITLE: Preparation of [[(carboxyheterocyclyl)carbamoyl]pyrrolidinylthio]carbapenems as antibiotics
 INVENTOR(S): Jung, Frederic Henri; **Arnould, Jean Claude**
 PATENT ASSIGNEE(S): Zeneca Ltd., UK; Zeneca Pharma S.A.
 SOURCE: Eur. Pat. Appl., 27 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 581500	A1	19940202	EP 1993-305607	19930716
EP 581500	B1	19980909		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CA 2099818	AA	19940122	CA 1993-2099818	19930705
AT 170859	E	19980915	AT 1993-305607	19930716
ES 2121585	T3	19981201	ES 1993-305607	19930716
JP 06179674	A2	19940628	JP 1993-177903	19930719
US 5441949	A	19950815	US 1994-307048	19940916
PRIORITY APPLN. INFO.:			EP 1992-402105	A 19920721
			US 1993-86836	B1 19930707
OTHER SOURCE(S):			MARPAT 121:205125	
GI				



AB Title compds. [I; R1 = MeCH(OH), MeCHF, CH2OH; R2,R3 = H, alkyl; Z = (iso)quinolinediyl, quinazolinediyl, quinoxalinediyl, etc.] were prepared Thus, disodium (1R,5S,6S,8R,2'S,4'S)-2-[2-(8-carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate, prepared in 5 steps from 6-amino-8-carboxyquinoline (preparation given), had MIC of 0.13 and 0.03 µg/mL against Staphylococcus aureus Oxford and Escherichia coli DCO, resp.

L23 ANSWER 17 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 1993:80676 HCAPLUS
 DOCUMENT NUMBER: 118:80676
 TITLE: New applications of the Mitsunobu reaction in the synthesis of C-2 N-methyl carbapenems
 AUTHOR(S): Arnould, J. C.; Landier, F.; Pasquet, M. J.
 CORPORATE SOURCE: Cent. Rech., ICI Pharma, Reims, 51100, Fr.
 SOURCE: Tetrahedron Letters (1992), 33(47), 7133-6
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 118:80676
 GI



AB N-Acyl amides and N-acylamino heterocycles reacted regioselectively with 2-hydroxymethylcarbapenems I (R = OH, R1 = H, SiMe2CMe3) under Mitsunobu conditions to give I (R = NR2CO2CH2CH:CH2, R2 = 3-pyridyl, C6H4CH2NHCO2CH2CH:CH2-4, C6H4CH2OSiMe2CMe3-4, CH2CH2NHCO2CH2CH:CH2, 2-imidazolyl, substituted thiazolyl, pyrimidinyl, CO2CH2CH:CH2).


L23 ANSWER 18 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:511326 HCAPLUS
 DOCUMENT NUMBER: 117:111326
 TITLE: Synthesis and antibacterial activity of C-4 substituted monobactams
 AUTHOR(S): Arnould, J. C.; Boutron, P.; Pasquet, M. J.
 CORPORATE SOURCE: Cent. Rech., ICI-Pharma, Reims, 51064, Fr.
 SOURCE: European Journal of Medicinal Chemistry (1992), 27(2), 131-40
 CODEN: EJMCA5; ISSN: 0223-5234
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Monobactams I [R = Me, CMe₂CO₂H; R₁ = OEt, OH, NHCH₂CO₂H, NHCH₂CO₂Me, NHCH₂CN, NHC₆H₃(OH)_{2-3,4}, 4-methylpiperazino, NHCH₂CH₂R₂; R₂ = NH₂, 1-methyl-4-pyridiniumylamino, 2-thioxoimidazolidin-1-yl (Q), 3,4-(HO)₂C₆H₃CONH] were prepared from 6-aminopenicillanic acid. I (R = Me, R₁ = OH, NHCH₂CO₂H, NHCH₂CH₂Q) showed good to moderate activity against Gram-neg. bacteria with the exception of *Pseudomonas aeruginosa*. Introduction of a catechol moiety on the C(4) side chain only slightly improved the activity against *P. aeruginosa*.

L23 ANSWER 19 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1992:448157 HCAPLUS
 DOCUMENT NUMBER: 117:48157
 TITLE: Synthesis and structure-activity relationships of cephalosporins with C-3' catechol-containing residues
 AUTHOR(S): Arnould, J. C.; Bertrandie, A.; Bird, T. G. C.; Boucherot, D.; Jung, F.; Lohmann, J. J.; Olivier, A.; Bailey, J. P.; Bell, W.; Davies, G. M.
 CORPORATE SOURCE: Cent. Rech. Chem. Vrilly, ICI Pharma, Reims, 51100, Fr.
 SOURCE: Journal of Medicinal Chemistry (1992), 35(14), 2631-42
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Cephalosporins with new catechol substituents at C-3' have been synthesized, including novel compds. with C-3' C-C bonds. Many of these compds. have high potency against gram-neg. bacteria, in particular against resistant strains like *Pseudomonas aeruginosa*. Structure-activity relationships are discussed in terms of their dependence on the pK_a of the C-3' catechol and also in terms of steric and conformational factors of the C-3' substituent. The best overall properties were found in compds. with a bulky and/or conformationally restricted acidic C-3' catechol, such as I (R = H, cyano).

L23 ANSWER 20 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1992:448155 HCAPLUS
 DOCUMENT NUMBER: 117:48155
 TITLE: Pharmacokinetics of catechol cephalosporins. The

effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model

AUTHOR(S): Bird, T. G. C.; Arnould, J. C.; Bertrandie, A.; Jung, F. H.


CORPORATE SOURCE: Cent. Rech., ICI PHARMA, Reims, 51064, Fr.

SOURCE: Journal of Medicinal Chemistry (1992), 35(14), 2643-51
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Two series of cephalosporins (38 compds.) have been synthesized, bearing at C-3' catechols substituted with various electron-withdrawing groups and differing links, and were evaluated for their in vitro antibacterial activity and their pharmacokinetics in marmosets. Compds. bearing an isobutyric oxime substituent, proved to be highly active against Gram-neg. organisms and were especially noteworthy for showing long elimination phase (β) half-lives in marmosets. It was established that introduction of electron-withdrawing substituents greatly increased the β half-lives of compds. (I, R = H, $t_{1/2}$ = 1.25 h, serum concentration = 27 mg/h per L; I, R = 5-Cl, $t_{1/2}$ = 4.5 h, serum concentration = 638 mg/h per L) and that the nature of the link also influenced $t_{1/2}$. Acidities (pKa values) of the substituted catechols were measured, and relationships between the acidities and half-lives were evaluated. Thus it was established that the more acidic catechols gave the longest half-lives (I, R = 2,5-Cl₂, $t_{1/2}$ = 8.2 h, serum concentration = 461 mg/h per L). Further elaboration of the catechol to bicyclic systems maintained good pharmacokinetics when the pKa was sufficiently acidic.

L23 ANSWER 21 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1989:514966 HCAPLUS

DOCUMENT NUMBER: 111:114966

TITLE: Cephalosporin compounds, process for their preparation and their pharmaceutical compositions

INVENTOR(S): Arnould, Jean Claude; Bird, Thomas Geoffrey Colerick

PATENT ASSIGNEE(S): ICI-Pharma S. A., Fr.

SOURCE: Eur. Pat. Appl., 34 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

EP 304155 A2 19890222 EP 1988-306355 19880712
 EP 304155 A3 19901031
 EP 304155 B1 19951115
 R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE
 AT 130299 E 19951215 AT 1988-306355 19880712
 US 5013730 A 19910507 US 1988-219779 19880718
 JP 01040488 A2 19890210 JP 1988-181958 19880722
 PRIORITY APPLN. INFO.: EP 1987-401720 A 19870723
 OTHER SOURCE(S): MARPAT 111:114966
 GI



AB Title compds. I [A = syn-R2ON (R2 = H, C1-6 alkyl, C3-8 cycloalkyl, C1-3-alkyl-C3-6-cycloalkyl, PhNHCO, PhCH2NHCO, C1-5 cyanoalkyl, 2-amidinoethyl, thietan-3-yl, 2-oxopyrrolidinyl, etc.); R1 = 5-aminoisothiazol-3-yl, 5-amino-1,2,4-thiadiazol-3-yl, 3-aminopyrazol-5-yl, 4-aminopyrimidin-2-yl; R4 = H, MeO, HCONH; R5 = H, C1-4 alkyl, halo-C1-4-alkyl, C3-6 alkenyl, Ph-C1-4-alkyl, 5-6-membered heteroaryl-C1-4-alkyl, etc.; R6 = substituted N-containing heterocyclyl] and their N-oxides, salts, and cations, useful as antibiotics (no data), were prepared To 3-(aminomethyl)-7-[2-(2-aminothiazol-4-yl)-2-[(Z)-1-carboxy-1-methylethoxyimino]acetamido]ceph-3-em-4-carboxylic acid in DMF was added Et3N and 1-(3,4-diacetoxybenzoylmethyl)-4-(methylthio)pyrimidium chloride (preparation given) to give 7-[(2-aminothiazol-4-yl)-2-[(Z)-1-carboxy-1-methylethoxyimino]acetamido]-3-[N-[1-(3,4-diacetoxybenzoylmethyl)-4-pyrimidino]aminomethyl]ceph-3-em-4-carboxylic acid.

L23 ANSWER 22 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1989:514965 HCAPLUS

DOCUMENT NUMBER: 111:114965

TITLE: Preparation of (carboxamidomethyl)cephemcarboxylic acids as antibiotics

INVENTOR(S): **Arnould, Jean Claude**; Jung, Frederick Henri; Boucherot, Dominique; Strawson, Colin John; Davies, David Huw

PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK; ICI-Pharma S. A.

SOURCE: Eur. Pat. Appl., 78 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 304158	A1	19890222	EP 1988-306420	19880713
EP 304158	B1	19940622		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				

HU 47942	A2	19890428	HU 1988-3692	19880715
HU 201949	B	19910128		
FI 8803439	A	19890124	FI 1988-3439	19880720
ZA 8805271	A	19890329	ZA 1988-5271	19880720
DK 8804148	A	19890124	DK 1988-4148	19880722
NO 8803275	A	19890124	NO 1988-3275	19880722
AU 8819762	A1	19890127	AU 1988-19762	19880722
JP 01093592	A2	19890412	JP 1988-182006	19880722
CN 1031378	A	19890301	CN 1988-106393	19880723
US 5019570	A	19910528	US 1988-223988	19880725
US 5232918	A	19930803	US 1991-653149	19910211
US 5371220	A	19941206	US 1992-886392	19920521
PRIORITY APPLN. INFO.:			EP 1987-401718	A 19870723
			US 1988-223988	A3 19880725
			US 1991-653149	A3 19910211

OTHER SOURCE(S): MARPAT 111:114965

GI For diagram(s), see printed CA Issue.

AB Cephalosporins having Q as a 3-position substituent [R1 = H, (substituted) C1-6 alkyl, etc.; Het = 5- or 6-membered heterocyclic ring Q1, Q2; A = CH, N; B = O, S, etc.; 1 or 2 of D, E, F, and G = N, the remainder = CH; or Het = pyrazinone, pyridinone, etc.; Het is fused by any 2 adjacent C atoms to the benzene ring and is bonded via a C atom to the CH₂NR1CO group; R2, R3 = OH, in vivo hydrolyzable ester thereof; R3 is ortho to R2] were prepared as antibiotics. Reaction of 6,7-bis(phenylacetoxy)-1,4-dihydro-1-ethyl-4-oxoquinoline-3-carbonyl chloride with 3-(aminomethyl)-7-[2-(2-amino-4-thiazolyl)-2-[(Z)-[(1-carboxy-1-methylethoxy)imino]]acetamido]ceph-3-em-4-carboxylic acid in DMF containing Et₃N, followed by deprotection and workup, gave 7-[2-(2-amino-4-thiazolyl)-2-[(Z)-[(1-carboxy-1-methylethoxy)imino]]acetamido]-3-[(1,4-dihydro-1-ethyl-6,7-dihydroxy-4-oxoquinolin-3-carboxamido)methyl]ceph-3-em-4-carboxylic acid (I). I had min. inhibitory concns. of 0.008 µg/mL and 16 µg/mL, resp., against Escherichia coli DCO and Staphylococcus aureus 147 N.

L23 ANSWER 23 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1988:492660 HCAPLUS

DOCUMENT NUMBER: 109:92660

TITLE: Preparation of aminomethylcephem derivatives as antibiotics

INVENTOR(S): Arnould, Jean Claude; Lohmann, Jean Jacques; Pasquet, Georges

PATENT ASSIGNEE(S): ICI-Pharma S. A., Fr.

SOURCE: Eur. Pat. Appl., 51 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
EP 225182	A2	19870610	EP 1986-309279	19861127
EP 225182	A3	19881214		
EP 225182	B1	19930210		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ZA 8608506	A	19870729	ZA 1986-8506	19861107
AU 8665145	A1	19870604	AU 1986-65145	19861114
AU 585091	B2	19890608		
HU 43078	A2	19870928	HU 1986-4885	19861126
HU 196813	B	19890130		
DK 8605717	A	19870528	DK 1986-5717	19861127

FI 8604836	A	19870528	FI 1986-4836	19861127
JP 62155286	A2	19870710	JP 1986-280947	19861127
AT 85616	E	19930215	AT 1986-309279	19861127
US 5013731	A	19910507	US 1990-512069	19900419
PRIORITY APPLN. INFO.:			EP 1985-402331	A 19851127
			US 1986-936721	B1 19861125
			EP 1986-309279	A 19861127

GI




AB The title compds. I [X = S, O, CH₂, SO (R or S configuration); R₁ = (substituted) 2-aminothiazol-4-yl, 2-aminooxazol-4-yl, 5-aminoisothiazol-3-yl, 5-amino-1,2,4-thiadiazol-3-yl, 3-aminopyrazol-5-yl, 3-aminopyrazol-4-yl, 2-aminopyrimidin-5-yl, 2-aminopyrid-6-yl, 4-aminopyrimidin-2-yl, 2-amino-1,3,4-thiadiazol-5-yl, 5-amino-1-methyl-1,2,4-triazol-3-yl; R₅₀ = chloromethylene, :NOR₂ wherein R₂ = H, (substituted) C₁-6 alkyl, C₃-8 cycloalkyl, etc.; R₃ = H, MeO; R₄ = H, C₁-4 alkyl, halo(C₁-4)alkyl, hydroxy(C₁-4)alkyl, etc.; R₅ = aromatic heterocyclic fused ring system linked via C], useful as antibiotics, were prepared via II and III. A mixture of 3-ethylaminomethyl-7-[2-(2-aminothiazol-4-yl)-2-((Z)-1-carboxy-1-methylethoxyimino)acetamido]ceph-3-em-4-carboxylic acid and 1,7-dimethyl-4-methylthiopyrazolo[3,4-d]pyrimidine in DMF containing Et₃N was heated at 50° for 3 h to give IV. I are said to have in vitro MIC₅₀ values of <4 µg/mL against *Staphylococcus aureus*.

L23 ANSWER 24 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1984:406818 HCAPLUS
 DOCUMENT NUMBER: 101:6818
 TITLE: Halophenyl glyceride esters

INVENTOR(S): **Arnould, Jean Claude;** Evans, John Raymond;
 Jones, Geraint; Thomson, David Summers
 PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK; ICI-Pharma S. A.
 SOURCE: Eur. Pat. Appl., 33 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 99177	A1	19840125	EP 1983-303339	19830609
EP 99177	B1	19860827		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
US 4587262	A	19860506	US 1983-501758	19830606
ZA 8304135	A	19840425	ZA 1983-4135	19830607
AT 21686	E	19860915	AT 1983-303339	19830609
AU 8315698	A1	19851003	AU 1983-15698	19830610
AU 562207	B2	19870604		
IL 68950	A1	19880531	IL 1983-68950	19830610
HU 31053	O	19840428	HU 1983-2121	19830615
HU 191531	B	19870330		
FI 8302227	A	19831219	FI 1983-2227	19830617
NO 8302203	A	19831219	NO 1983-2203	19830617
DD 210029	A5	19840530	DD 1983-252126	19830617
ES 523376	A1	19841001	ES 1983-523376	19830617
CS 241061	B2	19860313	CS 1983-4456	19830617
CS 241088	B2	19860313	CS 1984-3943	19830617
CA 1221983	A1	19870519	CA 1983-430604	19830617
ES 530744	A1	19850616	ES 1984-530744	19840316
ES 530744	A5	19850715		
ES 530745	A1	19851101	ES 1984-530745	19840316
ES 530745	A5	19851128		
PRIORITY APPLN. INFO.:			EP 1982-401119	A 19820618
			EP 1983-303339	A 19830609

GI



AB Phenoxyphenyl alkanedioates I (R and R4 are Cl, Br; R1 and R2 are alkyl, alkenyl; R3 = H, Cl, Br; Z = alkylene, alkylalkylene), which were prepared, exhibited bactericidal activity and they are useful in the treatment of acne. Glutamic anhydride was treated with triclosan, the monoester product was converted to the resp. acid chloride, and the latter was treated with [Me(CH2)6CO2CH2]2CHOH and pyridine to give I [Z = (CH2)3, R = R3 = R4 = Cl, R1 = R2 = Me(CH2)6].

L23 ANSWER 25 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1983:88353 HCAPLUS
 DOCUMENT NUMBER: 98:88353

TITLE: Highly stereoselective synthesis and rearrangement of β -amino α -bromo chalcones

AUTHOR(S): Arnould, J. C.; Feigenbaum, A.; Henin, F.

CORPORATE SOURCE: Lab. Photochim., UER, Reims, 51062, Fr.

SOURCE: Journal of Chemical Education (1983), 60(1), 82
CODEN: JCEDA8; ISSN: 0021-9584

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An experiment involving a series of easy steps illustrating important stereoselective reactions in organic chemical and suitable for advanced students is described. The reactions involve the bromination of a chalcone, the conversion of the brominated chalcone to a bromopiperidinodiphenylpropanone, and conversion of this product to α -piperidinochalcone.

L23 ANSWER 26 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1981:586962 HCAPLUS

DOCUMENT NUMBER: 95:186962

TITLE: Photochemical reactivity of 2-dialkylamino-2-cyclohexenones and the corresponding ammonium salts

AUTHOR(S): Arnould, J. C.; Cossy, J.; Pete, J. P.


CORPORATE SOURCE: Lab. Photochim., UER Sci., Reims, 51062, Fr.

SOURCE: Tetrahedron (1981), 37(10), 1921-6
CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: French

GI



AB Irradiation of 2-(dialkylamino)-2-cyclohexenones gave α -ketoazetidines. E.g., cyclohexenone I on irradiation in Et₂O for 1 h gave 65% of an epimeric mixture of azetidines II. Irradiation of the corresponding ammonium salts in hydroxylic solvents led only to adduct formation.

L23 ANSWER 27 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1980:639103 HCAPLUS

DOCUMENT NUMBER: 93:239103

TITLE: Photochemical reactivity of α -aminoenones: cyclization and new type of reaction to α -sulfonamidocyclohexenones

AUTHOR(S): Arnould, J. C.; Cossy, J.; Pete, J. P.

CORPORATE SOURCE: Lab. Photochim., Unite Enseign. Rech. Sci., Reims, 51062, Fr.


SOURCE: Tetrahedron (1980), 36(11), 1585-92
CODEN: TETRAB; ISSN: 0040-4020

DOCUMENT TYPE: Journal

LANGUAGE: French


OTHER SOURCE(S): CASREACT 93:239103

GI



AB The photochem. behavior of 2-alkylamino-2-cyclohexenones depends on the N-substituents. 2-Methanesulfonamido-2-cyclohexenone gave only α -oxoazetidines, but desulfonation and aryl migration processes compete in the irradiation of the corresponding 2-arenesulfonamido compds. The main reactions of the corresponding 2-anilino and 2-benzoylamido compds. were divinylamine and photo-Fries rearrangement, resp. Thus, cyclohexenone I ($R = R_1 = \text{Me}$) was irradiated in Et₂O for 2 h to give 75% oxoazetidine II ($R_2 = \text{Me}$, $R_3 = \text{H}$). However, I ($R = \text{Et}$, $R_1 = p\text{-MeC}_6\text{H}_4$) on irradiation in EtOH for 3 h gave 30% oxoazetidine II ($R_2 = p\text{-MeC}_6\text{H}_4$, $R_3 = \alpha\text{-Me}$) and 25% cyclohexenone III.

L23 ANSWER 28 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1980:445524 HCAPLUS
 DOCUMENT NUMBER: 93:45524
 TITLE: Photolysis of conjugated heterosubstituted linear ketones
 AUTHOR(S): Arnould, J. C.; Enger, A.; Feigenbaum, A.; Pete, J. P.
 CORPORATE SOURCE: Lab. Photochim., UER Sci., Reims, 51062, Fr.
 SOURCE: Tetrahedron (1979), 35(21), 2501-2
 CODEN: TETRAB; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI



AB Photoenolization of Me₂C:CRCOME ($R = \text{OMe}$, piperidino) is preferred to H abstraction α to the heteroatom, whereas similar photolysis of E- and/or Z-PhCH:CRCOPh ($R = \text{OMe}$, NEt₂, piperidino, morpholino) gave oxetanol

I and isoquinolines II [R1 = Et, R2 = Me; R1R2 = (CH2)4, CH2CH2OCH2], resp. The differences in the photoreactivity of these mols. are discussed and the conformational control of the H γ abstraction process by the excited CO function is analyzed.

L23 ANSWER 29 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1979:9896 HCAPLUS

DOCUMENT NUMBER: 90:9896

TITLE: Effect of heat treatment on the structural evolution of iron-carbon-chromium-vanadium alloys

AUTHOR(S): Schissler, Jean Marie; Arnould, Jean; Parent-Simonin, Simone

CORPORATE SOURCE: Fr.

SOURCE: Fonderie (Paris) (1978), 380, 209-23

CODEN: FONDAP; ISSN: 0015-6094

DOCUMENT TYPE: Journal

LANGUAGE: French

AB Austenitization at moderate and elevated temps. was studied. The austenitization at moderate temperature consisted of heating to Ac3 + 50 to 100° and quenching to form martensite. This is followed by either tempering at 250° or hardening by precipitation of secondary carbides at 550°. The high-temperature austenitization was done at >1100° followed by quenching. Structures of tempered martensite and austenite were studied by dilatometric anal., microprobe anal., optical and electron microscopy, and electron diffraction.

L23 ANSWER 30 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1978:583648 HCAPLUS

DOCUMENT NUMBER: 89:183648

TITLE: Chromium-vanadium white cast irons. Their value for wear resistance

AUTHOR(S): Parent-Simonin, Simone; Arnould, Jean; Schissler, Jean Marie

CORPORATE SOURCE: Cent. Tech. Ind. Fonderie, Paris, Fr.

SOURCE: Fonderie (Paris) (1978), 33(375), 43-53

CODEN: FONDAP; ISSN: 0015-6094

DOCUMENT TYPE: Journal

LANGUAGE: French

AB A study was performed on 12 varieties of cast iron with high V content accompanied by Cr (1, 5, 15%) and with or without Ni. The mech. properties and wear resistance were determined after casting and after heat treatment. With grade 3 (Cr 15%, V 8.5%, and C 1.96%) in the as-cast state, high mech. properties were obtained with excellent friction behavior. The grades with Cr 15%, V 6%, and Ni 0.8% had performances equal to those of cast iron 15-3(A2), whose qualities are well known for resistance to abrasive wear. If the conditions of use necessitated a simultaneous resistance to wear by impact and abrasive friction the grades with high V are indicated. The presence of Cr does not appear indispensable but a little Ni or Mn is necessary.

L23 ANSWER 31 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1977:139454 HCAPLUS

DOCUMENT NUMBER: 86:139454


TITLE: Photolysis of 2(N-alkyl-arylsulfonylamido) cyclohexenone. An unusual and useful desulfonation reaction

AUTHOR(S): Arnould, Jean C.; Cossy, Janine; Pete, Jean P.

CORPORATE SOURCE: Lab. Photochim., U.E.R. Sci., Reims, Fr.

SOURCE: Tetrahedron Letters (1976), (43), 3919-22

DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB The title compds. (I; R = Et, PhCH₂, CH₂:CHCH₂, Me₂CH, R₁ = C₆H₄Me-4; R = Et, Me₂CH, R₁ = α-, β-C₁₀H₇; R = Me₂CH, R₁ = Ph) underwent photochem. desulfonation and rearrangement to give 10-70% aminoarylcyclohexenones II. A mechanistic scheme, involving radical intermediates, is described.

L23 ANSWER 32 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1976:580745 HCAPLUS

DOCUMENT NUMBER: 85:180745

TITLE: Study of the decomposition of post-bainitic austenite in iron-carbon-silicon alloys of 1% carbon and 4% silicon during isothermal holding at 420°C. Effect of 1% addition of manganese

AUTHOR(S): Schissler, J. M.; Arnould, J.; Metauer, G.

CORPORATE SOURCE: Lab. Metall., CNRS, Nancy, Fr.

SOURCE: Memoires Scientifiques de la Revue de Metallurgie (1975), 72(11), 779-92

CODEN: MRMTAU; ISSN: 0025-9128

DOCUMENT TYPE: Journal

LANGUAGE: French

AB In an Fe alloy [51668-81-6] containing 1.15% C and 3.9% Si, the bainitic transformation at 420° proceeded by 2 sep. stages. The initial γ-phase transformed to a lenticular ferrite [12427-24-6] (α-phase) with Widmanstaetten structure in the residual austenite [12244-31-4] matrix enriched by .apprx.2% C. The 2nd step consisted of the transformation of the matrix to α-phase, an aged carbide 1st proposed by Konoval (Nature 184, 1959, 1862), and a new Si carbide having orthorhombic structure. The addition of Mn destroyed the inhibiting action of Si in the formation of carbides at 420°. The alloy no longer formed post-bainitic austenite but ferrite phase and another new orthorhombic Si carbide. The effect of Mn disappeared when the holding temperature of bainite [12427-23-5] was decreased to 330°.

L23 ANSWER 33 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1975:563965 HCAPLUS

DOCUMENT NUMBER: 83:163965

TITLE: Photochemistry of α-dialkylamino enones. I. New oxidative cyclization of chalcone derivatives

AUTHOR(S): Arnould, J. C.; Pete, J. P.

CORPORATE SOURCE: Lab. Photochim., U.E.R. Sci., Reims, Fr.

SOURCE: Tetrahedron Letters (1975), (29), 2459-62

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English
 GI For diagram(s), see printed CA Issue.
 AB Photolysis of (E)- or (Z)-PhCH:C(NRCH₂R₁)COPh [R = Et, R₁ = Me; RR₁ = (CH₂)₄, (CH₂)₂OCH₂] gave the isoquinolines I together with chalcone.

L23 ANSWER 34 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1975:563919 HCAPLUS
 DOCUMENT NUMBER: 83:163919
 TITLE: Photochemistry of α -dialkylamino enones. II.
 Photocyclization of (dialkylamino)cyclohexenones and
 p-tolylsulfonylalkylaminocyclohexenones
 AUTHOR(S): Arnould, J. C.; Pete, J. P.
 CORPORATE SOURCE: Lab. Photochim., U.E.R. Sci., Reims, Fr.
 SOURCE: Tetrahedron Letters (1975), (29), 2463-6
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: English

GI For diagram(s), see printed CA Issue.
 AB Irradiation of 2-piperidino-2-cyclohexenone in Et₂O or EtOH at 366 nm gave >30% I. Similar irradiation of the tolylsulfonylaminocyclohexenones II (R = Me, Ph, R₁ = H) gave the corresponding azabicyclooctanes III. Photolysis of II (R = CH:CH₂, R₁ = H) in EtOH gave 40% III (R = CH:CH₂) and 35% IV (R = H), whereas II (R = CH:CH₂, R₁ = Me) gave 25% IV (R = Me) as the only isolable material.

L23 ANSWER 35 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1975:458208 HCAPLUS
 DOCUMENT NUMBER: 83:58208
 TITLE: Photolysis of α -alkoxycycloalkanones
 AUTHOR(S): Arnould, J. C.; Pete, J. P.
 CORPORATE SOURCE: Lab. Photochim., Fac. Sci., Reims, Fr.
 SOURCE: Tetrahedron (1975), 31(7), 815-23
 CODEN: TETRAB; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI For diagram(s), see printed CA Issue.
 AB Irradiation of α -alkoxycyclohexanones in EtOH gave the corresponding dealkoxylated compound as the predominant product, with ring cleaved esters and oxetanols. E.g., α -methoxycyclohexanone gave 80% cyclohexanone, 4% cyclohexanol, 12% MeO(CH₂)₅CO₂Et and 1% I. Cholestanone II gave 90% III and 10% IV. Similar treatment of α -methoxycyclopentanone gave 32% cyclopentanone and 32% cis- and 20% trans-MeOCH:CH(CH₂)₂CHO. 2-Methoxyindan-1-one gave 70% indanone and 30% oxetanol V. 2-Methoxynorbornanone on irradiation underwent epimerization. The dealkoxylation occurred by a Norrish Type II mechanism via a cycloalkenol which rearranged to the ketone or underwent cycloaddn. with the departing ketone to give the oxetanol.

L23 ANSWER 36 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1972:525583 HCAPLUS
 DOCUMENT NUMBER: 77:125583
 TITLE: Photolysis of α -alkoxycyclohexanones
 AUTHOR(S): Arnould, J. C.; Pete, J. P.
 CORPORATE SOURCE: Dep. Chim., Fac. Sci., Rheims, Fr.
 SOURCE: Tetrahedron Letters (1972), (24), 2415-18
 CODEN: TELEAY; ISSN: 0040-4039
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI For diagram(s), see printed CA Issue.
 AB Photolysis of the α -alkoxycyclohexanones (I) (R = Me, Et, Me₂CH,

PhCH₂) in EtOH gave cyclohexanone as the major product. The acids (II) (R = Me, Et, Me₂CH) and compd. III were also isolated. 2-Methoxytetralone was photolyzed in EtOH to give 42% IV, 8% V, and 15% VI.

L23 ANSWER 37 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1954:37310 HCAPLUS

DOCUMENT NUMBER: 48:37310

ORIGINAL REFERENCE NO.: 48:6670f-i,6671a

TITLE: Recent improvements in refractory cements and hydraulic concretes

AUTHOR(S): Arnould, Jean

SOURCE: Chimie et Industrie (Paris) (1953), 70, 1081-5

CODEN: CHIEAN; ISSN: 0009-4358

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB An account of the use of Ca aluminate hydraulic cement in the preparation of refractory concretes. Depending on conditions to be met, 1 cu. m. may contain 250-500 kg. of aluminous cement, together with "chamotte" (precalcined clay), containing 25-40% Al₂O₃. The composition of the cement and its

m.p., approx. 1400°, limits its application, but admixts. with carborundum may permit use at this temperature "Super-refractory 250" is a hydraulic cement now in quantity production, containing Al₂O₃ 70-2, CaO 26-9, SiO₂ and Fe₂O₃ 0.5-1.0%. Its setting, hardening, and crystallizing properties are comparable to the regular type; the setting time is about 4 hrs., the reaction exothermic. The ratio of cement to mixing water is 1.75-2.2. Slow heating to 600° can be started 24-48 hrs. after setting; then the normal working temperature can be reached. Cement-250 (Segger cone 23) m. 1580°. In admixt. with pure carborundum it may exceed 1745°. The cement cannot be used alone because of shrinkage and checking on heating. Loss of water between 500° and 1100° causes a friable condition and prevents its use below 1100°. Above this temperature the constituents recombine and unite with the aggregate. Combinations of cement-250 with white carborundum or pure Al₂O₃ allows use of working temps. of 1600-1700°. The d. of such concretes is 2.8-3.5. The filter must be refractory, clean, and free from fusible matter (Fe₂O₃, CaO, SiO₂, and alkalis), and be previously calcined at the working temperature. The size distribution should be standardized, not to exceed

30 mm. diameter. The quantity is chosen according to the service conditions and for the hardness desired. The more cement the higher the mech. strength; the less cement the more refractory the concrete. Graphs show the shrinkages under load of 2 kg./sq. cm. of various concretes subjected to temps. up to 1800° for periods up to 5 hrs. These are approx. 4-5% for mixts. at 300 kg./cu. m. The cement-250 mixts. with carborundum resist thermal shocks because of their low coefficient of expansion, 2.5-5.0 + 10⁻⁶ between 0° and 1400°. Values of the coefficient of thermal conductivity are given as 0.79-1.15 cal./sq. m./m./hr./°C. for cement-250 containing chamotte and carborundum, resp. Other values found for the carborundum mixture, graphed for temps. 200-1400°, are 1.6-2.6.

L23 ANSWER 38 OF 38 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1926:13757 HCAPLUS

DOCUMENT NUMBER: 20:13757

ORIGINAL REFERENCE NO.: 20:1701g-i,1702a-b

TITLE: A refractory hydraulic cement

AUTHOR(S): Arnould, J.

SOURCE: Chimie et Industrie (Paris) (1926), 15, 184-8

CODEN: CHIEAN; ISSN: 0009-4358

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB A mixture of fused cement ("electric" or "aluminous" cement), MgO calcined at 1000° and water glass gives a good cement which stands up at fairly high temps., but which unfortunately sets too rapidly. A 1:2 mixture of fused cement and of calcined (above 1070°) and ground bauxite constitutes a true hydraulic cement, which, on mixing with 22-30% H₂O, begins to set in 1 hr. and is completely set in 4-6 hrs. It hardens very rapidly, and after 3 days has a crushing strength of 145 kg. per cm.² and a tensile strength of 21 kg. per cm.². It can be made into concrete by using 1, 2 or 3 parts of broken-up old refractory bricks (screened, or preferably washed, to remove dust) to 3 parts of cement, which is used and handled the same as ordinary portland cement concrete. Both the cement (fused cement-bauxite mixture) and the concrete after setting soften at 1350-1400° and m. at about 1600°. The cement has a crushing strength of 20 kg. up to 1200-50°, which drops to 2 kg. at 1300-50°; above this it becomes quite soft, but does not flow. The crushing strength curve at high temps. lies between the corresponding curves of bauxite and of carborundum. Both the cement and the concrete have a very small shrinkage, 1-1.5% at 1350°, and as low as 0.5% in some cases. They are remarkably resistant to sudden changes in temps. and do not crack on rapid cooling from 1380° to 20°. Strength tests on the cold cement after heating to various temps. showed a certain degree of friability (probably due to elimination of H₂O of constitution), which appeared at about 800°, reached a maximum at 1000-1200°, and disappeared at about 1300°. The friability decreases with the proportion of bauxite in the mixture. Friability in the concrete can be completely eliminated by heating once above 1250°. The addition of broken refractory in the concrete decreases the shrinkage, increases the strength, prevents cracking of the concrete, and cheapens the product, but increases the friability. BeO gives the same results as Al₂O₃, which confirms the place assigned to it in the table of elements, but is of no practical interest. Presence of up to 3% TiO₂ in the bauxite causes no trouble. Using an aluminous cement prepared by clinkering instead of fusion raises the m. p. of the cement-bauxite mixture by about 50°. The friability can be reduced, and even eliminated completely, by addition of a little powdered flint or powdered Na silicate (of low alkalinity and consequently non-hygroscopic); but this lowers the m. and softening points.

=>